"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,MX,A,MX 2012004195 A,043-713-940-928-758,2013-10-15,2013,MX 2012004195 A,2012-04-09,MX 2012004195 A,2012-04-09,BORE LOCATING DEVICE FOR FIXING INTRAMEDULLARY NAIL.,"The present invention consists of three main parts which together form a medical device, one of said parts being a console, which is the main part of the operation, without this part the device would not be able to work, since it would be just a CPU, the console having a LCD screen, four push-buttons in the exterior portion, if one element fails it would be easily fix or replaced, since they are easily acquired; the second part is a joystick, which is a secondary element for the operation of the device, similarly if the control fails, it would be easily repaired, since the inner portion of the control has two push-buttons that are easily acquired in any store of electronic components; the third part includes a base with a cylindrical- or ring-shape scanner, this being an essential part of the invention with an easy arrangement, in case the motor, sensors or laser fails, these would be easily acquired in stores of electronic components, and quickly repaired as they are easily replaced. These parts form the medical device, which together facilitate a surgery.",GONZALEZ SERGIO CRUZ,GONZALEZ SERGIO CRUZ;;MALDONADO JORGE ARMANDO VEGA,,https://lens.org/043-713-940-928-758,Patent Application,no,0,0,1,1,0,,A61B17/17;;A61B17/58;;A61B17/72,,0,0,,,,PENDING
2,US,A1,US 2010/0314091 A1,005-812-937-870-247,2010-12-16,2010,US 86154810 A,2010-08-23,US 86154810 A;;MX NL03000043 A;;US 50467006 A;;US 76990704 A,2003-11-17,WATER COOLED PANEL,"A water cooled panel includes a continuous coil having a plurality of straight pipe sections and “U” shaped 180° elbow sections that are integral part of the pipe, the continuous coil included by a pipe having a wall thickness of from 0.270 inches to 0.600 inches and an outer diameter of from 2.375 inches to 3.5 inches",MELTER S A DE C V,URIBE QUINTANILLA ANTONIO;;GONZALEZ CRUZ JORGE CARLOS,MELTER S.A. DE C.V (2003-12-10),https://lens.org/005-812-937-870-247,Patent Application,yes,20,2,2,8,0,B21D11/00;;B21D11/00;;B21D7/00;;B21D7/00;;B21D11/07;;B21D11/07;;B21D37/16;;B21D37/16;;B21D53/027;;B21D53/027;;B21D53/06;;B21D53/06;;F28D7/082;;F28D7/082;;Y10T29/4938;;Y10T29/4938,F28F1/00,165/177,0,0,,,,EXPIRED
3,CA,A1,CA 2487617 A1,042-923-564-038-653,2005-05-17,2005,CA 2487617 A,2004-11-16,MX NL03000043 A,2003-11-17,WATER COOLED PANEL AND FORMING METHOD,"A bending method for producing a coil using a thick wall pipe, comprising a simultaneous hot bending and pressing of the pipe by which it is possible to obtain a coil without welded 180.degree. elbows since the return sections are integral part of the pipe.",MELTER S A DE C V,CRUZ JORGE CARLOS GONZALEZ;;QUINTANILLA ANTONIO URIBE,,https://lens.org/042-923-564-038-653,Patent Application,no,0,0,6,8,0,B21D11/00;;B21D11/07;;B21D11/00;;B21D11/07,B21D11/00;;B21D11/07,,0,0,,,,INACTIVE
4,US,A1,US 2006/0277963 A1,135-379-168-146-674,2006-12-14,2006,US 50467006 A,2006-08-16,US 50467006 A;;MX NL03000043 A;;US 76990404 A,2003-11-17,Water cooled panel,A water cooled panel is comprised by a continuous coil having a plurality of straight pipe sections and “U” shaped 180° elbow sections that are integral part of the pipe.,MELTER S A DE C V,URIBE QUINTANILLA ANTONIO;;GONZALEZ CRUZ JORGE C,MELTER S.A. DE C.V (2003-12-10),https://lens.org/135-379-168-146-674,Patent Application,yes,15,0,6,8,0,B21D11/00;;B21D11/07;;B21D11/00;;B21D11/07,B21D11/00;;F28F1/00;;B21D11/07,72/369;;165/177,0,0,,,,DISCONTINUED
5,US,B2,US 8235100 B2,071-420-759-563-48X,2012-08-07,2012,US 86154810 A,2010-08-23,US 86154810 A;;MX NL03000043 A;;US 50467006 A;;US 76990704 A,2003-11-17,Water cooled panel,"A tubular cooling element includes a continuous coil having a plurality of straight pipe sections and “U” shaped 180° elbow sections that are an integral part of the tubular cooling element, the continuous coil including a pipe having a wall thickness of from 0.270 inches to 0.600 inches and an outer diameter of from 2.375 inches to 3.5 inches.",URIBE QUINTANILLA ANTONIO;;GONZALEZ CRUZ JORGE CARLOS;;MELTER S A DE C V,URIBE QUINTANILLA ANTONIO;;GONZALEZ CRUZ JORGE CARLOS,MELTER S.A. DE C.V (2003-12-10),https://lens.org/071-420-759-563-48X,Granted Patent,yes,20,0,2,8,0,B21D11/00;;B21D11/00;;B21D7/00;;B21D7/00;;B21D11/07;;B21D11/07;;B21D37/16;;B21D37/16;;B21D53/027;;B21D53/027;;B21D53/06;;B21D53/06;;F28D7/082;;F28D7/082;;Y10T29/4938;;Y10T29/4938,F28F1/00,165/177;;165/172;;29/890.047,0,0,,,,ACTIVE
6,US,A1,US 2005/0103085 A1,038-123-590-618-432,2005-05-19,2005,US 76990404 A,2004-02-03,MX NL03000043 A,2003-11-17,Water cooled panel and forming method,"A bending method for producing a coil using a thick wall pipe, comprising a simultaneous hot bending and pressing of the pipe by which it is possible to obtain a coil without welded 180° elbows since the return sections are integral part of the pipe.",MELTER S A DE C V,URIBE QUINTANILLA ANTONIO;;GONZALEZ CRUZ JORGE C,MELTER S.A. DE C.V (2003-12-10),https://lens.org/038-123-590-618-432,Patent Application,yes,6,3,6,8,0,B21D11/00;;B21D11/07;;B21D11/00;;B21D11/07,B21D11/00;;B21D11/07,72/369,0,0,,,,EXPIRED
7,US,B2,US 6539738 B2,190-509-208-732-553,2003-04-01,2003,US 87781301 A,2001-06-08,US 87781301 A;;US 21052800 P,2000-06-08,Compact solar-powered air conditioning systems,"
    A design of a compact solar air conditioning system especially suited for tropical climates includes an air-cooled single-effect absorption machine driven by an array of high performance flat-plate collectors along with a thermal storage tank. The absorption machine uses lithium-bromide as a refrigerant and a water-based absorption fluid. The operation of the compact solar air conditioning system is determined by an optimal control strategy. 
",UNIV PUERTO RICO,GONZALEZ-CRUZ JORGE E;;BEAUCHAMP-BAEZ GERSON,UNIVERSITY OF PUERTO RICO (2001-07-05),https://lens.org/190-509-208-732-553,Granted Patent,yes,25,39,2,2,0,F25B27/007;;F25B27/007;;F25B15/06;;F25B15/06;;Y02A30/27;;Y02A30/27;;Y02B30/62;;Y02B30/62,F25B15/06;;F25B27/00,62/235.1;;62/476;;62/484,1,1,004-949-093-169-83X,10.1115/1.3445757,"S.A. Klein, J. A. Duffie, W. A. Beckman-Transient Considerations of Flat-Plate Solar Collectors-Journal of Engineering for Power-Apr. 1974-pp. 109-113-Solar Energy Laboratory, The University of Wisconsin, Madison, Wisconsin, USA.",EXPIRED
8,US,A1,US 2003/0041608 A1,069-231-572-509-606,2003-03-06,2003,US 87781301 A,2001-06-08,US 87781301 A;;US 21052800 P,2000-06-08,COMPACT SOLAR-POWERED AIR CONDITIONING SYSTEMS,"
   A design of a compact solar air conditioning system especially suited for tropical climates includes an air-cooled single-effect absorption machine driven by an array of high performance flat-plate collectors along with a thermal storage tank. The absorption machine uses lithium-bromide as a refrigerant and a water-based absorption fluid. The operation of the compact solar air conditioning system is determined by an optimal control strategy. 
",GONZALEZ-CRUZ JORGE E.;;BEAUCHAMP-BAEZ GERSON,GONZALEZ-CRUZ JORGE E;;BEAUCHAMP-BAEZ GERSON,UNIVERSITY OF PUERTO RICO (2001-07-05),https://lens.org/069-231-572-509-606,Patent Application,yes,0,46,2,2,0,F25B27/007;;F25B27/007;;F25B15/06;;F25B15/06;;Y02A30/27;;Y02A30/27;;Y02B30/62;;Y02B30/62,F25B15/06;;F25B27/00,62/235.1;;62/476;;62/238.3,0,0,,,,EXPIRED
9,US,B2,US 7121131 B2,187-297-952-889-479,2006-10-17,2006,US 76990404 A,2004-02-03,MX NL03000043 A,2003-11-17,Water cooled panel and forming method,"A bending method for producing a coil using a thick wall pipe, comprising a simultaneous hot bending and pressing of the pipe by which it is possible to obtain a coil without welded 180° elbows since the return sections are integral part of the pipe.",MELTER S A DE C V,URIBE QUINTANILLA ANTONIO;;GONZALEZ CRUZ JORGE CARLOS,MELTER S.A. DE C.V (2003-12-10),https://lens.org/187-297-952-889-479,Granted Patent,yes,8,1,6,8,0,B21D11/00;;B21D11/07;;B21D11/00;;B21D11/07,B21D7/16;;B21D11/00;;B21D11/07,72/369;;72/128;;72/342.5;;72/364,0,0,,,,ACTIVE
10,US,B2,US 9996279 B2,108-071-012-792-960,2018-06-12,2018,US 201514975576 A,2015-12-18,US 201514975576 A,2015-12-18,Integrity protection for system management mode,"Various embodiments are directed to providing integrity protection for a system management mode. During initialization, a hash value of a system management mode control routine may be determined. Subsequently, during operation, the hash value may be compared to a hash value of a system management mode control routine to be executed. The system management mode control routine to be executed may be determined to be authentic if the hash values are the same.",INTEL CORP,GONZALEZ DIAZ JORGE E;;CRUZ ALCARAZ JUAN MANUEL,INTEL CORPORATION (2016-02-02),https://lens.org/108-071-012-792-960,Granted Patent,yes,6,0,7,7,0,G06F21/51;;G06F21/57;;G06F21/64;;G06F13/24;;G06F21/51;;G06F21/57;;G06F21/64;;G06F3/0619;;G06F3/065;;G06F3/0685;;G06F12/1408;;G06F13/24;;G06F2212/1052;;G06F2213/24;;H04L9/3234;;H04L9/3236,G06F3/06;;G06F12/14;;G06F13/24;;H04L9/32,,2,0,,,"International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2016/062953, dated Mar. 10, 2017, 15 pages.;;Gulley et al., “Haswell Cryptographic Performance”, Intel, White Paper, Jul. 2013, 11 pages.",ACTIVE
11,US,A1,US 2018/0293010 A1,129-767-834-477-887,2018-10-11,2018,US 201816005237 A,2018-06-11,US 201816005237 A;;US 201514975576 A,2015-12-18,INTEGRITY PROTECTION FOR SYSTEM MANAGEMENT MODE,"Various embodiments are directed to providing integrity protection for a system management mode. During initialization, a hash value of a system management mode control routine may be determined. Subsequently, during operation, the hash value may be compared to a hash value of a system management mode control routine to be executed. The system management mode control routine to be executed may be determined to be authentic if the hash values are the same.",INTEL CORP,GONZALEZ DIAZ JORGE E;;CRUZ ALCARAZ JUAN MANUEL,,https://lens.org/129-767-834-477-887,Patent Application,yes,0,0,7,7,0,G06F21/51;;G06F21/57;;G06F21/64;;G06F13/24;;G06F21/51;;G06F21/57;;G06F21/64;;G06F3/0619;;G06F3/065;;G06F3/0685;;G06F12/1408;;G06F13/24;;G06F2212/1052;;G06F2213/24;;H04L9/3234;;H04L9/3236,G06F3/06;;G06F12/14;;G06F13/24;;G06F21/51;;G06F21/57;;G06F21/64;;H04L9/32,,0,0,,,,ACTIVE
12,US,B2,US 10296246 B2,114-612-009-694-08X,2019-05-21,2019,US 201816005237 A,2018-06-11,US 201816005237 A;;US 201514975576 A,2015-12-18,Integrity protection for system management mode,"Various embodiments are directed to providing integrity protection for a system management mode. During initialization, a hash value of a system management mode control routine may be determined. Subsequently, during operation, the hash value may be compared to a hash value of a system management mode control routine to be executed. The system management mode control routine to be executed may be determined to be authentic if the hash values are the same.",INTEL CORP,GONZALEZ DIAZ JORGE E;;CRUZ ALCARAZ JUAN MANUEL,,https://lens.org/114-612-009-694-08X,Granted Patent,yes,8,0,7,7,0,G06F21/51;;G06F21/57;;G06F21/64;;G06F13/24;;G06F21/51;;G06F21/57;;G06F21/64;;G06F3/0619;;G06F3/065;;G06F3/0685;;G06F12/1408;;G06F13/24;;G06F2212/1052;;G06F2213/24;;H04L9/3234;;H04L9/3236,G06F21/57;;G06F3/06;;G06F12/14;;G06F13/24;;G06F21/51;;G06F21/64;;H04L9/32,,0,0,,,,ACTIVE
13,US,B2,US 10664178 B2,093-217-229-862-639,2020-05-26,2020,US 201816147464 A,2018-09-28,US 201816147464 A;;US 201816005237 A;;US 201514975576 A,2015-12-18,Integrity protection for system management mode,"Various embodiments are directed to providing integrity protection for a system management mode. During initialization, a hash value of a system management mode control routine may be determined. Subsequently, during operation, the hash value may be compared to a hash value of a system management mode control routine to be executed. The system management mode control routine to be executed may be determined to be authentic if the hash values are the same.",INTEL CORP,GONZALEZ DIAZ JORGE E;;CRUZ ALCARAZ JUAN MANUEL,,https://lens.org/093-217-229-862-639,Granted Patent,yes,5,0,7,7,0,G06F21/51;;G06F21/57;;G06F21/64;;G06F13/24;;G06F21/51;;G06F21/57;;G06F21/64;;G06F3/0619;;G06F3/065;;G06F3/0685;;G06F12/1408;;G06F13/24;;G06F2212/1052;;G06F2213/24;;H04L9/3234;;H04L9/3236,G06F3/06;;G06F12/14;;G06F13/24;;G06F21/51;;G06F21/57;;G06F21/64;;H04L9/32,,0,0,,,,ACTIVE
14,WO,A1,WO 2017/105781 A1,116-048-248-410-775,2017-06-22,2017,US 2016/0062953 W,2016-11-18,US 201514975576 A,2015-12-18,INTEGRITY PROTECTION FOR SYSTEM MANAGEMENT MODE,"Various embodiments are directed to providing integrity protection for a system management mode. During initialization, a hash value of a system management mode control routine may be determined. Subsequently, during operation, the hash value may be compared to a hash value of a system management mode control routine to be executed. The system management mode control routine to be executed may be determined to be authentic if the hash values are the same.",INTEL CORP,GONZALEZ DIAZ JORGE E;;CRUZ ALCARAZ JUAN MANUEL,,https://lens.org/116-048-248-410-775,Patent Application,yes,5,0,7,7,0,G06F21/51;;G06F21/57;;G06F21/64;;G06F13/24;;G06F21/51;;G06F21/57;;G06F21/64;;G06F3/0619;;G06F3/065;;G06F3/0685;;G06F12/1408;;G06F13/24;;G06F2212/1052;;G06F2213/24;;H04L9/3234;;H04L9/3236,G06F21/53;;G06F21/50;;G06F21/54,,0,0,,,,PENDING
15,US,A1,US 2019/0034101 A1,058-434-480-150-596,2019-01-31,2019,US 201816147464 A,2018-09-28,US 201816147464 A;;US 201816005237 A;;US 201514975576 A,2015-12-18,INTEGRITY PROTECTION FOR SYSTEM MANAGEMENT MODE,"Various embodiments are directed to providing integrity protection for a system management mode. During initialization, a hash value of a system management mode control routine may be determined. Subsequently, during operation, the hash value may be compared to a hash value of a system management mode control routine to be executed. The system management mode control routine to be executed may be determined to be authentic if the hash values are the same.",INTEL CORP,GONZALEZ DIAZ JORGE E;;CRUZ ALCARAZ JUAN MANUEL,,https://lens.org/058-434-480-150-596,Patent Application,yes,5,1,7,7,0,G06F21/51;;G06F21/57;;G06F21/64;;G06F13/24;;G06F21/51;;G06F21/57;;G06F21/64;;G06F3/0619;;G06F3/065;;G06F3/0685;;G06F12/1408;;G06F13/24;;G06F2212/1052;;G06F2213/24;;H04L9/3234;;H04L9/3236,G06F3/06;;G06F12/14;;G06F13/24;;G06F21/51;;G06F21/57;;G06F21/64;;H04L9/32,,0,0,,,,ACTIVE
16,US,A1,US 2017/0177245 A1,124-811-750-397-330,2017-06-22,2017,US 201514975576 A,2015-12-18,US 201514975576 A,2015-12-18,INTEGRITY PROTECTION FOR SYSTEM MANAGEMENT MODE,"Various embodiments are directed to providing integrity protection for a system management mode. During initialization, a hash value of a system management mode control routine may be determined. Subsequently, during operation, the hash value may be compared to a hash value of a system management mode control routine to be executed. The system management mode control routine to be executed may be determined to be authentic if the hash values are the same.",GONZALEZ DIAZ JORGE E;;CRUZ ALCARAZ JUAN MANUEL,GONZALEZ DIAZ JORGE E;;CRUZ ALCARAZ JUAN MANUEL,INTEL CORPORATION (2016-02-02),https://lens.org/124-811-750-397-330,Patent Application,yes,3,3,7,7,0,G06F21/51;;G06F21/57;;G06F21/64;;G06F13/24;;G06F21/51;;G06F21/57;;G06F21/64;;G06F3/0619;;G06F3/065;;G06F3/0685;;G06F12/1408;;G06F13/24;;G06F2212/1052;;G06F2213/24;;H04L9/3234;;H04L9/3236,G06F3/06;;G06F12/14;;G06F13/24;;H04L9/32,,0,0,,,,ACTIVE
17,US,A1,US 2002/0053214 A1,082-468-549-204-448,2002-05-09,2002,US 87781401 A,2001-06-08,US 87781401 A;;US 21053400 P,2000-06-08,Automation and control of solar air conditioning systems,"
   A solar powered air conditioning system includes an absorption machine coupled to three primary loops. A heat loop provides energy to the absorption machine. A cooling tower loop exhausts heat from the absorption machine. A chilled water loop is used to draw heat from a room or building. The heat loop provides energy from a boiler and/or from a number of solar collectors. In one mode of operation, the solar collectors circulate through a storage tank. The flow through the solar collectors is regulated to maximize energy collection. 
",MELENDEZ-GONZALEZ LUIS V.;;GONZALEZ-CRUZ JORGE E.;;BEAUCHAMP-BAEZ GERSON,MELENDEZ-GONZALEZ LUIS V;;GONZALEZ-CRUZ JORGE E;;BEAUCHAMP-BAEZ GERSON,UNIVERSITY OF PUERTO RICO (2001-06-08),https://lens.org/082-468-549-204-448,Patent Application,yes,0,39,2,2,0,F24F5/0046;;F24F2005/0064;;F25B27/007;;F25B29/006;;Y02B10/20;;Y02B30/62;;Y02A30/272;;Y02A30/27;;F25B27/007;;F25B29/006;;F24F5/0046;;Y02B10/20;;F24F2005/0064;;Y02B30/62;;Y02A30/272;;Y02A30/27,F24F5/00;;F25B27/00;;F25B29/00,62/235.1,0,0,,,,EXPIRED
18,US,B2,US 6536677 B2,016-219-381-309-009,2003-03-25,2003,US 87781401 A,2001-06-08,US 87781401 A;;US 21053400 P,2000-06-08,Automation and control of solar air conditioning systems,"
    A solar powered air conditioning system includes an absorption machine coupled to three primary loops. A heat loop provides energy to the absorption machine. A cooling tower loop exhausts heat from the absorption machine. A chilled water loop is used to draw heat from a room or building. The heat loop provides energy from a boiler and/or from a number of solar collectors. In one mode of operation, the solar collectors circulate through a storage tank. The flow through the solar collectors is regulated to maximize energy collection. 
",UNIV PUERTO RICO,MELENDEZ-GONZALEZ LUIS V;;GONZALEZ-CRUZ JORGE E;;BEAUCHAMP-BAEZ GERSON,UNIVERSITY OF PUERTO RICO (2001-06-08),https://lens.org/016-219-381-309-009,Granted Patent,yes,25,23,2,2,0,F24F5/0046;;F24F2005/0064;;F25B27/007;;F25B29/006;;Y02B10/20;;Y02B30/62;;Y02A30/272;;Y02A30/27;;F25B27/007;;F25B29/006;;F24F5/0046;;Y02B10/20;;F24F2005/0064;;Y02B30/62;;Y02A30/272;;Y02A30/27,F24F5/00;;F25B27/00;;F25B29/00,237  2B;;126/587;;126/714;;62/324.4,1,1,004-949-093-169-83X,10.1115/1.3445757,"S.A. Klein, J. A. Duffie, W. A. Beckman-Transient Considerations of Flat-Plate Solar Collectors-Journal of Engineering for Power-Apr. 1974- pp. 109-113-Solar Energy Laboratory, The Universiy of Wisconsin, Madison, Wisconsin, USA.",EXPIRED
19,US,B2,US 7595864 B2,029-197-058-107-252,2009-09-29,2009,US 28279905 A,2005-11-18,US 28279905 A,2005-11-18,Optical sensor for the instantaneous detection and identification of bioaerosols,"The invention relates to an apparatus and a process of using the said apparatus in the in-time air sampling, detection and identification of bioaereosols; wherein identification of the said aerosol is based on a multiphoton laser diagnostic technique in combination with the velocity and aerodynamic size of the particular bioaerosol.",GONZALEZ CRUZ JORGE E;;ORTIZ VEGA ALFREDO;;SALAZAR IZQUIERDO VICTOR M,GONZALEZ CRUZ JORGE E;;ORTIZ VEGA ALFREDO;;SALAZAR IZQUIERDO VICTOR M,CARIBBEAN BIOTECHNOLOGIES INC (2006-11-09),https://lens.org/029-197-058-107-252,Granted Patent,yes,18,0,4,4,0,G01J3/4406;;G01N21/6402;;G01N21/6486;;G01J3/4406;;G01N21/6486;;G01N21/6402,G01J3/30,356/73;;356/318;;356/337,10,7,021-184-533-140-542;;021-438-828-381-367;;072-614-837-841-257;;109-667-949-670-237;;005-389-621-748-477;;076-864-954-785-108;;010-754-818-112-505,pmc38229;;10.1073/pnas.93.20.10763;;8855254;;10.1080/02786829708965436;;11701518;;10.1146/annurev.bioeng.2.1.399;;10.1080/027868200303461;;10816101;;10.1042/bst0280070;;10.1080/02786829808965514;;18250761;;10.1364/ao.36.000958,"Xu, C. et al, Multiphoton fluorescence excitation: New spectral windows for biological nonlinear microscopy, Proc. Natl Acad. Sci., 1996, pp. 10763-10768, vol. 93, USA.;;Semlett, D. et al., Fluctuations and Noise of the Optical Output Power of Laser Diodes and the Effect on Optical Particle Size Determination, Aerosol Science and Technology, 1997, pp. 356-367.;;Gadella, B. M. et al, Multi-photon excitation microscopy for advanced biomedical imaging, http://www.vetscite.org/publish/articles/000040/print.html, 2003, pp. 1-19.;;So, P. T. C. et al, Two-Photon Excitation Fluorescence Microscopy, Annu. Rev. Biomed. Eng., 2000, pp. 399-429, USA.;;Ananih, G. et al, Theoretical Analysis of the Performance of the TSI Aerodynamic Particle Sizer, Aerosol Science and Technology, 1988, pp. 189-199, Elsevier Science Publishing Co., Inc., USA.;;Brosseau, L. M. et al, Differences in Detected Fluorescence Among Several Bacterial Species Measured with a Direct-Reading Particle Sizer and Fluorescence Detector, Aerosol Science and Technology, 2000, pp. 545-558, Taylor and Francis, USA.;;Soini, E. et al, Two-photon fluorescence excitation in detection of biomolecules Biochemical Society Transactions, 2000, pp. 70-74, vol. 28, part 2, Turku, Finland.;;Tirri, M. et al, Low cost lasers challenge ultrafas systems in two-photon excitation applications, Opto-Electron. Rev., 2003, pp. 39-44, 11, No. 1, Turku, Finland.;;Pinnick, R. G., Aerosol Fluorescence Spectrum Analyzer for Rapid Measurement of Single Micrometer-Sized Airborne Biological Particles, Aerosol Science and Technology, 1998, pp. 95-104, Elsevier Science Inc., USA.;;Faris, G. W. et al, Spectrally resolved absolute fluorescence cross sections for cacillus spores, Applied Optics, 1997, pp. 958-967, Vo. 36, No. 4, USA.",ACTIVE
20,US,B2,US 8013984 B2,132-706-376-684-481,2011-09-06,2011,US 58353009 A,2009-08-24,US 58353009 A;;US 28279905 A,2005-11-18,Optical sensor for the instantaneous detection and identification of bioaerosols,"A novel apparatus comprising three main systems: air sampling, detection and computerized electric system; and method of using the same in the sampling, detection and identification of bioaerosols, wherein the identification of the said bioaerosol is base on a multiphoton laser diagnostic technique along with the velocity and aerodynamic size of the particular bioaerosol. After exposing the said bioaerosols with near infrared wavelength laser, the obtained fluorescence spectra has been shown to be unique and particular for each bioaerosol, thus allowing the characterization of the said particles.",GONZALEZ CRUZ JORGE E;;ORTIZ VEGA ALFREDO;;SALAZAR IZQUIERDO VICTOR M,GONZALEZ CRUZ JORGE E;;ORTIZ VEGA ALFREDO;;SALAZAR IZQUIERDO VICTOR M,,https://lens.org/132-706-376-684-481,Granted Patent,yes,9,4,4,4,0,G01J3/4406;;G01N21/6402;;G01N21/6486;;G01J3/4406;;G01N21/6486;;G01N21/6402,G01N21/00,356/73;;356/417,0,0,,,,ACTIVE
21,US,A1,US 2009/0310128 A1,159-828-033-747-837,2009-12-17,2009,US 58353009 A,2009-08-24,US 58353009 A;;US 28279905 A,2005-11-18,Novel optical sensor for the instantaneous detection and identification of bioaerosols,"A novel apparatus comprising three main systems: air sampling, detection and computerized electric system; and method of using the same in the sampling, detection and identification of bioaerosols, wherein the identification of the said bioaerosol is base on a multiphoton laser diagnostic technique along with the velocity and aerodynamic size of the particular bioaerosol. After exposing the said bioaerosols with near infrared wavelength laser, the obtained fluorescence spectra has been shown to be unique and particular for each bioaerosol, thus allowing the characterization of the said particles.",GONZALEZ CRUZ JORGE E;;ORTIZ VEGA ALFREDO;;SALAZAR IZQUIERDO VICTOR M,GONZALEZ CRUZ JORGE E;;ORTIZ VEGA ALFREDO;;SALAZAR IZQUIERDO VICTOR M,,https://lens.org/159-828-033-747-837,Patent Application,yes,9,0,4,4,0,G01J3/4406;;G01N21/6402;;G01N21/6486;;G01J3/4406;;G01N21/6486;;G01N21/6402,G01J3/30;;G01N21/00,356/73;;356/318,0,0,,,,ACTIVE
22,US,A1,US 2008/0204746 A1,194-730-816-652-061,2008-08-28,2008,US 28279905 A,2005-11-18,US 28279905 A,2005-11-18,Novel optical sensor for the instantaneous detection and identification of bioaerosols,"The invention relates to an apparatus and a process of using the said apparatus in the in-time air sampling, detection and identification of bioaereosols; wherein identification of the said aerosol is based on a multiphoton laser diagnostic technique in combination with the velocity and aerodynamic size of the particular bioaerosol.",GONZALEZ CRUZ JORGE E;;VEGA ALFREDO ORTIZ;;SALAZAR IZQUIERDO VICTOR M,GONZALEZ CRUZ JORGE E;;VEGA ALFREDO ORTIZ;;SALAZAR IZQUIERDO VICTOR M,CARIBBEAN BIOTECHNOLOGIES INC (2006-11-09),https://lens.org/194-730-816-652-061,Patent Application,yes,18,10,4,4,0,G01J3/4406;;G01N21/6402;;G01N21/6486;;G01J3/4406;;G01N21/6486;;G01N21/6402,G01J3/42,356/319,0,0,,,,ACTIVE
23,WO,A1,WO 2020/190995 A1,179-879-013-088-657,2020-09-24,2020,US 2020/0023257 W,2020-03-18,US 201962893402 P;;US 201962819899 P,2019-03-18,DESALINATION SYSTEM,"A heating system for use in the solar powered heating of water. In one embodiment, the heating system is used in conjunction with a solar water farm to desalinate water. The water farm can be utilized on a variety of scales and can be applied to agricultural farms for large scale reclamation of deserts.",UNIV CITY NEW YORK RES FOUND;;SUN FRESH WATER LLC,SADEGH ALI;;GONZALEZ-CRUZ JORGE;;D'ALBA JOSEPH;;ST PIERRE GEORGE;;FARINICK GEORGE,,https://lens.org/179-879-013-088-657,Patent Application,yes,6,4,4,5,0,B01D3/02;;C02F1/14;;C02F2201/009;;C02F2209/02;;C02F2103/08;;B01D1/0035;;B01D1/0082;;B01D5/006;;B01D1/0035;;B01D3/02;;C02F1/14;;C02F2103/08;;C02F2201/009,B01D1/00;;B01D3/02;;C02F1/14;;C02F1/26,,0,0,,,,PENDING
24,US,B2,US 10150050 B2,051-143-609-941-459,2018-12-11,2018,US 201715628890 A,2017-06-21,US 201715628890 A;;US 201514969076 A;;US 201662352706 P;;US 201462091888 P;;US 201562186779 P,2014-12-15,Solar powered water purification device with cylindrical structure,"A device for purifying water by solar power is described. The device has bottom and top sections, each being half-cylinders contacting one another along a flat edge to provide an elongated cylinder. The bottom section has an evacuated area with an optically transparent bottom surface that light can pass through to heat a liquid tray in the top section. A side-gutter directs water that condenses on an interior surface of the top section to an output port for collection.",UNIV CITY NEW YORK RES FOUND;;SUN FRESH WATER LLC,SADEGH ALI M;;GONZALEZ-CRUZ JORGE E;;D'ALBA JOSEPH JAMES;;ST PIERRE GEORGE VICTOR,SUN FRESH WATER LLC (2016-04-21);;RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (2016-01-05),https://lens.org/051-143-609-941-459,Granted Patent,yes,16,2,2,4,0,B01D5/0066;;Y02A20/212;;Y02A20/142;;B01D1/0035;;B01D1/04;;B01D3/085;;B01D3/02;;C02F1/14;;C02F1/08;;C02F2201/009;;C02F2103/08;;B01D1/0035;;B01D1/04;;B01D3/085;;B01D3/02;;C02F1/14;;C02F1/08;;C02F2201/009;;C02F2103/08;;B01D5/0066;;Y02A20/212;;Y02A20/142,B01D1/04;;B01D1/00;;B01D3/02;;B01D3/08;;B01D5/00;;C02F1/08;;C02F1/14;;C02F103/08,,13,10,022-489-263-946-928;;062-334-295-499-442;;041-983-843-565-788;;045-509-777-815-095;;163-867-243-081-160;;117-857-402-008-861;;085-391-822-076-376;;000-994-493-562-099;;125-997-624-408-144;;047-467-938-730-069,10.1016/s0306-2619(98)00018-x;;10.1016/j.desal.2004.08.013;;10.1016/j.renene.2008.03.013;;10.1016/j.renene.2010.08.009;;10.1016/j.desal.2010.09.032;;10.1016/j.desal.2010.10.062;;10.1016/j.desal.2012.02.013;;10.5402/2012/569381;;10.1016/j.ijheatmasstransfer.2009.10.008;;10.1063/1.1619206,"http://mathworld.wolfram.com/HorizontalCylindricalSegment.html (accessed Jun. 22, 2018).;;Kalogirou, Soteris; Use of parabolic trough solar energy collectors for sea-water desalination; Applied Energy; 1998; pp. 65-88; vol. 60; Elsevier.;;Al-Hayek, I. et al; The effect of using different designs of solar stills on water distillation; Desalination; 2004; pp. 121-127; vol. 169; Elsevier.;;Ismail, Basel I.; Design and performance of a transportable hemispherical solar still; Renewable Energy; Jul. 2, 2008; pp. 145-150; vol. 34; Elsevier.;;Murugavel, K. et al.; Performance study on basin type double slope solar still with different wick materials and minimum mass of water; Renewable Energy; Aug. 25, 2010; pp. 612-620; vol. 36; Elsevier.;;Mahdi, J.T. et al.; An experimental wick-type solar still system: Design and construction; Desalination; Nov. 9, 2010; pp. 233-238 vol. 267; Elsevier.;;Esfahani, J. et al.; Utilization of thermoelectric cooling in a portable active solar still—An experimental study on winter days; Desalination; Nov. 26, 2010; pp. 198-205 vol. 269; Elsevier.;;Ahsan, A. et al.; Design, fabrication and performance analysis of an improved solar still; Desalination; Mar. 13, 2012; pp. 105-112 vol. 292; Elsevier.;;Arunkumar, T. et al.; An experimental study on a hemispherical solar still; Desalination; Dec. 21, 2011; pp. 342-348 vol. 286; Elsevier.;;Arunkumar, T. et al.; Experimental Study on Various Solar Still Designs; ISRN Renewable Energy; 2012; pp. 1-10; vol. 2012, Article ID 569381.;;Forrest, E. et al.; Augmentation of nucleate boiling heat transfer and critical heat flux using nanoparticle thin-film coatings; International Journal of Heat and Mass Transfer; Oct. 31, 2009; pp. 58-67; vol. 53; Elsevier.;;Chu, K. et al.; Structured surfaces for enhanced pool boiling heat transfer; Applied Physics Letters; Jun. 11, 2012; pp. 1-4; vol. 100; AIP Publishing.;;You, S.M. et al.; Effect of nanoparticles on critical heat flux of water in pool boiling heat transfer; Applied Physics Letters; Oct. 20, 2003; vol. 83, No. 16; American Institute of Physics.",ACTIVE
25,US,A1,US 2017/0291118 A1,070-053-363-585-30X,2017-10-12,2017,US 201715628890 A,2017-06-21,US 201715628890 A;;US 201514969076 A;;US 201662352706 P;;US 201462091888 P;;US 201562186779 P,2014-12-15,SOLAR POWERED WATER PURIFICATION DEVICE WITH CYLINDRICAL STRUCTURE,"A device for purifying water by solar power is described. The device has bottom and top sections, each being half-cylinders contacting one another along a flat edge to provide an elongated cylinder. The bottom section has an evacuated area with an optically transparent bottom surface that light can pass through to heat a liquid tray in the top section. A side-gutter directs water that condenses on an interior surface of the top section to an output port for collection.",UNIV CITY NEW YORK RES FOUND;;SUN FRESH WATER LLC,SADEGH ALI M;;GONZALEZ-CRUZ JORGE E;;D'ALBA JOSEPH JAMES;;ST PIERRE GEORGE VICTOR,SUN FRESH WATER LLC (2016-04-21);;RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (2016-01-05),https://lens.org/070-053-363-585-30X,Patent Application,yes,0,3,2,4,0,B01D5/0066;;Y02A20/212;;Y02A20/142;;B01D1/0035;;B01D1/04;;B01D3/085;;B01D3/02;;C02F1/14;;C02F1/08;;C02F2201/009;;C02F2103/08;;B01D1/0035;;B01D1/04;;B01D3/085;;B01D3/02;;C02F1/14;;C02F1/08;;C02F2201/009;;C02F2103/08;;B01D5/0066;;Y02A20/212;;Y02A20/142,B01D1/00;;B01D1/04;;B01D3/02;;B01D3/08;;C02F1/08;;C02F1/14,,0,0,,,,ACTIVE
26,US,A1,US 2019/0139163 A1,045-021-128-701-590,2019-05-09,2019,US 201816189624 A,2018-11-13,US 201816189624 A;;US 201414530099 A;;US 201762584294 P,2014-10-31,METHOD FOR FORECASTING ENERGY DEMANDS THAT INCORPORATES URBAN HEAT ISLAND,"A method for forecasting energy demand for a single building, a neighborhood or a city in an urban environment is disclosed. The method balances energy production between (1) a renewable energy source and (2) an energy grid source based in predicted demand and predicted supply. The method treats urban heat island (UHI) calculations as being dynamically impacted by predicted weather conditions to calculate a weather-adjusted UHI. Predicted energy consumption rates for weather conditions use the weather-adjusted UHI to increase accuracy of the prediction.",UNIV CITY NEW YORK RES FOUND,GONZALEZ-CRUZ JORGE E;;AREND MARK;;LEGBANDT THOMAS;;GUTIERREZ ESTATIO;;MOSHARY FRED;;ORTIZ LUIS,RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (2015-10-26),https://lens.org/045-021-128-701-590,Patent Application,yes,0,5,1,2,0,G06Q50/06;;G06Q10/04;;Y02A30/60;;Y04S10/50;;Y02A30/00;;G06Q50/06;;G06N5/04;;G05D23/1934;;G05B2219/2642;;G06Q10/04;;Y02A30/60,G06Q50/06;;G06N5/04,,0,0,,,,DISCONTINUED
27,CU,A1,CU 21630 A1,157-377-953-669-533,1987-10-12,1987,CU 36216 A,1984-11-28,CU 36216 A,1984-11-28,OCTOGONAL CAGE SYSTEM FOR INTENSIVE FISH BREEDING,,PROYECTOS NAVALES CENTRO,CRUZ INCLAN JORGE FELIX;;GONZALEZ ARTURO;;FERNANDEZ AZQUI ROBERTO;;MARIN ALONSO LUIS;;ALVAREZ MCRITTY FIDEL,,https://lens.org/157-377-953-669-533,Limited Patent,no,0,0,1,1,0,,A01K63/00,,0,0,,,,EXPIRED
28,US,B2,US 11401174 B2,118-012-640-847-646,2022-08-02,2022,US 202017440951 A,2020-03-18,US 202017440951 A;;US 201962819899 P;;US 201962893402 P;;US 2020/0023257 W,2019-03-18,Desalination system,A heating system for use in the solar powered heating of water. The heating system is used in conjunction with a solar water farm to desalinate water. The water farm can be utilized on a variety of scales and can be applied to agricultural farms for large scale reclamation of deserts.,UNIV CITY NEW YORK RES FOUND;;SUN FRESH WATER LLC,SADEGH ALI M;;GONZALEZ-CRUZ JORGE E;;D'ALBA JOSEPH JAMES;;ST PIERRE GEORGE VICTOR;;FARINICK GEORGE,SUN FRESH WATER LLC (2021-07-03);;RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (2021-08-23),https://lens.org/118-012-640-847-646,Granted Patent,yes,25,0,4,5,0,B01D3/02;;C02F1/14;;C02F2201/009;;C02F2209/02;;C02F2103/08;;B01D1/0035;;B01D1/0082;;B01D5/006;;B01D1/0035;;B01D3/02;;C02F1/14;;C02F2103/08;;C02F2201/009,C02F1/14;;B01D1/00;;B01D3/02;;C02F103/08,,1,0,,,"ISA/US; International Search Report/Written Opinion for corresponding International Application PCT/US2020/023257 dated Jun. 26, 2020.",ACTIVE
29,AU,A1,AU 2020/240036 A1,163-449-856-319-213,2021-11-04,2021,AU 2020/240036 A,2020-03-18,US 201962893402 P;;US 201962819899 P;;US 2020/0023257 W,2019-03-18,Desalination system,"A heating system for use in the solar powered heating of water. In one embodiment, the heating system is used in conjunction with a solar water farm to desalinate water. The water farm can be utilized on a variety of scales and can be applied to agricultural farms for large scale reclamation of deserts.",UNIV CITY NEW YORK RES FOUND;;SUN FRESH WATER LLC,SADEGH ALI M;;GONZALEZ-CRUZ JORGE E;;D'ALBA JOSEPH JAMES;;ST PIERRE GEORGE VICTOR;;FARINICK GEORGE,,https://lens.org/163-449-856-319-213,Patent Application,no,0,0,4,5,0,B01D3/02;;C02F1/14;;C02F2201/009;;C02F2209/02;;C02F2103/08;;B01D1/0035;;B01D1/0082;;B01D5/006;;B01D1/0035;;B01D3/02;;C02F1/14;;C02F2103/08;;C02F2201/009,B01D1/00;;B01D3/02;;C02F1/14;;C02F1/26,,0,0,,,,PENDING
30,US,A1,US 2022/0363566 A1,045-372-356-705-504,2022-11-17,2022,US 202217878581 A,2022-08-01,US 202217878581 A;;US 202117440951 A;;US 2020/0023257 W;;US 201962893402 P;;US 201962819899 P,2019-03-18,DESALINATION SYSTEM,"A heating system for use in the solar powered heating of water. In one embodiment, the heating system is used in conjunction with a solar water farm to desalinate water. The water farm can be utilized on a variety of scales and can be applied to agricultural farms for large scale reclamation of deserts.",UNIV CITY NEW YORK RES FOUND;;SUN FRESH WATER LLC,SADEGH ALI M;;GONZALEZ-CRUZ JORGE E;;D'ALBA JOSEPH JAMES;;ST PIERRE GEORGE VICTOR;;FARINICK GEORGE,,https://lens.org/045-372-356-705-504,Patent Application,yes,0,0,1,5,0,Y02A20/212;;C02F1/14;;C02F1/048;;C02F2103/08;;C02F2103/365;;C02F2303/24;;C02F2201/009;;B01D1/0035;;C02F1/14;;C02F2103/08;;C02F1/048;;C02F1/043,C02F1/14;;C02F1/04,,0,0,,,,PENDING
31,WO,A2,WO 2024/015977 A2,167-806-851-277-091,2024-01-18,2024,US 2023/0070235 W,2023-07-14,US 202263389678 P;;US 202263401874 P;;US 202363488636 P;;US 202363503086 P,2022-07-15,THERMAL DESALINATION SYSTEM,"A thermal desalination system connected to a heat source, such as a power plant that generates waste heat, that produces a heated liquid. The heated liquid is routed to a heat exchanger and/or a desalination device before being returned to the heat source. When present, the heat exchanger preheats water for subsequent purification by distillation, thereby producing potable water.",UNIV CITY NEW YORK RES FOUND;;SUN FRESH WATER LLC,SADEGH ALI M;;GONZALEZ-CRUZ JORGE E;;D'ALBA JOSEPH JAMES;;ST PIERRE GEORGE VICTOR;;FARINICK GEORGE,,https://lens.org/167-806-851-277-091,Patent Application,yes,0,0,1,1,0,Y02A20/124;;C02F1/14,C02F1/14,,0,0,,,,PENDING
32,US,A1,US 2022/0089461 A1,181-910-896-747-330,2022-03-24,2022,US 202017440951 A,2020-03-18,US 202017440951 A;;US 201962819899 P;;US 201962893402 P;;US 2020/0023257 W,2019-03-18,DESALINATION SYSTEM,"A heating system for use in the solar powered heating of water. In one embodiment, the heating system is used in conjunction with a solar water farm to desalinate water. The water farm can be utilized on a variety of scales and can be applied to agricultural farms for large scale reclamation of deserts.",UNIV CITY NEW YORK RES FOUND;;SUN FRESH WATER LLC,SADEGH ALI M;;GONZALEZ-CRUZ JORGE E;;D'ALBA JOSEPH JAMES;;ST PIERRE GEORGE VICTOR;;FARINICK GEORGE,SUN FRESH WATER LLC (2021-07-03);;RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (2021-08-23),https://lens.org/181-910-896-747-330,Patent Application,yes,0,0,4,5,0,B01D3/02;;C02F1/14;;C02F2201/009;;C02F2209/02;;C02F2103/08;;B01D1/0035;;B01D1/0082;;B01D5/006;;B01D1/0035;;B01D3/02;;C02F1/14;;C02F2103/08;;C02F2201/009,C02F1/14;;B01D1/00;;B01D3/02,,0,0,,,,ACTIVE
33,MX,A,MX 2015014004 A,115-218-993-626-042,2017-04-03,2017,MX 2015014004 A,2015-10-02,MX 2015014004 A,2015-10-02,FRUCTOOLIGOSACCHARIDES PRODUCTION PROCESS FROM SUCROSE BY USING YEAST PERMEATED CELLS OF THE CANDIDA GENUS.,"The present disclosure is related to the fructooligosaccharides production, using yeast permeated cells of the Candida genus. As an example of the present invention, those obtained from apicultural Candida NRRL Y-67124. The characteristic details of the present invention are related to a permeated cells production process, a method for formulating a substrate for an enzymatic reaction, a fructooligosaccharides production process by means of enzymatic synthesis from any sucrose source using the permeated cells.",CENTRO DE INVESTIGACIÓN Y ASISTENCIA EN TECNOLOGÍA Y DISEÑO DEL ESTADO DE JALISCO A C,JORGE ALBERTO RODRIGUEZ GONZALEZ;;DR JAVIER PLACIDO ARRIZON GAVIÑO;;DRA LORENA AMAYA DELGADO;;LUIS ENRIQUE ORDAZ CRUZ,,https://lens.org/115-218-993-626-042,Patent Application,no,0,0,1,1,0,,C12N1/16;;C07H3/06;;C12P19/00,,0,0,,,,PENDING
34,CU,A1,CU 22411 A1,080-149-604-653-801,1996-01-31,1996,CU 1993036 A,1993-04-06,CU 1993036 A,1993-04-06,COMPUTERIZED ROTOMETER FOR RODENTS,"PERTENECE AL CAMPO DE LA MEDICION DE MAGNITUDES FISICAS, PARTICULARMENTE A LA RAMA DE LA INDICACION DE VUELTAS Y SU OBJETIVO ES EVALUAR DE FORMA TOTALMENTE AUTOMATIZADA EL COMPORTAMIENTO ROTACIONAL EN ROEDORES SOMETIDOS A EXPERIMENTO. EL ROTOMETRO ESTA COMPUESTO POR: RECIPIENTES (1-1,....,1-4); DONDE SE SITUAN LOS ROEDORES SOMETIDOS AL EXPERIMENTO, UNO EN CADA RECIPIENTE. DETECTORTES DE ROTACION (2-1,...,2-4); SON DISPOSITIVOS ELECTROMECANICOS SITUADOS EN LA PARTE SUPERIOR DE LOS RECIPIENTES; QUE SE INTERCONECTAN CON EL INDICADOR DE ROTACION (3) MEDIANTE UN CABLE, SU FUNCION ES DAR SEÑALES ELECTRICAS CADA VEZ QUE EL ROEDOR DE UNA VUELTA. INDICADOR DE ROTACION (3); ES UN BLOQUE DE ELEMENTOS (PLACA O TARJETA) QUE VA SITUADO DENTRO DE UNA MICROCOMPUTADORA IBM-COMPATIBLE (4), EL CUAL PERMITE CONFORMAR LAS SEÑALES ENTREGADAS POR LOS DETECTORES DE ROTACION Y, MEDIANTE EL BUS DE LA MICROCOMPUTADORA, INDICAR AL ASEGURAMIENTO DE PROGRAMA (5) QUE UNO O VARIOS ROEDORES COMPLETARON UNA VUELTA , ASI COMO EL SENTIDO DE LAS MISMAS; A CADA PLACA PUEDEN CONECTARSE HASTA 4 DETECTORES DE ROTACION. ASEGURAMIENTO DE PROGRAMA (5); RECOPILA LOS DATOS ENTREGADOS POR EL INDICADOR DE ROTACION (3) EN EL TIEMPO, OBTIENE LA FRECUENCIA DE VUELTAS POR MINUTO DE HASTA 4 ROEDORES SIMULTANEAMENTE, GENERA TABLAS Y GRAFICAS PARA CADA ROEDOR DEL GRUPO EXPERIMENTAL Y EL PROMEDIO DEL GRUPO COMPLETO; ADEMAS REALIZA EL ALMACENAMIENTO EN MEMORIA DE LOS DATOS POR GRUPO PARA UN POSTERIOR ANALISIS ESTADISTICO. LOS RESULTADOS PUEDEN SER VISUALIZADOS EN LA PANTALLA DE LA MICROCOMPUTADORA O IMPRIMIDOS EN UN IMPRESOR ACOPLADO A LA MISMA.\!",INST CENTRAL DE INVESTIGACIONE,CRUZ HERNANDEZ ANGEL G;;RODRIGUEZ SALAVER ALLIE;;NIUBO JORGE IRENE DE LA C;;GONZALEZ SANCHEZ DAVID F;;ALONSO HERNANDEZ PEDRO,,https://lens.org/080-149-604-653-801,Limited Patent,no,0,0,1,1,0,,G01P13/04,,0,0,,,,EXPIRED
35,ES,B2,ES 2265714 B2,154-125-791-375-371,2008-06-01,2008,ES 200400611 A,2004-03-12,ES 200400611 A,2004-03-12,PROCEDIMIENTO DE OBTENCION DE EXTRACTOS ANTIOXIDANTES A PARTIR DE BAGAZO DE UVA FERMENTADO Y DESTILADO.,"Procedimiento de obtención de extractos antioxidantes a partir de bagazo de uva fermentado y destilado y utilización de los extractos como antioxidantes. El procedimiento se lleva a cabo mediante separación del líquido contenido en el residuo sólido procedente de la industria alcoholera, por prensado, filtración o centrifugado, lavado con agua del sólido de la etapa anterior, unión de las dos fases líquidas obtenidas en las anteriores operaciones en una sola, filtración o centrifugado de la misma, extracción de dicho líquido con disolventes apolares, destilación de la fase orgánica una vez separada de la fase acuosa y deshidratación del residuo.",UNIV SANTIAGO COMPOSTELA,PINELO JIMENEZ MANUEL;;SINEIRO TORRES JORGE;;NUNEZ GARCIA MARIA JOSE;;MOURE VARELA ANDRES;;CRUZ FREIRE JOSE MANUEL;;DOMINGUEZ GONZALEZ HERMINIA,,https://lens.org/154-125-791-375-371,Granted Patent,no,0,0,2,2,0,A61K35/00;;A61Q19/08;;A23L33/105,A23L33/105;;A23L3/3472;;A61K35/00;;A61P17/18;;A61Q19/08,,0,0,,,,ACTIVE
36,ES,A1,ES 2265714 A1,128-303-062-984-800,2007-02-16,2007,ES 200400611 A,2004-03-12,ES 200400611 A,2004-03-12,Production of anti oxidant extracts from grape bagasse comprises centrifugation of the liquid separated from the wine waste and mixed with wash water for extraction of apolar solvents,"The production of anti-oxidant extracts from grape bagasse has separation of the liquid from the wine-making solid waste by pressing, filtration or centrifugation. Filtration and centrifugation of the liquid mixed with water meanwhile used to wash the solid matter, is followed by extraction of the liquid by apolar solvents. EMBODIMENT - Distillation of the organic phase separated from the aqueous phase, and dehydration of the residue, complete the process.",UNIV SANTIAGO COMPOSTELA,PINELO JIMENEZ MANUEL;;SINEIRO TORRES JORGE;;NUNEZ GARCIA MARIA JOSE;;MOURE VARELA ANDRES;;CRUZ FREIRE JOSE MANUEL;;DOMINGUEZ GONZALEZ HERMINIA,,https://lens.org/128-303-062-984-800,Patent Application,no,2,1,2,2,0,A61K35/00;;A61Q19/08;;A23L33/105,A23L33/105;;A23L3/3472;;A61K35/00;;A61P17/18;;A61Q19/08,,3,3,086-595-430-896-253;;081-194-519-839-627;;003-704-029-148-602,10.1016/s0308-8146(99)00046-1;;10.1016/s0308-8146(97)00128-3;;10.1016/s0308-8146(00)00223-5,"BONILLA, F. et al. Extraction of phenolic compounds from red grape marc for use as food lipid antioxidants. Food Chemistry. 1999, Vol. 66, p�ginas 209-215.;;PEKIC, B. et al. Stydy of the extraction of proanthocyanidins from grape seeds. Food Chemistry. 1998, Vol. 61, N� 1/2, p�ginas 201-206.;;MOURE, A. et al. Natural antioxidants from residual sources. Food Chemistry. 01.02.2001. Vol. 72, N� 2,p�ginas 145-171.",ACTIVE
37,US,A1,US 2023/0265438 A1,145-278-318-339-309,2023-08-24,2023,US 202117999956 A,2021-05-26,EP 20382449 A;;EP 20382947 A;;EP 2021064077 W,2020-05-27,NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL,"The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.",ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE;;SILENCE THERAPEUTICS GMBH,SCHAEPER UTE;;DAMES SIBYLLE;;SCHUBERT STEFFEN;;MARTÍNEZ DE LA CRUZ ALFONSO;;SIMÓN ESPINOSA JORGE;;GONZALEZ RECIO IRENE;;MARTÍNEZ CHANTAR MARÍA LUZ,ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (2022-05-05);;SILENCE THERAPEUTICS GMBH (2022-11-25),https://lens.org/145-278-318-339-309,Patent Application,yes,0,0,7,7,554,C12N15/1138;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;C12N15/113;;A61K48/00;;A61K31/713;;A61K47/549;;A61P1/16;;A61P13/12;;A61P11/00;;C12N2310/312;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;A61K47/549;;A61P1/16;;A61K31/713;;C12N15/1138,C12N15/113;;A61K31/713;;A61K47/54;;A61P1/16,,0,0,,,,PENDING
38,ES,B2,ES 2249979 B2,129-134-933-553-806,2007-07-16,2007,ES 200400889 A,2004-04-13,ES 200400889 A,2004-04-13,DISPOSITIVO DEFLECTOR PARA EVITAR LA ROTURA DE GRANO EN LOS ELEVADORES DE CANGILONES EN MOLINOS ARROCEROS Y SIMILARES.,"Dispositivo deflector para evitar la rotura de grano en los elevadores de cangilones en molinos arroceros y similares. En el sistema de transporte y elevación de arroz y otros cereales, actualmente utilizado mediante cintas sinfín (2) provistas de cangilones (1), se produce un porcentaje significativo de grano roto que tiene un precio sensiblemente inferior en el mercado y reduce la calidad de producción. Se minimiza este problema al incorporar en la parte baja del elevador, sobre la polea (3) de la cinta sinfín (2), una placa metálica oblicua (11) que se extiende verticalmente por los laterales para quedar sujeta a las placas de anclaje de los soportes de cojinete (7) del eje horizontal (9) de la polea aludida (3). El dispositivo deflector que materializa la placa metálica (11), se forma con dos piezas (12 y 13) que se acoplan entre sí mediante tornillos periféricos. Los bordes laterales de la superficie oblicua (14) están provistos de cintas de flecos (22) de apoyo sobre los ramales de lacinta de transporte (2). Ambas piezas (12 y 13) están provistas de sendas ranuras longitudinales centrales (18 y 19) para permitir su montaje independiente y que por ellas pase la chapa (6) de separación de los conductos de elevación y bajada del elevador.",IND LUIS PERIS S A,GOMEZ-SENENT MARTINEZ ELISEO;;ALCAIDE MARZAL JORGE;;DIEGO MAS JOSE ANTONIO;;FERRER GISBERT PABLO;;GOMEZ NAVARRO TOMAS;;GONZALEZ CRUZ M CARMEN,,https://lens.org/129-134-933-553-806,Granted Patent,no,0,0,2,2,0,B65G17/30,B65G17/30,,0,0,,,,INACTIVE
39,AU,A1,AU 2021/281511 A1,110-657-568-176-442,2023-01-05,2023,AU 2021/281511 A,2021-05-26,EP 20382449 A;;EP 20382947 A;;EP 2021064077 W,2020-05-27,Nucleic acids for inhibiting expression of CNNM4 in a cell,"The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.",ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE,SCHAEPER UTE;;DAMES SIBYLLE;;SCHUBERT STEFFEN;;DE LA CRUZ ALFONSO MARTINEZ;;ESPINOSA JORGE SIMON;;RECIO IRENE GONZALEZ;;CHANTAR MARIA LUZ MARTINEZ,,https://lens.org/110-657-568-176-442,Patent Application,no,0,0,7,7,0,C12N15/1138;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;C12N15/113;;A61K48/00;;A61K31/713;;A61K47/549;;A61P1/16;;A61P13/12;;A61P11/00;;C12N2310/312;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;A61K47/549;;A61P1/16;;A61K31/713;;C12N15/1138,C12N15/113;;A61K31/713;;A61P3/06;;A61P3/12;;A61P11/00;;A61P13/12;;C07H21/02,,0,0,,,,PENDING
40,CA,A1,CA 3184050 A1,168-046-689-896-480,2021-12-02,2021,CA 3184050 A,2021-05-26,EP 20382449 A;;EP 20382947 A;;EP 2021064077 W,2020-05-27,NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL,"The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.",ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE,SCHAEPER UTE;;DAMES SIBYLLE;;SCHUBERT STEFFEN;;DE LA CRUZ ALFONSO MARTINEZ;;ESPINOSA JORGE SIMON;;RECIO IRENE GONZALEZ;;CHANTAR MARIA LUZ MARTINEZ,,https://lens.org/168-046-689-896-480,Patent Application,no,0,0,7,7,554,C12N15/1138;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;C12N15/113;;A61K48/00;;A61K31/713;;A61K47/549;;A61P1/16;;A61P13/12;;A61P11/00;;C12N2310/312;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;A61K47/549;;A61P1/16;;A61K31/713;;C12N15/1138,A61K31/713;;A61P3/06;;A61P3/12;;A61P11/00;;A61P13/12;;C07H21/02;;C12N15/113,,0,0,,,,PENDING
41,EP,A1,EP 4158023 A1,071-273-573-903-901,2023-04-05,2023,EP 21731058 A,2021-05-26,EP 20382449 A;;EP 20382947 A;;EP 2021064077 W,2020-05-27,NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL,,ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE,SCHAEPER UTE;;DAMES SIBYLLE;;SCHUBERT STEFFEN;;DE LA CRUZ ALFONSO MARTINEZ;;ESPINOSA JORGE SIMON;;RECIO IRENE GONZALEZ;;CHANTAR MARIA LUZ MARTINEZ,,https://lens.org/071-273-573-903-901,Patent Application,yes,0,0,7,7,0,C12N15/1138;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;C12N15/113;;A61K48/00;;A61K31/713;;A61K47/549;;A61P1/16;;A61P13/12;;A61P11/00;;C12N2310/312;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;A61K47/549;;A61P1/16;;A61K31/713;;C12N15/1138,C12N15/113;;A61K31/713;;A61P3/06;;A61P3/12;;A61P11/00;;A61P13/12;;C07H21/02,,0,0,,,,PENDING
42,ES,A1,ES 2249979 A1,067-162-274-365-625,2006-04-01,2006,ES 200400889 A,2004-04-13,ES 200400889 A,2004-04-13,"Baffle plate device for avoiding breakage of bucket elevator in rice mills, has metallic plate that vertically extends between lateral anchor plates of bearing supports arranged with respect to horizontal axis of pulleys of bucket elevator",The device has a metallic plate that vertically extends between lateral anchor plates of bearing supports arranged with respect to horizontal axis of pulleys of a bucket elevator. A deflector with two sections is coupled to the metallic plate with the use of peripheral screws. The metallic plate has an oblique surface whose lateral edges are provided with fringe support tapes branching over transport tape of bucket elevator. The sections of the deflector have longitudinal central grooves for permitting independent assembly and passage of separation plate of the elevator conduits and elevator slope. The bucket elevator is included in the transport and elevation of rice and other cereals.,IND LUIS PERIS S A,GOMEZ-SENENT MARTINEZ ELISEO;;ALCAIDE MARZAL JORGE;;DIEGO MAS JOSE ANTONIO;;FERRER GISBERT PABLO;;GOMEZ NAVARRO TOMAS;;GONZALEZ CRUZ M CARMEN,,https://lens.org/067-162-274-365-625,Patent Application,no,5,0,2,2,0,B65G17/30,B65G17/30,,0,0,,,,INACTIVE
43,WO,A1,WO 2021/239825 A1,114-948-821-003-293,2021-12-02,2021,EP 2021064077 W,2021-05-26,EP 20382449 A;;EP 20382947 A,2020-05-27,NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL,"The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.",SILENCE THERAPEUTICS GMBH;;ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE,SCHAEPER UTE;;DAMES SIBYLLE;;SCHUBERT STEFFEN;;DE LA CRUZ ALFONSO MARTINEZ;;ESPINOSA JORGE SIMON;;RECIO IRENE GONZALEZ;;CHANTAR MARIA LUZ MARTINEZ,,https://lens.org/114-948-821-003-293,Patent Application,yes,5,1,7,7,554,C12N15/1138;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;C12N15/113;;A61K48/00;;A61K31/713;;A61K47/549;;A61P1/16;;A61P13/12;;A61P11/00;;C12N2310/312;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;A61K47/549;;A61P1/16;;A61K31/713;;C12N15/1138,C12N15/113;;A61K31/713;;A61P3/06;;A61P3/12;;A61P11/00;;A61P13/12;;C07H21/02,,36,28,177-219-146-369-560;;000-603-861-384-601;;020-889-810-184-118;;042-817-626-361-589;;050-465-752-695-671;;018-020-177-526-297;;059-393-958-757-089;;030-947-399-044-830;;050-860-384-249-941;;030-380-024-697-291;;117-083-651-038-635;;000-603-861-384-601;;016-226-735-201-149;;107-369-963-620-633;;074-645-636-920-586;;098-128-668-802-045;;037-328-887-183-014;;162-192-995-063-548;;007-399-576-302-194;;016-369-411-268-45X;;017-844-374-123-898;;020-889-810-184-118;;029-953-786-324-918;;005-316-633-999-516;;055-262-725-856-021;;007-731-741-746-293;;000-051-774-250-370;;019-544-082-144-273,24339795;;pmc3854942;;10.1371/journal.pgen.1003983;;10.1093/jb/mvy095;;30476181;;pmc4348944;;10.1172/jci76614;;25347473;;pmc7321783;;10.1016/j.omtn.2020.05.026;;32590173;;33571553;;10.1016/j.jhep.2021.01.043;;pmc8217299;;9486653;;10.1038/35888;;10.1038/35078107;;11373684;;22069063;;10.1002/path.2993;;pmc3916955;;10.1002/hep.28431;;26707365;;31065991;;10.1007/s12325-019-00960-3;;pmc6824389;;26069819;;pmc4455825;;10.1093/ndtplus/sfr163;;10.1093/jb/mvy095;;30476181;;15486293;;10.1126/science.1103160;;24462317;;10.1016/j.metabol.2013.12.003;;12526714;;10.1021/bc0256244;;12223279;;10.1016/s0304-4165(02)00318-5;;7961705;;10.1016/s0021-9258(18)46855-x;;10.1021/jm00009a014;;7739012;;10.1038/mt.2010.85;;pmc2911264;;20461061;;18358718;;10.1016/j.bmcl.2008.03.013;;10.1016/s0021-9258(19)83641-4;;3838314;;pmc4348944;;10.1172/jci76614;;25347473;;10.1038/labinvest.2014.151;;25531568;;pmc4310762;;13428781;;10.1016/s0021-9258(18)64849-5;;27750004;;10.1021/jacs.6b07927;;25434769;;10.1021/ja505986a;;25753666;;pmc4381059;;25539914;;10.1093/nar/gku1336;;10.1093/nar/gkv137;;pmc4381043;;25712100;;pmc4381071;;pmc5570069;;10.1093/nar/gkx507;;28591791,"DAISUKE YAMAZAKI ET AL: ""Basolateral Mg2+ Extrusion via CNNM4 Mediates Transcellular Mg2+ Transport across Epithelia: A Mouse Model"", PLOS GENETICS, vol. 9, no. 12, 5 December 2013 (2013-12-05), pages e1003983, XP055592421, DOI: 10.1371/journal.pgen.1003983;;FUNATO YOSUKE ET AL: ""Molecular function and biological importance of CNNM family Mg2+ transporters"", JOURNAL OF BIOCHEMISTRY, vol. 165, no. 3, 11 November 2018 (2018-11-11), GB, pages 219 - 225, XP055793932, ISSN: 0021-924X, DOI: 10.1093/jb/mvy095;;YOSUKE FUNATO ET AL: ""Membrane protein CNNM4-dependent Mg2+ efflux suppresses tumor progression"", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 124, no. 12, 27 October 2014 (2014-10-27), GB, pages 5398 - 5410, XP055592288, ISSN: 0021-9738, DOI: 10.1172/JCI76614;;WEINGÄRTNER ADRIEN ET AL: ""Less Is More: Novel Hepatocyte-Targeted siRNA Conjugates for Treatment of Liver-Related Disorders"", MOLECULAR THERAPY: NUCLEIC ACIDS., vol. 21, 1 September 2020 (2020-09-01), US, pages 242 - 250, XP055794193, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2020.05.026;;SIMÓN JORGE ET AL: ""Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH"", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 75, no. 1, 9 February 2021 (2021-02-09), pages 34 - 45, XP086627269, ISSN: 0168-8278, [retrieved on 20210209], DOI: 10.1016/J.JHEP.2021.01.043;;FIRE ET AL., NATURE, vol. 391, no. 6669, 19 February 1998 (1998-02-19), pages 806 - 11;;ELBASHIR ET AL., NATURE, vol. 411, no. 6836, 24 May 2001 (2001-05-24), pages 494 - 8;;WATTSCOREY, JOURNAL OF PATHOLOGY, vol. 226, 2012, pages 365 - 379;;YOUNOSSI ET AL., HEPATOLOGY, vol. 64, 2016, pages 73 - 84;;POVSIC ET AL., ADV. THER., vol. 36, 2019, pages 1574 - 1594;;YOUNOSSI ET AL., CLIN. GASTROENTEROL. HEPATOL., vol. 4, 2018, pages 748 - 755;;BAAIJ ET AL., PHYSIOL. REV., vol. 1920, 2015, pages 1 - 46;;JAHNEN-DECHENT, CLIN. KIDNEY J., vol. 5, 2012, pages i3 - i14;;FUNATOMIKI, J. BIOCHEM., vol. 165, no. 3, 2019, pages 219 - 225;;OZCAN ET AL., SCIENCE, vol. 306, no. 80, 2004, pages 457;;BARBAGALLO ET AL., METABOLISM, vol. 63, 2014, pages 502 - 509;;DUBBER ET AL., BIOCONJUG. CHEM., vol. 14, no. 1, January 2003 (2003-01-01), pages 239 - 46;;WEIGEL, P.H., BIOCHIM. BIOPHYS. ACTA, vol. 1572, no. 2-3, 19 September 2002 (2002-09-19), pages 341 - 63;;ISHIBASHI,S., J BIOL. CHEM., vol. 269, no. 45, 11 November 1994 (1994-11-11), pages 27803 - 6;;BIESSEN EA ET AL., J MED CHEM., vol. 38, no. 9, 28 April 1995 (1995-04-28), pages 1538 - 46;;AKINC ET AL., MOL THER, vol. 18, no. 7, July 2010 (2010-07-01), pages 1357 - 64;;PARK, H. ET AL., BIOORG MED CHEM LETT, vol. 18, no. 7, 2008, pages 2250 - 5;;""Remington: The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;GRYNKIEWIZ ET AL., J BIOL CHEM., vol. 260, no. 6, 1985, pages 3440 - 50;;""Encyclopaedia of Pharmaceutical Technology"", 2007, INFORMA HEALTHCARE USA (INC.;;J. PHARM. SCI., vol. 66, 1977, pages 2;;FUNATO ET AL., J CLIN INVEST, vol. 124, no. 12, 2014, pages 5398 - 5410;;FERNANDEZ-ALVAREZ ET AL., LAB INVEST, vol. 95, no. 2, 2015, pages 223 - 36;;WAGNER ET AL., TOXICOL APPL PHARMACOL, vol. 237, no. 2, 2009, pages 246;;FOLCH ET AL., J BIOL CHEM., vol. 226, no. 1, 1957, pages 497 - 509;;GRUSKOS ET AL., J. AM. CHEM. SOC., vol. 138, no. 44, 2016, pages 14639 - 14649;;HOEVELMANN ET AL., CHEM. SCI., vol. 7, 2016, pages 128 - 135;;NAIR ET AL., J. AM. CHEM. SOC., vol. 136, no. 49, 2014, pages 16958 - 1696;;PRAKASH, NUCLEIC ACIDS RES., vol. 43, no. 6, 2015, pages 2993 - 3011;;HARASZTI, NUCLEIC ACIDS RES., vol. 45, no. 13, 2017, pages 7581 - 7592",PENDING
44,KR,A,KR 20230018429 A,180-173-503-312-181,2023-02-07,2023,KR 20227045417 A,2021-05-26,EP 20382449 A;;EP 20382947 A;;EP 2021064077 W,2020-05-27,세포에서 CNNM4의 발현을 억제하기 위한 핵산,"본 발명은 CNNM4(사이클린 M4) 유전자 발현을 방해하거나 억제하는 핵산 생성물에 관한 것이다. 또한 비-알코올성 지방간 질환 (NAFLD), 비-알코올성 지방간염 (NASH), 간 지방증, 간 섬유증, 간경변증, 간암 및 마그네슘 조절장애와 연관된 다른 질환을 포함하여 간 질환과 같은 질환의 치료에서의 CNNM4 억제의 치료적 용도에 관한 것이다.",ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE,SCHAEPER UTE;;DAMES SIBYLLE;;SCHUBERT STEFFEN;;DE LA CRUZ ALFONSO MARTINEZ;;ESPINOSA JORGE SIMON;;RECIO IRENE GONZALEZ;;CHANTAR MARIA LUZ MARTINEZ,,https://lens.org/180-173-503-312-181,Patent Application,no,0,0,7,7,0,C12N15/1138;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;C12N15/113;;A61K48/00;;A61K31/713;;A61K47/549;;A61P1/16;;A61P13/12;;A61P11/00;;C12N2310/312;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;A61K47/549;;A61P1/16;;A61K31/713;;C12N15/1138,C12N15/113;;A61K31/713;;A61K47/54;;A61K48/00;;A61P1/16;;A61P11/00;;A61P13/12,,0,0,,,,PENDING
45,DK,T3,DK 1611252 T3,089-621-286-915-223,2009-11-23,2009,DK 04723215 T,2004-03-25,ES 200300708 A;;EP 2004003219 W,2003-03-26,In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE;;MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SANTA CRUZ SIMON;;SAENZ JIMENEZ MARIA;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORINA,,https://lens.org/089-621-286-915-223,Granted Patent,no,0,0,9,9,0,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/574,,0,0,,,,ACTIVE
46,AT,T1,AT E437963 T1,107-347-605-832-284,2009-08-15,2009,AT 04723215 T,2004-03-25,ES 200300708 A;;EP 2004003219 W,2003-03-26,IN-VITRO VERFAHREN ZUM NACHWEIS EINES ÜBERGANGSZELLKARZINOMS DER BLASE,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SANTA CRUZ SIMON;;SAENZ JIMENEZ MARIA;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORINA;;GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE,,https://lens.org/107-347-605-832-284,Granted Patent,no,0,0,9,9,0,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/574,,0,0,,,,INACTIVE
47,US,A1,US 2007/0092878 A1,111-012-849-866-085,2007-04-26,2007,US 55060804 A,2004-03-25,ES 200300708 A;;EP 2004003219 W,2003-03-26,In vitro method to detect bladder transitional cell carcinoma,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,MARTINEZ ANTONIO M;;BUELA LAUREANO S;;CRUZ SIMON S;;JIMENEZ MARIA P S;;SANCHEZ-VALLEJO CORINA J;;ROMAN JOSE J G;;GONZALEZ JORGE C;;VILA MIGUEL M,PROGENIKA BIOPHARMA S.A (2005-10-24);;ONCONOMATRIX S.L (2011-12-19),https://lens.org/111-012-849-866-085,Patent Application,yes,1,11,9,9,18,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/53;;G01N33/574,435/6;;435/7.1;;435/7.23,0,0,,,,ACTIVE
48,EP,B1,EP 1611252 B1,193-124-853-616-928,2009-07-29,2009,EP 04723215 A,2004-03-25,EP 2004003219 W;;ES 200300708 A,2003-03-26,IN VITRO METHOD TO DETECT BLADDER TRANSITIONAL CELL CARCINOMA,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SANTA CRUZ SIMON;;SAENZ JIMENEZ MARIA PILAR;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORIN;;GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE,"ONCOMATRIX, S.L. (2012-03-21);;PROGENIKA BIOPHARMA, S.A. (2009-02-25);;ONCOMATRIX, S.L., ES (2012-05-24);;ONCOMATRIX, S.L., DERIO, ES (2012-05-24)",https://lens.org/193-124-853-616-928,Granted Patent,yes,0,3,9,9,0,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/574,,1,1,000-840-121-185-93X,pmc83965;;10.1128/mcb.19.3.1720;;10022859,"GYGI ET AL: ""Correlation between protein and mRNA abundance in yeast"", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 3, March 1999 (1999-03-01), pages 1720 - 1730, XP002923559",ACTIVE
49,US,B2,US 8124331 B2,005-290-035-143-897,2012-02-28,2012,US 55060804 A,2004-03-25,ES 200300708 A;;EP 2004003219 W,2003-03-26,In vitro method to detect bladder transitional cell carcinoma,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",MARTINEZ MARTINEZ ANTONIO;;BUELA LAUREANO SIMON;;SANTA CRUZ SIMON;;JIMENEZ MARIA PILAR SAENZ;;SANCHEZ-VALLEJO CORINA JUNQUERA;;ROMAN JOSE JAVIER GOMEZ;;GONZALEZ JORGE CUEVAS;;VILA MIGUEL MOLINA;;PROGENIKA BIOPHARMA SA,MARTINEZ ANTONIO MARTINEZ;;BUELA LAUREANO SIMON;;SANTA CRUZ SIMON;;JIMENEZ MARIA PILAR SAENZ;;SANCHEZ-VALLEJO CORINA JUNQUERA;;ROMAN JOSE JAVIER GOMEZ;;GONZALEZ JORGE CUEVAS;;VILA MIGUEL MOLINA,PROGENIKA BIOPHARMA S.A (2005-10-24);;ONCONOMATRIX S.L (2011-12-19),https://lens.org/005-290-035-143-897,Granted Patent,yes,3,2,9,9,18,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/00;;C12Q1/68;;G01N33/53;;G01N33/574,435/4;;435/7.1,5,4,051-074-275-622-311;;047-918-434-329-239;;034-655-610-437-746;;000-840-121-185-93X,14520460;;pmc2394287;;10.1038/sj.bjc.6601249;;10471491;;10.1038/12615;;9207791;;10.1038/ng0797-260;;pmc3901950;;pmc83965;;10.1128/mcb.19.3.1720;;10022859,"Matsumoto et al. (Oncol Rep. Nov. 2004;12(5):967-71, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/15492779?ordinalpos=85&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed-ResultsPanel.Pubmed-DefaultReportPanel.Pubmed-RVDocSum> on Oct. 5, 2009).;;Sturla et al. (FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells, British Journal of Cancer (2003) 89, pp. 1276-1284, published online on Sep. 30, 2003).;;Capellan, D., et al., Frequent Activating Mutations of FGFR3 in Human Bladder and Cervix Carcinomas, Nature Genetics, vol. 23, Sep. 1999.;;Chesi, M., et al., Frequent Translocation t(4;14)(p16.3;q32.3) in Multiple Myeloma is Associated with Increased Expression and Activating Mutations of Fibrolast Growth Factor Receptor 3, Nature Genetics, vol. 15, Jul. 1997.;;Gygi et al., Correlation between Protein and mRNA Abundance in Yeast. Molecular and Cellular Biology, Mar. 1999, vol. 19 No. 3 p. 1720-1730.",ACTIVE
50,EP,A1,EP 1611252 A1,096-446-889-802-664,2006-01-04,2006,EP 04723215 A,2004-03-25,EP 2004003219 W;;ES 200300708 A,2003-03-26,IN VITRO METHOD TO DETECT BLADDER TRANSITIONAL CELL CARCINOMA,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SANTA CRUZ SIMON;;SAENZ JIMENEZ MARIA PILAR;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORIN;;GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE,"ONCOMATRIX, S.L. (2012-03-21);;PROGENIKA BIOPHARMA, S.A. (2009-02-25);;ONCOMATRIX, S.L., ES (2012-05-24);;ONCOMATRIX, S.L., DERIO, ES (2012-05-24)",https://lens.org/096-446-889-802-664,Patent Application,yes,0,0,9,9,0,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/574,,0,0,,,,ACTIVE
51,WO,A1,WO 2004/085676 A1,155-584-292-802-681,2004-10-07,2004,EP 2004003219 W,2004-03-25,ES 200300708 A,2003-03-26,IN VITRO METHOD TO DETECT BLADDER TRANSITIONAL CELL CARCINOMA,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",MEDPLANT GENETICS S L;;MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SANTA CRUZ SIMON;;SAENZ JIMENEZ MARIA PILAR;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORIN;;GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE,MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SANTA CRUZ SIMON;;SAENZ JIMENEZ MARIA PILAR;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORIN;;GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE,,https://lens.org/155-584-292-802-681,Patent Application,yes,2,12,9,9,18,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/574,,2,2,047-918-434-329-239;;034-655-610-437-746,10471491;;10.1038/12615;;9207791;;10.1038/ng0797-260;;pmc3901950,"CAPPELLEN ET AL: ""Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas"", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 23, September 1999 (1999-09-01), pages 18 - 20, XP002181676, ISSN: 1061-4036;;CHESI M ET AL: ""FREQUENT TRANSLOCATION T(4;14)(P16.3;Q32.3) IN MULTIPLE MYELOMA IS ASSOCIATED WITH INCREASED EXPRESSION AND ACTIVATING MUTATIONS OF FIBROBLAST GROWTH FACTOR RECEPTOR 3"", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 16, no. 3, July 1997 (1997-07-01), pages 260 - 264, XP001030990, ISSN: 1061-4036",PENDING
52,US,B2,US 9309755 B2,131-079-057-993-184,2016-04-12,2016,US 201213644443 A,2012-10-04,US 201213644443 A;;US 201161544817 P,2011-10-07,Thermal expansion accommodation for circulated fluid systems used to heat subsurface formations,A method for accommodating thermal expansion of a heater in a formation includes flowing a heat transfer fluid through a conduit to provide heat to the formation and providing substantially constant tension to an end portion of the conduit that extends outside the formation. At least a portion of the end portion of the conduit is wound around a movable wheel used to apply tension to the conduit.,SHELL OIL CO,GONZALEZ MANUEL ALBERTO;;CRUZ ANTONIO MARIA GUIMARAES LEITE;;JUNG GONGHYUN;;NOEL JUSTIN MICHAEL;;OCAMPOS ERNESTO RAFAEL FONSECA;;PENSO JORGE ANTONIO;;HORWEGE JASON ANDREW;;LEVY STEPHEN MICHAEL;;RAGHU DAMODARAN,SHELL OIL COMPANY (2012-10-09),https://lens.org/131-079-057-993-184,Granted Patent,yes,101,2,10,10,0,E21B43/24;;E21B36/005;;E21B43/24;;E21B19/22;;E21B43/24,E21B19/22;;E21B43/24,,99,26,027-476-986-554-695;;144-630-415-131-714;;199-383-678-051-329;;150-325-886-123-725;;160-866-071-853-190;;053-708-580-600-404;;181-327-274-051-672;;156-686-774-914-874;;010-459-637-296-606;;116-682-625-924-228;;022-532-160-111-187;;014-356-032-370-707;;128-778-532-074-852;;038-965-603-173-956;;066-708-003-035-312;;034-896-162-245-341;;107-978-318-569-074;;029-824-941-903-610;;065-263-259-636-001;;020-545-242-728-164;;030-906-178-326-382;;059-490-777-040-761;;174-494-088-890-303;;005-480-587-707-475;;041-819-343-729-243;;031-962-957-134-825,10.2118/2210-pa;;10.1109/pcicon.1990.218105;;10.1021/bk-1983-0230.ch015;;10.1306/a96737b6-1738-11d7-8645000102c1865d;;10.1016/0016-2361(80)90195-7;;10.1021/i260035a006;;10.1021/bk-1983-0230.ch017;;10.1021/bk-1983-0230.ch001;;10.1021/bk-1981-0163.ch006;;10.1016/0016-2361(84)90336-3;;10.1021/ef00006a001;;10.1021/i200029a027;;10.1007/978-94-011-0317-6_16;;10.1016/0016-2361(79)90138-8;;10.2514/3.62552;;10.1016/0148-9062(76)90821-4;;10.2118/6730-ms;;10.1021/bk-1983-0230.ch024;;10.1016/0016-2361(83)90064-9;;10.1016/0016-2361(82)90260-5;;10.1016/0360-5442(92)90106-a;;10.1016/0168-1176(84)80079-8;;10.1016/0016-2361(78)90176-x;;10.1016/j.petrol.2004.06.005;;10.1109/28.120230;;10.2118/37117-ms,"Chinese Office Action for Chinese Office for Chinese Application 200980149452.7, mailed Dec. 13, 2012.;;Chinese Communication for Chinese Application No. 201080052180.8 mailed Jan. 31, 2013, 17 pages.;;Chinese Communication for Chinese Application No. 200980140451.2, mailed May 16, 2013.;;Chinese Communication for Chinese Application No. 200980140452.7, mailed Jul. 3, 2013, 11 pages.;;Russian Communication for Russian App. 2011119096, mailed Jun. 24, 2013.;;Australian Communication for Australian Patent Application No. 2010303253 mailed Jan. 4, 2013, 3 pages.;;Chinese Communication for Chinese Application No. 200980140451.2, mailed Nov. 29, 2013, 10 pages.;;PCT International Search Report, Application No. PCT/US2012/058582 dated Jan. 4, 2013.;;Some Effects of Pressure on Oil-Shale Retorting, Society of Petroleum Engineers Journal, J.H. Bae, Sep. 1969; pp. 287-292.;;New in situ shale-oil recovery process uses hot natural gas; The Oil & Gas Journal; May 16, 1966, p. 151.;;Evaluation of Downhole Electric Impedance Heating Systems for Paraffin Control in Oil Wells; Industry Applications Society 37th Annual Petroleum and Chemical Industry Conference; The Institute of Electrical and Electronics Engineers Inc., Bosch et al., Sep. 1990, pp. 223-227.;;New System Stops Paraffin Build-up; Petroleum Engineer, Eastlund et al., Jan. 1989, (3 pages).;;Oil Shale Retorting: Effects of Particle Size and Heating Rate on Oil Evolution and Intraparticle Oil Degradation; Campbell et al. In Situ 2(1), 1978, pp. 1-47.;;The Potential for In Situ Retorting of Oil Shale in the Piceance Creek Basin of Northwestern Colorado; Dougan et al., Quarterly of the Colorado School of Mines, pp. 57-72 1970.;;Retoring Oil Shale Underground-Problems & Possibilities; B.F. Grant, Qtly of Colorado School of Mines, pp. 39-46, 1960.;;Molecular Mechanism of Oil Shale Pyrolysis in Nitrogen and Hydrogen Atmospheres, Hershkowitz et al.; Geochemistry and Chemistry of Oil Shales, American Chemical Society, May, 1983 pp. 301-316.;;The Characteristics of a Low Temperature in Situ Shale Oil; George Richard Hill & Paul Dougan, Quarterly of the Colorado School of Mines, 1967; pp. 75-90.;;Direct Production of a Low Pour Point High Gravity Shale Oil; Hill et al., I & EC Product Research and Development, 6(1), Mar. 1967; pp. 52-59.;;Refining of Swedish Shale Oil, L. Lundquist, pp. 621-627, 1951.;;The Benefits of In Situ Upgrading Reactions to the Integrated Operations of the Orinoco Heavy-Oil Fields and Downstream Facilities, Myron Kuhlman, Society of Petroleum Engineers, Jun. 2000; pp. 1-14.;;Monitoring Oil Shale Retorts by Off-Gas Alkene/Alkane Ratios, John H. Raley, Fuel, vol. 59, Jun. 1980, pp. 419-424.;;The Shale Oil Question, Old and New Viewpoints, A Lecture in the Engineering Science Academy, Dr. Fredrik Ljungstrom, Feb. 23, 1950, published in Teknisk Trdskrift, Jan. 1951 p. 33-40.;;Underground Shale Oil Pyrolysis According to the Ljungstroem Method; Svenska Skifferolje Aktiebolaget (Swedish Shale Oil Corp.), IVA, vol. 24, 1953, No. 3, pp. 118-123.;;Kinetics of Low-Temperature Pyrolysis of Oil Shale by the IITRI RF Process, Sresty et al.; 15th Oil Shale Symposium, Colorado School of Mines, Apr. 1982 pp. 1-13.;;Bureau of Mines Oil-Shale Research, H.M. Thorne, Quarterly of the Colorado School of Mines, pp. 77-90, 1964.;;Application of a Microretort to Problems in Shale Pyrolysis, A. W. Weitkamp & L.C. Gutberlet, Ind. Eng. Chem. Process Des. Develop. vol. 9, No. 3, 1970, pp. 386-395.;;Oil Shale, Yen et al., Developments in Petroleum Science 5, 1976, pp. 187-189, 197-198.;;The Composition of Green River Shale Oils, Glenn L. Cook, et al., United Nations Symposium on the Development and Utilization of Oil Shale Resources, 1968, pp. 1-23.;;High-Pressure Pyrolysis of Green River Oil Shale, Burnham et al., Geochemistry and Chemistry of Oil Shales, American Chemical Society, 1983, pp. 335-351.;;Geochemistry and Pyrolysis of Oil Shales, Tissot et al., Geochemistry and Chemistry of Oil Shales, American Chemical Society, 1983, pp. 1-11.;;A Possible Mechanism of Alkene/Alkane Production, Burnham et al., Oil Shale, Tar Sands, and Related Materials, American Chemical Society, 1981, pp. 79-92.;;The Ljungstroem In-Situ Method of Shale Oil Recovery, G. Salomonsson, Oil Shale and Cannel Coal, vol. 2, Proceedings of the Second Oil Shale and Cannel Coal Conference, Institute of Petroleum, 1951, London, pp. 260-280.;;Developments in Technology for Green River Oil Shale, G.U. Dinneen, United Nations Symposium on the Development and Utilization of Oil Shale Resources, Laramie Petroleum Research Center, Bureau of Mines, 1968, pp. 1-20.;;The Thermal and Structural Properties of a Hanna Basin Coal, R.E. Glass, Transactions of the ASME, vol. 106, Jun. 1984, pp. 266-271.;;On the Mechanism of Kerogen Pyrolysis, Alan K. Burnham & James A. Happe, Jan. 10, 1984 (17 pages).;;Comparison of Methods for Measuring Kerogen Pyrolysis Rates and Fitting Kinetic Parameters, Burnham et al., Mar. 23, 1987, (29 pages).;;Further Comparison of Methods for Measuring Kerogen Pyrolysis Rates and Fitting Kinetic Parameters, Bumham et al., Sep. 1987, (16 pages).;;Shale Oil Cracking Kinetics and Diagnostics, Bissell et al., Nov. 1983, (27 pages).;;Mathematical Modeling of Modified in Situ and Aboveground Oil Shale Retorting, Robert L. Braun, Jan. 1981 (45 pages).;;Progress Report on Computer Model for In Situ Oil Shale Retorting, R.L. Braun & R.C.Y. Chin, Jul. 14, 1977 (34 pages).;;Chemical Kinetics and Oil Shale Process Design, Alan K. Burnham, Jul. 1993 (16 pages).;;Reaction Kinetics and Diagnostics for Oil Shale Retorting, Alan K. Burnham, Oct. 19, 1981 (32 pages).;;Reaction Kinetics Between Steam and Oil Shale Char, A.K. Burnham, Oct. 1978 (8 pages).;;General Kinetic Model of Oil Shale Pyrolysis, Alan K. Burnham & Robert L. Braun, Dec. 1984 (25 pages).;;Reaction Kinetics Between CO2 and Oil Shale Char, A.K. Burnham, Mar. 22, 1978 (18 pages).;;Reaction Kinetics Between CO2 and Oil Shale Residual Carbon. I. Effect of Heating Rate on Reactivity, Alan K. Burnham, Jul. 11, 1978 (22 pages).;;High-Pressure Pyrolysis of Colorado Oil Shale, Alan K. Burnham & Mary F. Singleton, Oct. 1982 (23 pages).;;A Possible Mechanism of Alkene/Alkane Production in Oil Shale Retorting, A.K. Burnham, R.L. Ward, Nov. 26, 1980 (20 pages).;;Enthalpy Relations for Eastern Oil Shale, David W. Camp, Nov. 1987 (13 pages).;;Oil Shale Retorting: Part 3 A Correlation of Shale Oil 1-Alkene/n-Alkane Ratios With Yield, Coburn et al., Aug. 1, 1977 (18 pages).;;The Composition of Green River Shale Oil, Glen L. Cook, et al., 1968 (12 pages).;;Thermal Degradation of Green River Kerogen at 150o to 350o C Rate of Production Formation, J.J. Cummins & W.E. Robinson, 1972 (18 pages).;;Retorting of Green River Oil Shale Under High-Pressure Hydrogen Atmospheres, LaRue et al., Jun. 1977 (38 pages).;;Retorting and Combustion Processes in Surface Oil-Shale Retorts, A.E. Lewis & R.L. Braun, May 2, 1980 (12 pages).;;Oil Shale Retorting Processes: A Technical Overview, Lewis et al., Mar. 1984 (18 pages).;;Study of Gas Evolution During Oil Shale Pyrolysis by Tams, Oh et al., Feb. 1988 (10 pages).;;The Permittivity and Electrical Conductivity of Oil Shale, A.J. Piwinskii & A. Duba, Apr. 28, 1975 (12 pages).;;Oil Degradation During Oil Shale Retorting, J.H. Raley & R.L. Braun, May 24, 1976 (14 pages).;;Kinetic Analysis of California Oil Shale by Programmed Temperature Microphyrolysis, John G. Reynolds & Alan K. Burnham, Dec. 9, 1991 (14 pages).;;Analysis of Oil Shale and Petroleum Source Rock Pyrolysis by Triple Quadrupole Mass Spectrometry: Comparisons of Gas Evolution at the Heating Rate of 10oC/Min., Reynolds et al. Oct. 5, 1990 (57 pages).;;Fluidized-Bed Pyrolysis of Oil Shale, J.H. Richardson & E.B. Huss, Oct. 1981 (27 pages).;;Retorting Kinetics for Oil Shale From Fluidized-Bed Pyrolysis, Richardson et al., Dec. 1981 (30 pages).;;Recent Experimental Developments in Retorting Oil Shale at the Lawrence Livermore Laboratory, Albert J. Rothman, Aug. 1978 (32 pages).;;The Lawrence Livermore Laboratory Oil Shale Retorts, Sandholtz et al. Sep. 18, 1978 (30 pages).;;Operating Laboratory Oil Shale Retorts in an In-Situ Mode, W. A. Sandholtz et al., Aug. 18, 1977 (16 pages).;;Some Relationships of Thermal Effects to Rubble-Bed Structure and Gas-Flow Patterns in Oil Shale Retorts, W. A. Sandholtz, Mar. 1980 (19 pages).;;Assay Products from Green River Oil Shale, Singleton et al., Feb. 18, 1986 (213 pages).;;Biomarkers in Oil Shale: Occurrence and Applications, Singleton et al., Oct. 1982 (28 pages).;;Occurrence of Biomarkers in Green River Shale Oil, Singleton et al., Mar. 1983 (29 pages).;;An Instrumentation Proposal for Retorts in the Demonstration Phase of Oil Shale Development, Clyde J. Sisemore, Apr. 19, 1977, (34 pages).;;Pyrolysis Kinetics for Green River Oil Shale From the Saline Zone, Burnham et al., Feb., 1982 (33 pages).;;SO2 Emissions from the Oxidation of Retorted Oil Shale, Taylor et al., Nov. 1981 (9 pages).;;Nitric Oxide (NO) Reduction by Retorted Oil Shale, R.W. Taylor & C.J. Morris, Oct. 1983 (16 pages).;;Coproduction of Oil and Electric Power from Colorado Oil Shale, P. Henrik Wallman, Sep. 24, 1991 (20 pages).;;13C NMR Studies of Shale Oil, Raymond L. Ward & Alan K. Burnham, Aug. 1982 (22 pages).;;Identification by 13C NMR of Carbon Types in Shale Oil and their Relationship to Pyrolysis Conditions, Raymond L. Ward & Alan K. Burnham, Sep. 1983 (27 pages).;;A Laboratory Study of Green River Oil Shale Retorting Under Pressure in a Nitrogen Atmosphere, Wise et al., Sep. 1976 (24 pages).;;Quantitative Analysis and Evolution of Sulfur-Containing Gases from Oil Shale Pyrolysis by Triple Quadrupole Mass Spectrometry, Wong et al., Nov. 1983 (34 pages).;;Quantitative Analysis & Kinetics of Trace Sulfur Gas Species from Oil Shale Pyrolysis by Triple Quadrupole Mass Spectrometry (TQMS), Wong et al., Jul. 5-7, 1983 (34 pages).;;Application of Self-Adaptive Detector System on a Triple Quadrupole MS/MS to High Expolsives and Sulfur-Containing Pyrolysis Gases from Oil Shale, Carla M. Wong & Richard W. Crawford, Oct. 1983 (17 pages).;;An Evaluation of Triple Quadrupole MS/MS for On-Line Gas Analyses of Trace Sulfur Compounds from Oil Shale Processing, Wong et al., Jan. 1985 (30 pages).;;General Model of Oil Shale Pyrolysis, Alan K. Burnham & Robert L. Braun, Nov. 1983 (22 pages).;;Proposed Field Test of the Lins Mehtod Thermal Oil Recovery Process in Athabasca McMurray Tar Sands McMurray, Alberta; Husky Oil Company cody, Wyoming, circa 1960.;;In Situ Measurement of Some Thermoporoelastic Parameters of a Granite, Berchenko et al., Poromechanics, A Tribute to Maurice Biot, 1998, p. 545-550.;;Tar and Pitch, G. Collin and H. Hoeke. Ullmann's Encyclopedia of Industrial Chemistry, vol. A 26, 1995, p. 91-127.;;Wellington et al., U.S. Appl. No. 60/273,354, filed Mar. 5, 2001.;;Geology for Petroleum Exploration, Drilling, and Production. Hyne, Norman J. McGraw-Hill Book Company, 1984, p. 264.;;Burnham, Alan, K. ""Oil Shale Retorting Dependence of timing and composition on temperature and heating rate"", Jan. 27, 1995, (23 pages).;;Campbell, et al., ""Kinetics of oil generation from Colorado Oil Shale"" IPC Business Press, Fuel, 1978, (3 pages).;;Rangel-German et al., ""Electrical-Heating-Assisted Recovery for Heavy Oil"", pp. 1-43, 2004.;;Kovscek, Anthony R., ""Reservoir Engineering analysis of Novel Thermal Oil Recovery Techniques applicable to Alaskan North Slope Heavy Oils"", pp. 1-6 circa 2004.;;Bosch et al. ""Evaluation of Downhole Electric Impedance Heating Systems for Paraffin Control in Oil Wells,"" IEEE Transactions on Industrial Applications, 1991, vol. 28; pp. 190-194.;;""McGee et al. ""Electrical Heating with Horizontal Wells, The heat Transfer Problem,"" International Conference on Horizontal Well Tehcnology, Calgary, Alberta Canada, 1996; 14 pp."";;Hill et al., ""The Characteristics of a Low Temperature in situ Shale Oil"" American Institute of Mining, Metallurgical & Petroleum Engineers, 1967 (pp. 75-90).;;Rouffignac, E. In Situ Resistive Heating of Oil Shale for Oil Production-A Summary of the Swedish Data, (4 pages), published prior to Oct. 2001.;;SSAB report, ""A Brief Description of the Ljungstrom Method for Shale Oil Production,"" 1950, (12 pages).;;Salomonsson G., SSAB report, The Lungstrom in Situ-Method for Shale Oil Recovery, 1950 (28 pages).;;""Swedish shale oil-Production method in Sweden,"" Organisation for European Economic Co-operation, 1952, (70 pages).;;SSAB report, ""Kvarn Torp"" 1958, (36 pages).",INACTIVE
53,CN,A,CN 103958824 A,033-825-580-257-535,2014-07-30,2014,CN 201280048984 A,2012-10-04,US 2012/0058582 W;;US 201161544817 P,2011-10-07,Thermal expansion accommodation for circulated fluid system used to heat subsurface formation,The invention discloses a method for accommodating thermal expansion of a heater in a formation. The method includes the steps of flowing a heat transfer fluid through a conduit to provide heat to the formation and providing substantially constant tension to an end portion of the conduit that extends outside the formation. At least a portion of the end portion of the conduit is wound around a movable wheel used to apply tension to the conduit.,SHELL INT RESEARCH,GONZALEZ MANUEL ALBERTO;;CRUZ ANTONIO MARIA GUIMARAES LEITE;;JUNG GONGHYUN;;NOEL JUSTIN MICHAEL;;OCAMPOS ERNESTO RAFAEL FONSECA;;PENSO JORGE ANTONIO;;HORWEGE JASON ANDREW;;LEVY STEPHEN MICHAEL;;RAGHU DAMODARAN,,https://lens.org/033-825-580-257-535,Patent Application,no,7,1,10,10,0,E21B43/24;;E21B36/005;;E21B43/24;;E21B19/22;;E21B43/24,E21B36/00,,0,0,,,,INACTIVE
54,WO,A2,WO 2013/052561 A2,150-830-890-761-735,2013-04-11,2013,US 2012/0058582 W,2012-10-04,US 201161544817 P,2011-10-07,THERMAL EXPANSION ACCOMMODATION FOR CIRCULATED FLUID SYSTEMS USED TO HEAT SUBSURFACE FORMATIONS,A method for accommodating thermal expansion of a heater in a formation includes flowing a heat transfer fluid through a conduit to provide heat to the formation and providing substantially constant tension to an end portion of the conduit that extends outside the formation. At least a portion of the end portion of the conduit is wound around a movable wheel used to apply tension to the conduit.,SHELL OIL CO;;SHELL INT RESEARCH,GONZALEZ MANUEL ALBERTO;;CRUZ ANTONIO MARIA GUIMARAES LEITE;;JUNG GONGHYUN;;NOEL JUSTIN MICHAEL;;OCAMPOS ERNESTO RAFAEL FONSECA;;PENSO JORGE ANTONIO;;HORWEGE JASON ANDREW;;LEVY STEPHEN MICHAEL;;RAGHU DAMODARAN,,https://lens.org/150-830-890-761-735,Patent Application,yes,0,0,10,10,0,E21B43/24;;E21B36/005;;E21B43/24;;E21B19/22;;E21B43/24,E21B43/24,,0,0,,,,PENDING
55,US,A1,US 2013/0087337 A1,003-105-142-346-462,2013-04-11,2013,US 201213644443 A,2012-10-04,US 201213644443 A;;US 201161544817 P,2011-10-07,THERMAL EXPANSION ACCOMMODATION FOR CIRCULATED FLUID SYSTEMS USED TO HEAT SUBSURFACE FORMATIONS,A method for accommodating thermal expansion of a heater in a formation includes flowing a heat transfer fluid through a conduit to provide heat to the formation and providing substantially constant tension to an end portion of the conduit that extends outside the formation. At least a portion of the end portion of the conduit is wound around a movable wheel used to apply tension to the conduit.,SHELL OIL CO;;SHELL OIL CO,GONZALEZ MANUEL ALBERTO;;CRUZ ANTONIO MARIA GUIMARAES LEITE;;JUNG GONGHYUN;;NOEL JUSTIN MICHAEL;;OCAMPOS ERNESTO RAFAEL FONSECA;;PENSO JORGE ANTONIO;;HORWEGE JASON ANDREW;;LEVY STEPHEN MICHAEL;;RAGHU DAMODARAN,SHELL OIL COMPANY (2012-10-09),https://lens.org/003-105-142-346-462,Patent Application,yes,2,6,10,10,0,E21B43/24;;E21B36/005;;E21B43/24;;E21B19/22;;E21B43/24,E21B43/24,166/303;;166/57,0,0,,,,INACTIVE
56,CA,A1,CA 2850741 A1,192-011-849-509-778,2013-04-11,2013,CA 2850741 A,2012-10-04,US 201161544817 P;;US 2012/0058582 W,2011-10-07,THERMAL EXPANSION ACCOMMODATION FOR CIRCULATED FLUID SYSTEMS USED TO HEAT SUBSURFACE FORMATIONS,A method for accommodating thermal expansion of a heater in a formation includes flowing a heat transfer fluid through a conduit to provide heat to the formation and providing substantially constant tension to an end portion of the conduit that extends outside the formation. At least a portion of the end portion of the conduit is wound around a movable wheel used to apply tension to the conduit.,SHELL INT RESEARCH,GONZALEZ MANUEL ALBERTO;;CRUZ ANTONIO MARIA GUIMARAES LEITE;;JUNG GONGHYUN;;NOEL JUSTIN MICHAEL;;OCAMPOS ERNESTO RAFAEL FONSECA;;PENSO JORGE ANTONIO;;HORWEGE JASON ANDREW;;LEVY STEPHEN MICHAEL;;RAGHU DAMODARAN,,https://lens.org/192-011-849-509-778,Patent Application,no,0,0,10,10,0,E21B43/24;;E21B36/005;;E21B43/24;;E21B19/22;;E21B43/24,E21B43/24,,0,0,,,,DISCONTINUED
57,WO,A3,WO 2013/052561 A3,139-325-435-451-799,2014-05-08,2014,US 2012/0058582 W,2012-10-04,US 201161544817 P,2011-10-07,THERMAL EXPANSION ACCOMMODATION FOR CIRCULATED FLUID SYSTEMS USED TO HEAT SUBSURFACE FORMATIONS,A method for accommodating thermal expansion of a heater in a formation includes flowing a heat transfer fluid through a conduit to provide heat to the formation and providing substantially constant tension to an end portion of the conduit that extends outside the formation. At least a portion of the end portion of the conduit is wound around a movable wheel used to apply tension to the conduit.,SHELL OIL CO;;SHELL INT RESEARCH,GONZALEZ MANUEL ALBERTO;;CRUZ ANTONIO MARIA GUIMARAES LEITE;;JUNG GONGHYUN;;NOEL JUSTIN MICHAEL;;OCAMPOS ERNESTO RAFAEL FONSECA;;PENSO JORGE ANTONIO;;HORWEGE JASON ANDREW;;LEVY STEPHEN MICHAEL;;RAGHU DAMODARAN,,https://lens.org/139-325-435-451-799,Search Report,yes,6,0,10,10,0,E21B43/24;;E21B36/005;;E21B43/24;;E21B19/22;;E21B43/24,E21B36/00,,0,0,,,,PENDING
58,MX,A,MX 2015013846 A,062-067-303-361-379,2017-03-29,2017,MX 2015013846 A,2015-09-29,MX 2015013846 A,2015-09-29,RIGID MECHANICAL STRUCTURE FOR SUSTAINING CHAMBERS OF AIRSHIPS.,"The invention discloses a rigid mechanical structure for ships, thereby achieving an appropriate fuselage by providing security and stability to the systems which integrate a self-sustained craft, such as airships, and allowing support by providing operability to the systems which protects cameras, storages and/or compartments. This rigid mechanical structure warrants a suitable distribution of loads in airships even better than that provided by state-of-the-art devices since said structure is based on the geometry of a diamond-like structure of silicon carbide which comprises a tetrahedral section, thereby increasing axial and transversal resistance that improves strength and stability when said sections are projected into the classical ellipsoid shapes, of these airships. However, the aforementioned diamond-like structure is not only applied to the ellipsoid, but may also be applied to oblate- or oblong-like forms for a high-altitude, rigid airship.",UNIV AUTONOMA DE NUEVO LEON,MAX SALVADOR HERNANDEZ;;SIMON MARTINEZ MARTINEZ;;FAUSTO ALEJANDRO SANCHEZ CRUZ;;GENRRY ROSSVIER CAVAZOS ALMAGUER;;MARCO ANTONIO SANROMÁN RESÉNDIZ;;JORGE ALBERTO GONZALEZ GUEVARA;;VICTOR MAXIMO ARREDONDO SOLIS;;JOSE VALENTIN GUZMAN GONZALEZ;;RENE MAURICIO CHAVEZ RODRIGUEZ;;JOSE RUBEN MORONES IBARRA,,https://lens.org/062-067-303-361-379,Patent Application,no,0,0,1,1,0,,B64C1/00,,0,0,,,,PENDING
59,MX,A,MX 2015017077 A,100-901-068-654-603,2017-06-12,2017,MX 2015017077 A,2015-12-11,MX 2015017077 A,2015-12-11,FUNCTIONALIZATION PROCESS OF A DISTILLED ALCOHOLIC BEVERAGE (TEQUILA) BY THE ADDITION OF WALNUT SHELL NATURAL ANTIOXIDANTS GRANTING ANTIOXIDANT ACTIVITY.,"The present disclosure is related to a process for obtaining a distilled alcoholic beverage (tequila) with antioxidant activity by the functionalization of the same by adding a walnut shell extract in a 5% tequila concentration which is subsequently stirred for 30 minutes at 250 rpm and passed through a muslin cloth to later filter the same through a thin pore paper filter. The antioxidant activity was evaluated by three different methods (ABTS +, DPPH and lipid oxidation inhibition) showing a great (96, 86 and 10% respectively) compared to commercial white and rested commercial tequilas. The results of the gas chromatography demonstrate that there is no modification in the profile of volatile compounds by the addition of the extract, while the sensorial analysis indicates that there is no difference in the acceptance of the tequila containing the extract or without the same. The results of the mass spectrometry indicate that in the nut shell extract, the main antioxidant compounds re ported in the same can be present (gallic acid, camaric acid, ellagic acid and catechin) and responsible for the antioxidant activity. This process proposes obtaining a distilled alcoholic beverage (tequila) with antioxidant activity by using an agro-industrial residue of great production in the country as a cheap and constant source of great capacity natural antioxidants.",UNIV AUTONOMA DE COAHUILA,HELIODORO DE LA GARZA TOLEDO;;CRISTOBAL NOE AGUILAR GONZALEZ;;JUAN ALBERTO ASCACIO VALDEZ;;LEONARDO SEPULVEDA TORRE;;RUTH ELIZABETH BELMARES CERDA;;JORGE ALEJANDRO AGUIRRE JOYA;;MÓNICA LIZETH CHÁVEZ GONZÁLEZ;;ANA VERÓNICA CHARLES RODGRÍGUEZ;;JORGE ENRIQUE WONG PAZ;;ALEJANDRO ZUGASTI CRUZ,,https://lens.org/100-901-068-654-603,Patent Application,no,0,1,1,1,0,,C12G3/08,,0,0,,,,PENDING
60,EP,A1,EP 4186528 A1,046-008-341-383-78X,2023-05-31,2023,EP 21383082 A,2021-11-30,EP 21383082 A,2021-11-30,OLIGOSACCHARIDE COMPLEXES AND USES,"The present disclosure provides complexes comprising i) a cationic oligosaccharide comprising one or more cationic moieties bonded to a trehalose, a sucrose, or an n-glucose moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives selected from: a sterol, a helper lipid, an immunomodulator, and a targeting molecule.",BIONTECH SE;;CONSEJO SUPERIOR INVESTIGACION;;UNIV SEVILLA,MORENO HERRERO JORGE;;HAAS HEINRICH;;ERBAR STEPHANIE;;STAHL THEO BENJAMIN;;GARCIA FERNANDEZ JOSE MANUEL;;BENITO HERNANDEZ JUAN MANUEL;;LÓPEZ FERNÁNDEZ JOSÉ;;ORTIZ MELLET MARÍA DEL CARMEN;;DE LA CRUZ RUIZ NOELIA;;GONZALEZ CUESTA MANUEL,,https://lens.org/046-008-341-383-78X,Patent Application,yes,13,0,1,15,0,A61P31/12;;A61K47/26;;A61K47/549;;A61K47/543;;A61K47/542;;A61K47/554;;C07H15/14;;C07H15/26;;A61K9/5123;;A61K9/0019,A61K47/54;;A61K47/26;;A61P31/12,,6,4,033-851-384-071-679;;029-865-253-859-83X;;033-851-384-071-679;;007-364-858-655-289,31268107;;10.1039/c9cc04489b;;33540942;;10.3390/pharmaceutics13020206;;pmc7913163;;31268107;;10.1039/c9cc04489b;;10.1002/jps.2600660104;;833720,"CARBAJO-GORDILLO ANA I. ET AL: ""Trehalose-based Siamese twin amphiphiles with tunable self-assembling, DNA nanocomplexing and gene delivery properties"", CHEMICAL COMMUNICATIONS, vol. 55, no. 57, 11 July 2019 (2019-07-11), UK, pages 8227 - 8230, XP055907712, ISSN: 1359-7345, DOI: 10.1039/C9CC04489B;;ALDOSARI BASMAH N. ET AL: ""Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines"", PHARMACEUTICS, vol. 13, no. 2, 2 February 2021 (2021-02-02), CH, pages 206, XP055929575, ISSN: 1999-4923, DOI: 10.3390/pharmaceutics13020206;;CARBAJO-GORDILLO ET AL., CHEM. COMM., vol. 55, 2019, pages 8227 - 8230;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;A. R. GENNARO: ""Remington's The Science and Practice of Pharmacy"", 2006, LIPPINCOTT, WILLIAMS & WILKINS;;""Remington: The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS",PENDING
61,KR,A,KR 20080080137 A,162-279-305-132-625,2008-09-02,2008,KR 20087015049 A,2008-06-20,CU 20050229 A,2005-11-22,METHODS AND PROTEINS FOR THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF DENGUE VIRUS AND OTHER FLAVIVIRUSES,"The invention relates to the pharmaceutical industry and describes a conserved area of the surface of the E protein, which can be used in the development of broad spectrum molecules which can be used in the prevention and/or treatment of infections caused by dengue virus 1-4 and other flaviviruses. The invention also relates to chimeric proteins which are intended for use as vaccines and for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses.",CT INGENIERIA GENETICA BIOTECH,CHINEA SANTIAGO GLAY;;HUERTA GALINDO VIVIAN;;MARTIN DUNN ALEJANDRO MIGUEL;;GAVILONDO COWLEY JORGE VICTOR;;FLEITAS SALAZAR NORALVIS;;GUIROLA CRUZ OSMANY;;GIL VALDES JEOVANIS;;ZULUETA MORALES AIDA;;HERMIDA CRUZ LISSET;;AYALA AVILA MARTA;;GONZALEZ ROCHE DIAMILE;;PAEZ MEIRELES ROLANDO;;TOLEDO MAYORA PATRICIA GABRIEL;;SARRIA NUNEZ MONICA;;MUSACCHIO LASA ALEXIS;;MAZOLA REYES YULIET,,https://lens.org/162-279-305-132-625,Patent Application,no,0,0,15,15,0,A61K39/00;;A61K39/12;;C07K14/005;;C07K2319/02;;C07K2319/21;;C12N2770/24022;;C12N2770/24122;;A61K2039/55566;;C12N2770/24134;;A61P31/14;;Y02A50/30;;C07K14/18;;C12N15/11;;C07K16/10;;A61K39/12;;C07K14/005;;C07K2319/02;;A61K39/00;;A61K39/12;;C07K2319/21;;C12N2770/24122;;C12N2770/24022;;C12N2770/24134;;A61K2039/55566;;Y02A50/30,A61K39/12;;C07K16/10;;C12N15/40,,0,0,,,,DISCONTINUED
62,AU,A1,AU 2006/317350 A1,031-859-612-966-233,2007-05-31,2007,AU 2006/317350 A,2006-11-21,CU 20050229 A;;CU 2006000015 W,2005-11-22,Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses,,CT INGENIERIA GENETICA BIOTECNOLOGIA,ROCHE DIAMILE GONZALEZ;;MORALES AIDA ZULUETA;;COWLEY JORGE VICTOR GAVILONDO;;SANTIAGO GLAY CHINEA;;LASA ALEXIS MUSACCHIO;;NUNEZ MONICA SARRIA;;SALAZAR NORALVIS FLEITAS;;DUNN ALEJANDRO MIGUEL MARTIN;;CRUZ OSMANY GUIROLA;;MEIRELES ROLANDO PAEZ;;CRUZ LISSET HERMIDA;;VALDES JEOVANIS GIL;;MAYORA PATRICIA GABRIELA TOLED;;REYES YULIET MAZOLA;;AVILA MARTA AYALA;;GALINDO VIVIAN HUERTA,,https://lens.org/031-859-612-966-233,Patent Application,no,0,0,15,15,0,A61K39/00;;A61K39/12;;C07K14/005;;C07K2319/02;;C07K2319/21;;C12N2770/24022;;C12N2770/24122;;A61K2039/55566;;C12N2770/24134;;A61P31/14;;Y02A50/30;;C07K14/18;;C12N15/11;;C07K16/10;;A61K39/12;;C07K14/005;;C07K2319/02;;A61K39/00;;A61K39/12;;C07K2319/21;;C12N2770/24122;;C12N2770/24022;;C12N2770/24134;;A61K2039/55566;;Y02A50/30,C07K14/18;;A61K39/12;;C07K16/10;;C07K19/00;;C12N15/40;;C12N15/62;;C12N15/63,,0,0,,,,DISCONTINUED
63,WO,A8,WO 2007/059715 A8,065-387-362-776-613,2008-02-14,2008,CU 2006000015 W,2006-11-21,CU 20050229 A,2005-11-22,METHODS AND PROTEINS FOR THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF DENGUE VIRUS AND OTHER FLAVIVIRUSES,"The invention relates to the pharmaceutical industry and describes a conserved area of the surface of the E protein, which can be used in the development of broad spectrum molecules which can be used in the prevention and/or treatment of infections caused by dengue virus 1-4 and other flaviviruses. The invention also relates to chimeric proteins which are intended for use as vaccines and for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses.",CT INGENIERIA GENETICA BIOTECH;;CHINEA SANTIAGO GLAY;;HUERTA GALINDO VIVIAN;;MARTIN DUNN ALEJANDRO MIGUEL;;GAVILONDO COWLEY JORGE VICTOR;;FLEITAS SALAZAR NORALVIS;;GUIROLA CRUZ OSMANY;;GIL VALDES JEOVANIS;;ZULUETA MORALES AIDA;;HERMIDA CRUZ LISSET;;AYALA AVILA MARTA;;GONZALEZ ROCHE DIAMILE;;PAEZ MEIRELES ROLANDO;;TOLEDO MAYORA PATRICIA GABRIEL;;SARRIA NUNEZ MONICA;;MUSACCHIO LASA ALEXIS;;MAZOLA REYES YULIET,CHINEA SANTIAGO GLAY;;HUERTA GALINDO VIVIAN;;MARTIN DUNN ALEJANDRO MIGUEL;;GAVILONDO COWLEY JORGE VICTOR;;FLEITAS SALAZAR NORALVIS;;GUIROLA CRUZ OSMANY;;GIL VALDES JEOVANIS;;ZULUETA MORALES AIDA;;HERMIDA CRUZ LISSET;;AYALA AVILA MARTA;;GONZALEZ ROCHE DIAMILE;;PAEZ MEIRELES ROLANDO;;TOLEDO MAYORA PATRICIA GABRIEL;;SARRIA NUNEZ MONICA;;MUSACCHIO LASA ALEXIS;;MAZOLA REYES YULIET,,https://lens.org/065-387-362-776-613,Patent Application,no,0,0,15,15,56,A61K39/00;;A61K39/12;;C07K14/005;;C07K2319/02;;C07K2319/21;;C12N2770/24022;;C12N2770/24122;;A61K2039/55566;;C12N2770/24134;;A61P31/14;;Y02A50/30;;C07K14/18;;C12N15/11;;C07K16/10;;A61K39/12;;C07K14/005;;C07K2319/02;;A61K39/00;;A61K39/12;;C07K2319/21;;C12N2770/24122;;C12N2770/24022;;C12N2770/24134;;A61K2039/55566;;Y02A50/30,C07K14/18;;A61K39/12;;C07K16/10;;C07K19/00;;C12N15/40;;C12N15/62;;C12N15/63,,0,0,,,,PENDING
64,WO,A3,WO 2007/059715 A3,145-578-729-824-290,2007-10-18,2007,CU 2006000015 W,2006-11-21,CU 20050229 A,2005-11-22,METHODS AND PROTEINS FOR THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF DENGUE VIRUS AND OTHER FLAVIVIRUSES,"The invention relates to the pharmaceutical industry and describes a conserved area of the surface of the E protein, which can be used in the development of broad spectrum molecules which can be used in the prevention and/or treatment of infections caused by dengue virus 1-4 and other flaviviruses. The invention also relates to chimeric proteins which are intended for use as vaccines and for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses.",CT INGENIERIA GENETICA BIOTECH;;CHINEA SANTIAGO GLAY;;HUERTA GALINDO VIVIAN;;MARTIN DUNN ALEJANDRO MIGUEL;;GAVILONDO COWLEY JORGE VICTOR;;FLEITAS SALAZAR NORALVIS;;GUIROLA CRUZ OSMANY;;GIL VALDES JEOVANIS;;ZULUETA MORALES AIDA;;HERMIDA CRUZ LISSET;;AYALA AVILA MARTA;;GONZALEZ ROCHE DIAMILE;;PAEZ MEIRELES ROLANDO;;TOLEDO MAYORA PATRICIA GABRIEL;;SARRIA NUNEZ MONICA;;MUSACCHIO LASA ALEXIS;;MAZOLA REYES YULIET,CHINEA SANTIAGO GLAY;;HUERTA GALINDO VIVIAN;;MARTIN DUNN ALEJANDRO MIGUEL;;GAVILONDO COWLEY JORGE VICTOR;;FLEITAS SALAZAR NORALVIS;;GUIROLA CRUZ OSMANY;;GIL VALDES JEOVANIS;;ZULUETA MORALES AIDA;;HERMIDA CRUZ LISSET;;AYALA AVILA MARTA;;GONZALEZ ROCHE DIAMILE;;PAEZ MEIRELES ROLANDO;;TOLEDO MAYORA PATRICIA GABRIEL;;SARRIA NUNEZ MONICA;;MUSACCHIO LASA ALEXIS;;MAZOLA REYES YULIET,,https://lens.org/145-578-729-824-290,Search Report,yes,3,0,15,15,56,A61K39/00;;A61K39/12;;C07K14/005;;C07K2319/02;;C07K2319/21;;C12N2770/24022;;C12N2770/24122;;A61K2039/55566;;C12N2770/24134;;A61P31/14;;Y02A50/30;;C07K14/18;;C12N15/11;;C07K16/10;;A61K39/12;;C07K14/005;;C07K2319/02;;A61K39/00;;A61K39/12;;C07K2319/21;;C12N2770/24122;;C12N2770/24022;;C12N2770/24134;;A61K2039/55566;;Y02A50/30,C07K14/18;;A61K39/12;;C07K16/10;;C07K19/00;;C12N15/40;;C12N15/62;;C12N15/63,,5,4,032-152-162-398-159;;062-218-207-541-076;;020-373-710-308-163;;122-371-304-182-621,15542644;;pmc525008;;10.1128/jvi.78.23.12919-12928.2004;;15837370;;10.1016/j.vaccine.2004.12.028;;10.1016/s0168-1656(99)00037-1;;10361725;;pmc7125516;;1698924;;10.1099/0022-1317-71-9-2107,"GONCALVEZ ANA P ET AL: ""Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein"", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 78, no. 23, December 2004 (2004-12-01), pages 12919 - 12928, XP002338600, ISSN: 0022-538X;;MOTA J ET AL: ""Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein"", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 26, 16 May 2005 (2005-05-16), pages 3469 - 3476, XP004852137, ISSN: 0264-410X;;THULLIER P ET AL: ""A recombinant Fab neutralizes dengue virus in vitro"", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 69, no. 2-3, 15 April 1999 (1999-04-15), pages 183 - 190, XP004168126, ISSN: 0168-1656;;DATABASE EBI [online] 1 October 2003 (2003-10-01), SHU L & ZUO L: ""no title"", XP002430600, retrieved from UNIPROT/TREMBL accession no. Q7TLC5 Database accession no. Q7TLC5;;MASON PW ET AL.: ""The antigenic structure of dengue type 1 virus envelope and NS1 proteins expressed in Escherichia coli"", JOURNAL OF GENERAL VIROLOGY, vol. 71, no. 9, September 1990 (1990-09-01), pages 2107 - 2114, XP002430578, ISSN: 0022-1317",PENDING
65,BR,A2,BR PI0618865 A2,132-974-113-881-10X,2011-09-13,2011,BR PI0618865 A,2006-11-21,CU 20050229 A;;CU 2006000015 W,2005-11-22,"área topográfica e altamente conservada, moléculas, ácido nucleico, proteìna, anticorpos, célula hospedeira, composição farmacêutica, e, método","AREA TOPOGRáFICA E ALTAMENTE CONSERVADA, MOLéCULAS, áCIDO NUCLEICO, PROTEìNA, ANTICORPOS, CéLULA HOSPEDEIRA, COMPOSIçãO FARMACêUTICA, E, MéTODO. A presente invenção se refere à indústria farmacêutica, descreve-se uma área conservada da superficie da proteína E, empregável no desenvolvimento de moléculas de amplo espectro úteis na prevenção e/ou tratamento das infecções por vírus dengue 1-4 e outros flavivírus. Além disso, a presente invenção se refere às proteínas quiméricas para uso como vacinas e tratamento profilático e terapêutico contra os quatro serotipos do vírus da dengue e outros flavivírus.",CT INGENIERIA GENETICA BIOTECH,SANTIAGO GLAY CHINEA;;GALINDO VIVIAN HUERTA;;DUNN ALEJANDRO MIGUEL MARTIN;;COWLEY JORGE VICTOR GAVILONDO;;SALAZAR NORALVIS FLEITAS;;CRUZ OSMANY GUIROLA;;VALDES JEOVANIS GIL;;MORALES AIDA ZULUETA;;CRUZ LISSET HERMIDA;;AVILA MARTA AYALA;;ROCHE DIAMILE GONZALEZ;;MEIRELES ROLANDO PAEZ;;MAYORA PATRICIA GABRIELA TOLEDO;;MUNEZ MONICA SARRIA;;LASA ALEXIA MUSACCHIO;;REYES YULIET MAZOLA,,https://lens.org/132-974-113-881-10X,Patent Application,no,0,0,15,15,0,A61K39/00;;A61K39/12;;C07K14/005;;C07K2319/02;;C07K2319/21;;C12N2770/24022;;C12N2770/24122;;A61K2039/55566;;C12N2770/24134;;A61P31/14;;Y02A50/30;;C07K14/18;;C12N15/11;;C07K16/10;;A61K39/12;;C07K14/005;;C07K2319/02;;A61K39/00;;A61K39/12;;C07K2319/21;;C12N2770/24122;;C12N2770/24022;;C12N2770/24134;;A61K2039/55566;;Y02A50/30,C07K14/18;;A61K39/12;;C07K16/10;;C07K19/00;;C12N15/40;;C12N15/62;;C12N15/63,,0,0,,,,DISCONTINUED
66,CA,A1,CA 2630629 A1,197-056-545-690-978,2007-05-31,2007,CA 2630629 A,2006-11-21,CU 20050229 A;;CU 2006000015 W,2005-11-22,METHODS AND PROTEINS FOR THE PROPHYLACTIC AND/OR THERAPEUTICTREATMENT OF THE FOUR SEROTYPES OF DENGUE VIRUS AND OTHER FLAVIVIRUSES,"The invention relates to the pharmaceutical industry and describes a conserv ed area of the surface of the E protein, which can be used in the development o f broad spectrum molecules which can be used in the prevention and/or treatmen t of infections caused by dengue virus 1-4 and other flaviviruses. The inventi on also relates to chimeric proteins which are intended for use as vaccines and for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses.",CT INGENIERIA GENETICA BIOTECH,GAVILONDO COWLEY JORGE VICTOR;;ZULUETA MORALES AIDA;;HUERTA GALINDO VIVIAN;;MARTIN DUNN ALEJANDRO MIGUEL;;AYALA AVILA MARTA;;GIL VALDES JEOVANIS;;GUIROLA CRUZ OSMANY;;GONZALEZ ROCHE DIAMILE;;TOLEDO MAYORA PATRICIA GABRIELA;;FLEITAS SALAZAR NORALVIS;;PAEZ MEIRELES ROLANDO;;CHINEA SANTIAGO GLAY;;MAZOLA REYES YULIET;;HERMIDA CRUZ LISSET;;MUSACCHIO LASA ALEXIS;;SARRIA NUNEZ MONICA,,https://lens.org/197-056-545-690-978,Patent Application,no,0,0,15,15,56,A61K39/00;;A61K39/12;;C07K14/005;;C07K2319/02;;C07K2319/21;;C12N2770/24022;;C12N2770/24122;;A61K2039/55566;;C12N2770/24134;;A61P31/14;;Y02A50/30;;C07K14/18;;C12N15/11;;C07K16/10;;A61K39/12;;C07K14/005;;C07K2319/02;;A61K39/00;;A61K39/12;;C07K2319/21;;C12N2770/24122;;C12N2770/24022;;C12N2770/24134;;A61K2039/55566;;Y02A50/30,C07K14/18;;A61K39/12;;C07K16/10;;C07K19/00;;C12N15/40;;C12N15/62;;C12N15/63,,0,0,,,,DISCONTINUED
67,ZA,B,ZA 200804874 B,078-500-632-903-162,2009-04-29,2009,ZA 200804874 A,2008-06-04,CU 20050229 A,2005-11-22,Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses,,CT INGENIERIA GENETICA BIOTECH,GLAY CHINEA SANTIAGO;;VIVIAN HUERTA GALINDO;;MIGUEL MARTIN DUNN ALEJANDRO;;VICTOR GAVILONDO COWLEY JORGE;;NORALVIS FLEITAS SALAZAR;;OSMANY GUIROLA CRUZ;;JEOVANIS GIL VALDES;;AIDA ZULUETA MORALES;;LISSET HERMIDA CRUZ;;MARTA AYALA AVILA;;DIAMILE GONZALEZ ROCHE;;ROLANDO PAEZ MEIRELES;;GABRIELA TOLEDO MAYORA PATRICIA;;MONICA SARRIA NUNEZ;;ALEXIS MUSACCHIO LASA;;YULIET MAZOLA REYES,,https://lens.org/078-500-632-903-162,Granted Patent,no,0,0,15,15,0,A61K39/00;;A61K39/12;;C07K14/005;;C07K2319/02;;C07K2319/21;;C12N2770/24022;;C12N2770/24122;;A61K2039/55566;;C12N2770/24134;;A61P31/14;;Y02A50/30;;C07K14/18;;C12N15/11;;C07K16/10;;A61K39/12;;C07K14/005;;C07K2319/02;;A61K39/00;;A61K39/12;;C07K2319/21;;C12N2770/24122;;C12N2770/24022;;C12N2770/24134;;A61K2039/55566;;Y02A50/30,A61K/;;C07K/;;C12N/,,0,0,,,,ACTIVE
68,AR,A1,AR 058215 A1,004-839-168-246-987,2008-01-23,2008,AR P060105098 A,2006-11-21,CU 20050229 A,2005-11-22,METODOS Y PROTEINAS PARA EL TRATAMIENTO PROFILACTICO Y O TERAPEUTICO DE LOS CUATRO SEROTIPOS DEL VIRUS DE DENGUE Y OTROS FLAVIVIRUS,"La presente está relacionada con la industria farmacéutica, se describe un área conservada de la superficie de la proteína E, empleable en el desarrollo de moléculas de amplio espectro utiles en la prevencion y/o tratamiento de las infecciones por virus dengue 1-4 y otros flavivirus. Además la presente se relaciona con proteínas quiméricas para uso como vacunas y tratamiento profiláctico y terapéutico contra los cuatro serotipos del virus de dengue y otros flavivirus.",CT INGENIERIA GENETICA BIOTECH,CHINEA SANTIAGO GLAY;;FLEITAS SALAZAR NORALVIS;;GUIROLA CRUZ OSMANY;;GONZALEZ ROCHE DIAMILE;;PAEZ MEIRELES ROLANDO;;TOLEDO MAYORA PATRICIA GABRIEL;;AYALA AVILA MARTA;;GAVILONDO COWLEY JORGE VICTOR;;MARTIN DUNN ALEJANDRO MIGUEL;;HUERTA GALINDO VIVIAN;;GIL VALDEZ JEOVANIS;;ZULUETA MORALES AIDA;;HERMIDA CRUZ LISSET;;SARRIA NUNEZ MONICA;;MUSACCHIO LASA ALEXIS;;MAZOLA REYES YULIET,,https://lens.org/004-839-168-246-987,Patent Application,no,0,0,15,15,0,A61K39/00;;A61K39/12;;C07K14/005;;C07K2319/02;;C07K2319/21;;C12N2770/24022;;C12N2770/24122;;A61K2039/55566;;C12N2770/24134;;A61P31/14;;Y02A50/30;;C07K14/18;;C12N15/11;;C07K16/10;;A61K39/12;;C07K14/005;;C07K2319/02;;A61K39/00;;A61K39/12;;C07K2319/21;;C12N2770/24122;;C12N2770/24022;;C12N2770/24134;;A61K2039/55566;;Y02A50/30,,,0,0,,,,PENDING
69,EP,A2,EP 1958959 A2,023-553-539-045-849,2008-08-20,2008,EP 06817996 A,2006-11-21,CU 2006000015 W;;CU 20050229 A,2005-11-22,METHODS AND PROTEINS FOR THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF DENGUE VIRUS AND OTHER FLAVIVIRUSES,"The present invention is related to the field of the pharmaceutical industry, and describes a conserved area on the surface of the E protein that can be used for the development of wide-spectrum antiviral molecules to be employed in the prophylaxis and/or treatment of infections due to Dengue Virus serotypes 1-4 and other flaviviruses. The invention also covers chimeric proteins to be used as vaccines or as a prophylactic or therapeutic treatment against the four serotypes of Dengue Virus and other flaviviruses.",CT INGENIERIA GENETICA BIOTECH,CHINEA SANTIAGO GLAY;;HUERTA GALINDO VIVIAN;;MARTIN DUNN ALEJANDRO MIGUEL;;GAVILONDO COWLEY JORGE VICTOR;;FLEITAS SALAZAR NORALVIS;;GUIROLA CRUZ OSMANY;;GIL VALDES JEOVANIS;;ZULUETA MORALES AIDA;;HERMIDA CRUZ LISSET;;AYALA AVILA MARTA;;GONZALEZ ROCHE DIAMILE;;PAEZ MEIRELES ROLANDO;;TOLEDO MAYORA PATRICIA GABRIEL;;SARRIA NUNEZ MONICA;;MUSACCHIO LASA ALEXIS;;MAZOLA REYES YULIET,,https://lens.org/023-553-539-045-849,Patent Application,yes,0,10,15,15,0,A61K39/00;;A61K39/12;;C07K14/005;;C07K2319/02;;C07K2319/21;;C12N2770/24022;;C12N2770/24122;;A61K2039/55566;;C12N2770/24134;;A61P31/14;;Y02A50/30;;C07K14/18;;C12N15/11;;C07K16/10;;A61K39/12;;C07K14/005;;C07K2319/02;;A61K39/00;;A61K39/12;;C07K2319/21;;C12N2770/24122;;C12N2770/24022;;C12N2770/24134;;A61K2039/55566;;Y02A50/30,C07K14/18;;A61K39/12;;C07K16/10;;C07K19/00;;C12N15/40;;C12N15/62;;C12N15/63,,0,0,,,,DISCONTINUED
70,WO,A2,WO 2007/059715 A2,176-092-051-092-122,2007-05-31,2007,CU 2006000015 W,2006-11-21,CU 20050229 A,2005-11-22,METHODS AND PROTEINS FOR THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF DENGUE VIRUS AND OTHER FLAVIVIRUSES,"The invention relates to the pharmaceutical industry and describes a conserved area of the surface of the E protein, which can be used in the development of broad spectrum molecules which can be used in the prevention and/or treatment of infections caused by dengue virus 1-4 and other flaviviruses. The invention also relates to chimeric proteins which are intended for use as vaccines and for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses.",CT INGENIERIA GENETICA BIOTECH;;CHINEA SANTIAGO GLAY;;HUERTA GALINDO VIVIAN;;MARTIN DUNN ALEJANDRO MIGUEL;;GAVILONDO COWLEY JORGE VICTOR;;FLEITAS SALAZAR NORALVIS;;GUIROLA CRUZ OSMANY;;GIL VALDES JEOVANIS;;ZULUETA MORALES AIDA;;HERMIDA CRUZ LISSET;;AYALA AVILA MARTA;;GONZALEZ ROCHE DIAMILE;;PAEZ MEIRELES ROLANDO;;TOLEDO MAYORA PATRICIA GABRIEL;;SARRIA NUNEZ MONICA;;MUSACCHIO LASA ALEXIS;;MAZOLA REYES YULIET,CHINEA SANTIAGO GLAY;;HUERTA GALINDO VIVIAN;;MARTIN DUNN ALEJANDRO MIGUEL;;GAVILONDO COWLEY JORGE VICTOR;;FLEITAS SALAZAR NORALVIS;;GUIROLA CRUZ OSMANY;;GIL VALDES JEOVANIS;;ZULUETA MORALES AIDA;;HERMIDA CRUZ LISSET;;AYALA AVILA MARTA;;GONZALEZ ROCHE DIAMILE;;PAEZ MEIRELES ROLANDO;;TOLEDO MAYORA PATRICIA GABRIEL;;SARRIA NUNEZ MONICA;;MUSACCHIO LASA ALEXIS;;MAZOLA REYES YULIET,,https://lens.org/176-092-051-092-122,Patent Application,yes,7,14,15,15,56,A61K39/00;;A61K39/12;;C07K14/005;;C07K2319/02;;C07K2319/21;;C12N2770/24022;;C12N2770/24122;;A61K2039/55566;;C12N2770/24134;;A61P31/14;;Y02A50/30;;C07K14/18;;C12N15/11;;C07K16/10;;A61K39/12;;C07K14/005;;C07K2319/02;;A61K39/00;;A61K39/12;;C07K2319/21;;C12N2770/24122;;C12N2770/24022;;C12N2770/24134;;A61K2039/55566;;Y02A50/30,C07K14/18;;C07K16/10;;C07K19/00;;C12N15/40;;C12N15/62,,100,90,054-012-399-437-906;;062-031-077-495-306;;076-340-777-182-498;;017-308-094-474-029;;058-552-527-680-242;;049-459-161-547-291;;032-802-332-370-119;;038-291-301-556-750;;001-787-428-724-965;;025-710-148-809-396;;043-266-160-832-710;;002-400-062-339-102;;003-610-857-111-12X;;010-087-652-824-724;;095-522-717-504-308;;104-914-888-754-536;;033-393-867-178-643;;010-790-839-052-917;;000-628-901-267-938;;025-475-108-880-14X;;026-014-137-578-032;;084-444-315-239-986;;001-787-428-724-965;;056-130-209-319-678;;054-012-399-437-906;;090-255-546-053-606;;071-007-239-179-901;;009-680-862-135-101;;020-508-937-352-463;;084-254-827-920-671;;122-872-209-378-576;;103-082-528-190-364;;010-192-032-710-827;;024-288-528-787-54X;;004-709-097-891-093;;095-522-717-504-308;;004-526-922-668-165;;066-618-959-042-008;;008-454-577-396-845;;077-685-903-714-230;;011-088-099-844-981;;066-211-815-695-603;;103-639-015-376-038;;095-661-003-189-596;;000-960-732-874-319;;012-047-499-789-876;;083-819-127-668-099;;073-481-366-280-528;;031-851-032-037-968;;027-561-417-348-812;;122-660-943-635-915;;001-499-192-360-838;;090-255-546-053-606;;011-219-690-714-049;;021-586-571-323-472;;069-201-599-787-342;;015-643-933-761-033;;110-950-547-367-664;;089-142-251-163-801;;056-201-471-905-934;;085-764-009-624-439;;039-676-361-532-623;;095-576-215-876-375;;020-079-405-751-639;;015-489-920-357-856;;008-565-599-035-890;;069-201-599-787-342;;020-373-710-308-163;;013-795-911-863-784;;007-219-842-138-075;;033-767-552-029-567;;069-450-943-413-364;;010-400-335-319-618;;020-180-279-123-629;;013-359-210-552-499;;018-615-791-106-463;;035-337-933-838-299;;158-261-806-420-924;;119-862-677-692-462;;115-802-414-738-000;;021-139-632-388-006;;106-637-969-277-380;;065-700-380-928-025;;020-882-693-207-605;;010-192-032-710-827;;013-452-637-389-025;;049-106-712-009-69X;;004-421-724-788-376;;035-337-933-838-299;;115-802-414-738-000,10.1016/s0065-3527(03)60011-4;;14689700;;13711073;;3450005;;10.1016/0035-9203(87)90042-3;;3277268;;10.1126/science.3277268;;10.1126/science.239.4839.476;;12759475;;pmc165817;;10.1073/pnas.0832193100;;pmc538574;;15613349;;10.1128/jvi.79.2.1223-1231.2005;;10.1038/375291a0;;7753193;;10.1016/s0065-3527(03)59003-0;;14696327;;14737159;;10.1038/nature02165;;10.1038/nm0897-866;;9256277;;10.1038/sj.embor.embor866;;pmc1326316;;12783086;;10.1084/jem.20021840;;12682107;;pmc2193896;;10.1128/jvi.69.9.5816-5820.1995;;pmc189449;;7637027;;1710648;;10.1099/0022-1317-72-6-1323;;1280384;;pmc7130970;;10.1016/0042-6822(92)90267-s;;pmc137023;;11991976;;10.1128/jvi.76.11.5480-5491.2002;;10.1128/jvi.71.11.8475-8481.1997;;9343204;;pmc192310;;10.1099/vir.0.18723-0;;12533715;;pmc4148076;;14528291;;10.1038/nsb990;;10.1016/s0092-8674(02)00660-8;;pmc4152842;;11893341;;10.2210/pdb1n6g/pdb;;pmc156766;;12773377;;10.1093/emboj/cdg270;;7529335;;10.1128/jvi.69.2.695-700.1995;;pmc188630;;14737159;;10.1038/nature02165;;pmc380989;;10.1038/sj.emboj.7600064;;14963486;;10.1016/s0065-3527(03)60011-4;;14689700;;10.4269/ajtmh.1952.1.30;;14903434;;10.1084/jem.146.1.201;;406347;;pmc2180729;;10.4049/jimmunol.144.8.3183;;2139079;;6824120;;10.4269/ajtmh.1983.32.154;;10.1128/iai.36.3.1036-1041.1982;;pmc551436;;6284641;;6607288;;3504546;;10.1016/0882-4010(87)90056-8;;10.1006/viro.1998.9200;;9657950;;pmc247724;;2463377;;10.1128/jvi.63.2.564-571.1989;;10.1007/s007050170017;;11811694;;1280384;;pmc7130970;;10.1016/0042-6822(92)90267-s;;10.1016/j.vaccine.2003.09.019;;15003657;;10.1111/j.1749-6632.2001.tb02702.x;;11797783;;15056045;;10.1586/14760584.3.2.199;;10.1016/s0264-410x(00)00040-2;;10821973;;14740950;;10.4269/ajtmh.2003.69.12;;10.4269/ajtmh.2003.69.6_suppl.0690001;;14756126;;10.1007/s00705-003-0007-y;;12721805;;11716091;;10.4269/ajtmh.2001.65.405;;pmc114964;;10.1128/jvi.75.16.7290-7304.2001;;11462001;;pmc111800;;10.1128/jvi.74.7.3020-3028.2000;;10708416;;10.1128/jvi.76.7.3318-3328.2002;;11884557;;pmc136019;;15207960;;10.1016/s0140-6736(04)16459-3;;11797784;;10.1111/j.1749-6632.2001.tb02703.x;;10.4269/ajtmh.2001.65.420;;11716093;;10.4269/ajtmh.1994.50.322;;8147490;;10.1016/s0264-410x(97)00128-x;;9413106;;10.4269/ajtmh.1952.1.30;;14903434;;10.1172/jci200421512;;10.1172/jci21512;;15057297;;pmc379334;;10.1128/jvi.78.9.4665-4674.2004;;pmc387713;;15078949;;15542643;;10.1128/jvi.78.23.12910-12918.2004;;pmc525007;;12573578;;10.1006/viro.2002.1704;;10608744;;10.1086/315215;;11145685;;10.4049/jimmunol.166.2.1057;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;10.1093/nar/22.22.4673;;pmc308517;;7984417;;10.4269/ajtmh.2001.65.159;;11508393;;14656459;;10.1016/j.jviromet.2003.09.024;;10.1099/0022-1317-82-8-1959;;11458003;;10.1099/0022-1317-83-8-2001;;12124464;;15542643;;10.1128/jvi.78.23.12910-12918.2004;;pmc525007;;10.1016/s0168-1656(99)00037-1;;10361725;;pmc7125516;;10.1038/90444;;9699631;;1942039;;10.1016/0022-2836(91)80186-x;;9126849;;10.1006/jmbi.1996.0897;;7154081;;10.1016/0022-2836(82)90153-x;;10.1021/ci000463o;;11410053;;10.1021/ci049714+;;10.1021/ci049714;;pmc1360656;;15667143;;12499312;;10.1093/bioinformatics/19.1.163;;3024394;;10.1016/0042-6822(86)90200-x;;5422620;;10.1038/227027a0;;10.1016/s0040-4039(01)90461-7;;10.1016/0167-7799(85)90068-x;;10.1016/0022-2836(86)90385-2;;3537305;;14963174;;pmc369223;;10.1128/jvi.78.5.2648-2652.2004;;14693807;;10.1093/bioinformatics/btg371;;10.1093/protein/14.2.105;;11297668;;10.1002/prot.10389;;12784371;;10.1006/viro.1998.9200;;9657950;;8943402;;10.4049/jimmunol.157.11.4963;;10.1096/fasebj.9.1.7821750;;7821750;;pmc2143761;;9260286;;10.1002/pro.5560060814;;5422620;;10.1038/227027a0;;10.1016/0022-2836(86)90385-2;;3537305,"HALSTEAD,S.B.: ""Neutralization and antibody-dependent enhancement of dengue viruses"", ADV. VIRUS RES, vol. 60, 2003, pages 421 - 467;;HAMMON WMC: ""New haemorragic fever in children in the Philippines and Thailand"", TRANS ASSOC PHYSICIANS, vol. 73, 1960, pages 140 - 155;;KOURI GP; GUZMAN MG; BRAVO JR: ""Why dengue hemorrhagic fever in Cuba? 2. An integral analysis"", TRANS ROY SOC TROP MED HYG, vol. 72, 1987, pages 821 - 823, XP026385692;;HALSTEAD SB: ""Pathogenesis of dengue: challenges to molecular biology"", SCIENCE, vol. 239, 1988, pages 476 - 481, XP000911208, DOI: doi:10.1126/science.3277268;;MODIS, Y. ET AL.: ""A ligand-binding pocket in the dengue virus envelope glycoprotein"", PROC. NATL. ACAD. SCI. U. S. A, vol. 100, 2003, pages 6986 - 6991, XP002736526, DOI: doi:10.1073/pnas.0832193100;;MODIS, Y. ET AL.: ""Variable Surface Epitopes in the Crystal Structure of Dengue Virus Type 3 Envelope Glycoprotein"", J. VIROL., vol. 79, no. 1, 2005, pages 223 - 1231;;REY,F.A. ET AL.: ""The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution"", NATURE, vol. 375, 1995, pages 299 - 298;;HEINZ, F. X; S. L. ALLISON.: ""Flavivirus structure and membrane fusion"", ADV VIRUS RES., vol. 59, 2003, pages 63 - 97, XP009147796, DOI: doi:10.1016/S0065-3527(03)59003-0;;MODIS, Y. ET AL.: ""Structure of the dengue virus envelope protein after membrane fusion"", NATURE, vol. 427, 2004, pages 313 - 319, XP008094797, DOI: doi:10.1038/nature02165;;CHEN, Y. ET AL.: ""Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate"", NAT. MED, vol. 3, 1997, pages 866 - 871;;NAVARRO-SANCHEZ, E. ET AL.: ""Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses"", EMBO REP, vol. 4, 2003, pages 1 - 6;;TASSANEETRITHEP, B. ET AL.: ""DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells"", J. EXP. MED., vol. 197, 2003, pages 823 - 829, XP002272514, DOI: doi:10.1084/jem.20021840;;ALLISON, S. L. ET AL.: ""Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form"", J. VIROL, vol. 69, 1995, pages 5816 - 5820, XP000885563;;RICE, C. M: ""Virology"", 1996, LIPPINCOTT-RAVEN, article ""Flaviviridae: the viruses and their replication"", pages: 931 - 959;;GUIRAKHOO, F. ET AL.: ""Fusion activity of flaviviruses: comparison of mature and immature (prM containing) tick-borne encephalitis virions."", J. GEN. VIROL., vol. 72, 1991, pages 1323 - 1329;;GUIRAKHOO, F.; BOLIN, R. A.; ROEHRIG, J. T: ""The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein"", VIROLOGY, vol. 191, 1992, pages 921 - 931, XP023051101, DOI: doi:10.1016/0042-6822(92)90267-S;;LORENZ, I. C. ET AL.: ""Folding and dimerization of tick borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum"", J. VIROL., vol. 76, 2002, pages 5480 - 5491, XP002282501, DOI: doi:10.1128/JVI.76.11.5480-5491.2002;;STADLER, K. ET AL.: ""Proteolytic activation of tick-borne encephalitis virus by furin"", J. VIROL., vol. 71, no. 847, 1997, pages 5 - 8481;;ELSHUBER, S. ET AL.: ""Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus"", J. GEN. VIROL., vol. 84, 2003, pages 183 - 191;;ZHANG W CHIPMAN PR ET AL.: ""Visualization of membrane protein domains by cryo- electron microscopy of dengue virus"", NAT STRUCT BIOL., vol. 10, 2003, pages 907 - 12;;KUHN, R.J. ET AL.: ""Structure of dengue virus: implications for flavivirus organization, maturation, and fusion"", CELL, vol. 108, 2002, pages 717 - 725;;ZHANG, Y. ET AL.: ""Structures of immature flavivirus particles"", EMBO J., vol. 22, 2003, pages 2604 - 2613;;ALLISON, S. L. ET AL.: ""Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH"", J. VIROL, vol. 69, 1995, pages 695 - 700;;MODIS, Y. ET AL.: ""Structure of the dengue virus envelope protein after membrane fusion"", NATURE, vol. 427, 2004, pages 313 - 319, XP008094797, DOI: doi:10.1038/nature02165;;BRESSANELLI, S. ET AL.: ""Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation"", EMBO J., vol. 23, 2004, pages 728 - 738, XP002988861, DOI: doi:10.1038/sj.emboj.7600064;;HALSTEAD S.B: ""Neutralization and antibody-dependent enhancement of dengue viruses"", ADV VIRUS RES., 2003, pages 421 - 67;;SABIN, A. B.: ""Research on dengue during World War"", AM. J. TROP. MED. HYG, vol. 1, 1952, pages 30 - 50;;HALSTEAD, S. B.; E. J. O'ROURKE: ""Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody"", J. EXP. MED., vol. 146, 1977, pages 201 - 217;;LITTAUA, R.; I. KURANE; F. A. ENNIS.: ""Human IgG Fc receptor // mediates antibody-dependent enhancement of dengue virus infection"", J. IMMUNOL., vol. 144, 1990, pages 3183 - 3186, XP002606240;;HALSTEAD, S.B.; ROJANASUPHOT, S.; SANGKAWIBHA, N.: ""Original antigenic sin in dengue"", AM. J. TROP. MED. HYG, vol. 32, 1983, pages 154 - 156;;BRANDT, W E. ET AL.: ""Infection enhancement of dengue type 2 virus in the U-937 human monocyte cell line by antibodies to flavivirus cross-reactive determinants"", INFECT. IMMUN, vol. 36, 1982, pages 1036 - 1041;;HALSTEAD, S. B. ET AL.: ""Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies"", J. IMMUNOL, vol. 132, 1984, pages 1529 - 1532;;MORENS, D. M.; S. B. HALSTEAD; N. J. MARCHETTE.: ""Profiles of antibody-dependent enhancement of dengue virus type 2 infection"", MICROB. PATHOG, vol. 3, 1987, pages 231 - 237, XP023312984, DOI: doi:10.1016/0882-4010(87)90056-8;;HEINZ. T. ET AL.: ""Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica"", VIROLOGY, vol. 246, 1998, pages 317 - 328, XP004445759, DOI: doi:10.1006/viro.1998.9200;;HEINZ, F. X; ROEHRIG, J. T.: ""Immunochemistry of Viruses. II. The Basis for Serodiagnosis and Vaccines"", 1990, ELSEVIER, article ""Flaviviruses"", pages: 289 - 305;;MANDL, C. W ET AL.: ""Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model"", J. VIROL., vol. 63, 1989, pages 564 - 571, XP009053965;;I. L. SERAFIN; J. G. AASKOV: ""Identification of epitopes on the envelope (E) protein of dengue 2 and dengue 3 viruses using monoclonal antibodies"", ARCH VIROL, vol. 146, 2001, pages 2469 - 2479;;GUIRAKHOO, F.; R. A. BOLIN; J. T. ROEHRIG: ""The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein"", VIROLOGY, vol. 191, 1992, pages 921 - 931, XP023051101, DOI: doi:10.1016/0042-6822(92)90267-S;;SHEPARD DS ET AL.: ""Cost-effectiveness of a pediatric dengue vaccine"", VACCINE, vol. 22, no. 9-10, 2004, pages 1275 - 80, XP004493392, DOI: doi:10.1016/j.vaccine.2003.09.019;;BARRETT, AD.: ""Current status of flavivirus vaccines"", ANN. N. Y. ACAD. SCI., vol. 951, 2001, pages 262 - 271, XP009037822;;CHANG GJ ET AL.: ""Recent advancement in flavivirus vaccine development"", EXPERT REV VACCINES, vol. 3, no. 2, 2004, pages 199 - 220, XP009061787, DOI: doi:10.1586/14760584.3.2.199;;BHAMARAPRAVATI, N.; SUTEE, Y.: ""Live attenuated tetravalent dengue vaccine"", VACCINE, vol. 18, 2000, pages 44 - 47, XP004203589, DOI: doi:10.1016/S0264-410X(00)00040-2;;ECKELS, KH. ET AL.: ""Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys"", AM. J. TROP. MED. HYG, vol. 69, 2003, pages 12 - 16, XP007912230;;INNIS, B.L.; ECKELS, KH.: ""Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command"", AM. J. TROP. MED. HYG, vol. 69, 2003, pages 1 - 4, XP008164083;;BLANEY, J.E, JR. ET AL.: ""Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice"", ARCH. VIROL., vol. 148, 2003, pages 999 - 1006;;DURBIN, AP ET AL.: ""Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region"", AM. J. TROP. MED. HYG, vol. 65, 2001, pages 405 - 413, XP002399566;;GUIRKHOO F; ARROYO J; PUGACHEV KV ET AL.: ""Construction, safety, and immunogenicity in non-human primates of a chimeric yellow fever-dengue virus tetravalent vaccine"", J VIROL, vol. 75, 2001, pages 7290 - 304;;HUANG CY; BUTRAPET S; PIERRO DJ ET AL.: ""Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine"", J VIROL, vol. 74, 2000, pages 3020 - 28, XP002174039, DOI: doi:10.1128/JVI.74.7.3020-3028.2000;;MARKOFF L; PANG X; HOUNG HS ET AL.: ""Derivation and characterization of a dengue 1 host-range restricted mutant virus that is attenuated and highly immunogenic in monkeys"", J VIROL, vol. 76, 2002, pages 3318 - 28, XP002324288, DOI: doi:10.1128/JVI.76.7.3318-3328.2002;;SELIGMAN SJ; GOULD EA: ""Live flavivirus vaccines: reasons for caution"", LANCET, vol. 363, no. 9426, 2004, pages 2073 - 5, XP004773764, DOI: doi:10.1016/S0140-6736(04)16459-3;;CHANG, G.J. ET AL.: ""Flavivirus DNA vaccines: current status and potential"", ANN. N. Y. ACAD. SCI., vol. 951, 2001, pages 272 - 285, XP009033267;;SIMMONS, M. ET AL.: ""Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine"", AM. J. TROP. MED. HYG, vol. 65, 2001, pages 420 - 426, XP055091828;;FEIGHNY, R.; BORROUS, J.; PUTNAK R.: ""Dengue type-2 virus envelope protein made using recombinant baculovirus protects mice against virus challenge"", AM. J. TROP. MED. HYG, vol. 50, no. 3, 1994, pages 322 - 328;;DEUBEL, V.; STAROPOLI, I.; MEGRET, F. ET AL.: ""Affinity-purified dengue-2 virus envelope glycoprotein induces neutralising antibodies and protective immunity in mice"", VACCINE, vol. 15, 1997, pages 1946 - 1954, XP004097390, DOI: doi:10.1016/S0264-410X(97)00128-X;;SABIN, A. B.: ""Research on dengue during World War II."", AM. J. TROP. MED. HYG, vol. 1, 1952, pages 30 - 50;;ROTHMAN AL: ""Dengue: defining protective versus pathologic immunity"", J. CLIN. INVEST, vol. 113, 2004, pages 946 - 951;;MEN, R. ET AL.: ""Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus"", J. VIROL, vol. 78, 2004, pages 4665 - 4674, XP002338599, DOI: doi:10.1128/JVI.78.9.4665-4674.2004;;GONCALVEZ, A.P. ET AL.: ""Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses"", J. VIROL., vol. 78, 2004, pages 12910 - 12918, XP002338601, DOI: doi:10.1128/JVI.78.23.12910-12918.2004;;WANG, W K. ET AL.: ""High levels of plasma dengue viral load during defervescence in patients with dengue haemorrhagic fever: implications for pathogenesis"", VIROLOGY, vol. 305, 2003, pages 330 - 338;;VAUGHN,D. W ET AL.: ""Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity"", J. INFECT. DIS, vol. 181, 2000, pages 2 - 9;;HAHN CS ET AL.: ""Bispecific monoclonal antibodies mediate binding of dengue virus to erythrocytes in a monkey model of passive viremia"", J IMMUNOL, vol. 166, 2001, pages 1057 - 65, XP002294689;;ALTSCHUL, S.F. ET AL.: ""Basic local alignment search tool"", J. MOL. BIOL., vol. 215, 1990, pages 403 - 410, XP002949123, DOI: doi:10.1006/jmbi.1990.9999;;PEARSON WR; LIPMAN DJ: ""Improved tools for biological sequence comparison"", PROC NATL ACAD SCI U S A., vol. 85, 1988, pages 2444 - 8, XP002060460, DOI: doi:10.1073/pnas.85.8.2444;;HIGGINS D. ET AL.: ""CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weightingposition-specific gap penalties and weight matrix choice"", NUCLEIC ACIDS RES., vol. 22, 1994, pages 4673 - 4680, XP002956304;;SIMMONS M; MURPHY GS; HAYES CG: ""Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine"", AM J TROP MED HYG, vol. 65, 2001, pages 159 - 61;;HERMIDA L ET AL.: ""A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice"", J VIROL METHODS, vol. 115, no. 1, January 2004 (2004-01-01), pages 41 - 9, XP002314675, DOI: doi:10.1016/j.jviromet.2003.09.024;;DREW PD ET AL.: ""Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not"", J GEN VIROL, vol. 82, 2001, pages 1959 - 63, XP002485639;;LANTTO J; FLETCHER JM; OHLIN M.: ""A divalent antibody format is required for neutralization of human cytomegalovirus via antigenic domain 2 on glycoprotein B"", J GEN VIROL., vol. 83, 2002, pages 2001 - 5, XP002505837;;GONCALVEZ AP ET AL.: ""Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses"", J VIROL, vol. 78, 2004, pages 12910 - 8, XP002338601, DOI: doi:10.1128/JVI.78.23.12910-12918.2004;;THULLIER, P. ET AL.: ""A recombinant Fab neutralizes dengue virus in vitro"", J. BIOTECHNOL., vol. 69, 1999, pages 183 - 190, XP004168126, DOI: doi:10.1016/S0168-1656(99)00037-1;;DAMES SA ET AL.: ""NMR structure of a parallel homotrimeric coiled coil"", NAT STRUCT BIOL, vol. 5, 1998, pages 687 - 91;;ROOMAN MJ; KOCHER JP; WODAK SJ: ""Prediction of protein backbone conformation based on seven structure assignments. Influence of local interactions"", J MOL BIOL., vol. 221, 1991, pages 961 - 79, XP024009536, DOI: doi:10.1016/0022-2836(91)80186-X;;JONES, G. Y COLS.: ""Development and validation of a genetic algorithm for flexible docking"", J. MOL. BIOL, vol. 267, 1997, pages 727 - 748, XP004462177, DOI: doi:10.1006/jmbi.1996.0897;;KUNTZ, I.D: ""A geometric approach to macromolecule-ligand interactions"", J. MOL. BIOL., vol. 161, 1982, pages 269 - 288, XP024019141, DOI: doi:10.1016/0022-2836(82)90153-X;;OLENDER, R.; ROSENFELD, R.: ""A fast algorithm for searching for molecules containing a pharmacophore in very large virtual combinatorial libraries."", J. CHEM. INF. COMPUT. SCI, vol. 4, no. 1, 2001, pages 731 - 738;;IRWING, J.J.; SCOICHET, B.K.: ""Zinc - A free Database of commercially available compounds for virtual screening"", J. CHEM. INF. MODEL., vol. 45, 2005, pages 177 - 182, XP055113478, DOI: doi:10.1021/ci049714+;;GLASER, F. ET AL., BIOINFORMATICS, vol. 19, 2003, pages 163 - 164;;DEUBEL V.; KINNEY R.M.; TRENT D.W: ""Nucleotide sequence and deduced amino acid sequence of the structural proteins of dengue type 2 virus, Jamaica genotype"", VIROLOGY, vol. 155, no. 2, 1986, pages 365 - 377, XP023050104, DOI: doi:10.1016/0042-6822(86)90200-X;;AGARWAL KL ET AL.: ""Total synthesis of the Gene for an alanine transfer ribonucleic acid from yeast"", NATURE, vol. 227, 1970, pages 27 - 34;;BEAUCAGE SL; CARUTHERS MH: ""Deoxynucleoside phosphoramidites- A new class of key intermediates for deoxypolynucleotide synthesis"", TETRAHEDRON LETTERS, vol. 22, 1981, pages 1859, XP002007271, DOI: doi:10.1016/S0040-4039(01)90461-7;;BULLOCK WO; FERNÁNDEZ JM; SHORT JM: ""XL-1Blue: A high efficiency plasmid transforming recA Escherichia coli K12 strain with beta-galactosidase selection"", BIOTECHNIQUES, vol. 5, 1987, pages 376 - 8, XP000675447;;SAMBROOK J; FRITSCH EF; MANIATIS T: ""Molecular cloning: A laboratory manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;SULKOWSKI, E.: ""Purification of proteins by IMAC"", TRENDS BIOTECHNOL, vol. 3, 1985, pages 1 - 7, XP023595042, DOI: doi:10.1016/0167-7799(85)90068-X;;SAMBROOK J; FRITSCH EF; MANIATIS T.: ""Molecular cloning: A laboratory manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;F. WAND B. A.: ""Moffatt. ""Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes"", J.MOL.BIOL., vol. 189.1, 1986, pages 113 - 30;;AUSUBEL, F.M. ET AL.: ""Current Protocols in Molecular Biology"", 1989, JOHN WILEY & SONS;;ROEHRIG JT ET AL.: ""Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein"", J VIROL., vol. 78, 2004, pages 2648 - 52;;S.R. COMEAU ET AL.: ""ClusPro: an automated docking and discrimination method for the prediction of protein complexes"", BIOINFORMATICS, vol. 20, 2004, pages 45 - 50, Retrieved from the Internet <URL:http://nrc.bu.edu/cluster>;;MANDELL JG ET AL.: ""Protein docking using continuum electrostatics and geometric fit"", PROTEIN ENG, vol. 14, 2001, pages 105 - 13;;CHEN R; LI L; WENG Z: ""ZDOCK: An Initial-stage Protein-Docking Algorithm"", PROTEINS, vol. 52, 2003, pages 80 - 87, XP002660220;;ROEHRIG, J.T.; BOLIN, R.A.; KELLY, R. G: ""Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica"", VIROLOGY, vol. 246, 1998, pages 317 - 328, XP004445759, DOI: doi:10.1006/viro.1998.9200;;LUND, J. ET AL., J. IMMUNOL., vol. 157, 1996, pages 4963 - 4969;;LUND, J. ET AL., FASEB. J., vol. 9, 1995, pages 115 - 119;;WILTSCHECK R ET AL.: ""Heteronuclear NMR assignments and secondary structure of the coiled coil trimerization domain from cartilage matrix protein in oxidized and reduced forms"", PROTEIN SCI., vol. 6, 1997, pages 1734 - 45;;AGARWAL KL ET AL.: ""Total synthesis of the Gene for an alanine transfer ribonucleic acid from yeast"", NATURE, vol. 227, 1970, pages 27 - 34;;BEAUCAGE SL; CARUTHERS MH: ""Deoxynucleoside phosphoramidites- A new class of key intermediates for deoxypolynucleotide synthesis."", TETRAHEDRON LETTERS, vol. 22, 1981, pages 1859, XP002007271, DOI: doi:10.1016/S0040-4039(01)90461-7;;BULLOCK WO; FEMANDEZ JM; SHORT JM: ""XL-1Blue: A high efficiency plasmid transforming recA Escherichia coli K12 strain with beta-galactosidase selection"", BIOTECHNIQUES, vol. 5, 1987, pages 376 - 8, XP000675447;;SULKOWSKI, E.: ""Purification of proteins by IMAC"", TRENDS BIOTECHNOL., vol. 3, 1985, pages 1 - 7, XP023595042, DOI: doi:10.1016/0167-7799(85)90068-X;;F. WAND B. A. MOFFATT: ""Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes"", J.MOL.BIOL., vol. 189, no. 1, 1986, pages 113 - 30;;AUSUBEL, F.M. ET AL.: ""Current Protocols in Molecular Biology"", 1989, JOHN WILEY & SONS",PENDING
71,EP,A1,EP 1526380 A1,092-460-189-910-23X,2005-04-27,2005,EP 03380236 A,2003-10-21,EP 03380236 A,2003-10-21,Methods for in vitro diagnosis and in vitro prognosis of cancer of the pancreas and for the development of drugs against cancer of the pancreas,"The present invention refers to an  in vitro  method to detect a cancer of the pancreas, especially a ductal adenocarcinoma of the pancreas, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the EFNB2 protein and/or the EDNRA protein, and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,DEL AMON IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUREDO GARCIA DE GALDEANO PE;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;ARGUELLES SANCHEZ MARIA ELADIA;;DE LOS TOYOS GONZALEZ JUAN RAM;;BARNEO SERRA LUIS,,https://lens.org/092-460-189-910-23X,Patent Application,yes,4,0,1,1,28,G01N33/57438;;G01N33/6893;;G01N2500/00,G01N33/574;;G01N33/68,,5,4,005-752-186-572-254;;002-124-695-618-648;;090-433-846-511-962;;052-187-065-750-38X,10.1002/cncr.10122;;11920461;;10.1007/s00432-002-0355-0;;12136247;;12651607;;10.1016/s0002-9440(10)63911-9;;pmc1851213;;10.2165/00128413-200012390-00013,"LIU W ET AL: ""COEXPRESSION OF EPHRIN-BS AND THEIR RECEPTORS IN COLON CARCINOMA"", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 94, no. 4, 15 February 2002 (2002-02-15), pages 934 - 939, XP001156840, ISSN: 0008-543X;;KATAOKA, H. ET AL: ""Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer"", J CANCER RES CLIN ONCOL, vol. 128, 2002, pages 343 - 348, XP001179752;;IACOBUZIO-DONAHUE, C.A. ET AL: ""Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays"", AMERICAN JOURNAL OF PATHOLOGY, vol. 162, no. 4, April 2003 (2003-04-01), pages 1151 - 1162, XP009027111;;HOTZ, H.G. ET AL: ""The effect of selective endothelin-A-receptor blockade on human pancreatic cancer in vivo"", PANCREAS, vol. 21, no. 4, 2000, pages 448, XP009036713;;MAITRE NATHALIE L ET AL: ""Endothelin receptor A (ETA) expressing tumors as potential targets for endothelin receptor antagonist therapy"", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 41, March 2000 (2000-03-01), & 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.; SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000, pages 528, XP001183532, ISSN: 0197-016X",DISCONTINUED
72,WO,A1,WO 2005/040813 A1,074-532-299-202-768,2005-05-06,2005,EP 2004012063 W,2004-10-22,ES 200302458 A,2003-10-22,XAG PROTEIN IN THE IN VITRO DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA,"The present invention refers to an in vitro method to detect pancreatic ductal adenocarcinoma in an individual, to determine the stage or severity of said condition in an individual, or to monitor the effect of therapy administered to an individual with either one or both of said condition; to screen for, identify, develop and evaluate the efficacy of compounds for the treatment of said condition of the pancreas aimed at developing new medicinal products, as well as agents that inhibit the expression and/or activity of the XAG protein (anterior gradient 2 homolog-Xenopus laevis-aliases: AGR2, AG2, GOB-4, HAG-2, XAG-2. UniGene: Hs.226391, GeneBank: NM&lowbar;006408) and/or the effects of said expression.",PROGENIKA BIOPHARMA SA;;DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUDERO GARCIA DE GALDEANO PE;;ARGUEELLES SANCHEZ MARIA ELADI;;DE LOS TOYOS GONZALEZ JUAN RAM;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;BARNEO SERRA LUIS;;SIMON BUELA LAUREANO,DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUDERO GARCIA DE GALDEANO PE;;ARGUEELLES SANCHEZ MARIA ELADI;;DE LOS TOYOS GONZALEZ JUAN RAM;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;BARNEO SERRA LUIS;;SIMON BUELA LAUREANO,,https://lens.org/074-532-299-202-768,Patent Application,yes,2,3,3,3,15,A61K38/00;;A61P35/00;;G01N33/57438;;G01N33/68;;G01N33/57438,G01N33/574;;G01N33/68,,5,5,090-433-846-511-962;;022-468-759-873-205;;002-697-867-701-594;;012-723-831-077-784;;042-543-946-920-903,12651607;;10.1016/s0002-9440(10)63911-9;;pmc1851213;;11830538;;9790916;;10.1006/bbrc.1998.9440;;12592373;;pmc2377166;;10.1038/sj.bjc.6600740;;15305381;;10.1002/ijc.20376,"IACOBUZIO-DONAHUE CHRISTINE A ET AL: ""Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays."", AMERICAN JOURNAL OF PATHOLOGY, vol. 162, no. 4, April 2003 (2003-04-01), pages 1151 - 1162, XP002319210, ISSN: 0002-9440;;RYU, BYUNGWOO ET AL RYU, BYUNGWOO ET AL: ""Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression Synthesis and crystal structure of"", CANCER RESEARCH , 62(3), 819-826 CODEN: CNREA8; ISSN: 0008-5472 CANCER RESEARCH , 62(3), 819-826 CODEN: CNREA8; ISSN: 0008-5472, 2002, XP002319211;;THOMPSON DEVON A ET AL: ""hAG-2, the human homologue of the Xenopus laevis cement gland gene 4 XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 251, no. 1, 9 October 1998 (1998-10-09), pages 111 - 116, XP002319212, ISSN: 0006-291X;;FLETCHER G C ET AL: ""hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan."", BRITISH JOURNAL OF CANCER, vol. 88, no. 4, 24 February 2003 (2003-02-24), pages 579 - 585, XP002319213, ISSN: 0007-0920;;MISSIAGLIA EDOARDO ET AL: ""Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis"", INTERNATIONAL JOURNAL OF CANCER, vol. 112, no. 1, 20 October 2004 (2004-10-20), pages 100 - 112, XP008043556, ISSN: 0020-7136",PENDING
73,EP,A1,EP 1526381 A1,140-893-318-217-419,2005-04-27,2005,EP 03380238 A,2003-10-21,EP 03380238 A,2003-10-21,Methods for in vitro diagnosis and in vitro prognosis of cancer of the pancreas and for the development of drugs against cancer of the pancreas,"The present invention refers to an  in vitro  method to detect a cancer of the pancreas, especially a ductal adenocarcinoma of the pancreas, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the DDEF2 protein and/or the effects of this expression.",MEDPLANT GENETICS S L,DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUREDO GARCIA DE GALDEANO PE;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;ARGUELLES SANCHEZ MARIA ELADIA;;DE LOS TOYOS GONZALEZ JUAN RAM;;BARNEO SERRA LUIS,"PROGENIKA BIOPHARMA, S.A. (2006-05-31)",https://lens.org/140-893-318-217-419,Patent Application,yes,1,2,1,1,15,G01N33/57438;;G01N33/6893;;G01N2500/00,G01N33/574;;G01N33/68,,8,7,151-593-502-617-118;;001-038-756-378-653;;090-433-846-511-962;;000-840-121-185-93X;;030-593-846-723-97X;;014-919-172-223-051;;058-074-005-829-851,10022920;;10.1128/mcb.19.3.2338;;pmc84026;;11820787;;10.1006/bbrc.2002.6350;;12651607;;10.1016/s0002-9440(10)63911-9;;pmc1851213;;pmc83965;;10.1128/mcb.19.3.1720;;10022859;;12750293;;pmc1867224;;10.1016/s0002-9440(10)62551-5;;11943709;;11704875;;10.1038/sj.onc.1204935,"ANDREEV, J. ET AL: ""Identification of a new Pyk2 target protein with Arf-GAP activity"", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 3, March 1999 (1999-03-01), pages 2338 - 2350, XP002273219;;KEOGH, R. J. ET AL: ""Human endothelial Pyk2 is expressed in two isoforms and associates with paxilin and p130Cas"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 290, 2002, pages 1470 - 1477, XP002273220;;IACOBUZIO-DONAHUE C. A. ET AL: ""Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays"", AMERCIAN JOURNAL OF PATHOLOGY, vol. 162, no. 4, April 2003 (2003-04-01), pages 1151 - 1152, XP009027111;;GYGI ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 3, 1999, pages 1720 - 1730;;SATO ET AL., AMERICAN JOURNAL OF PATHOLOGY, vol. 164, 1 May 2004 (2004-05-01), pages 903 - 914;;LOGSDON ET AL., CANCER RESEARCH, vol. 63, 1 May 2003 (2003-05-01), pages 2649 - 2657;;IACBUZIO-BONAHUE ET A.: ""Discovery of novel tumor markers of pancreatic cancer using global gene expression technology"", AMERICAN JOURNAL OF PATHOLOGY, vol. 160, 2002, pages 1239 - 1249, XP008003747;;CRNOGORAC-JURCEVOC ET AL.: ""Gene expression profiles of pancreatic cancer and stromal desmoplasia"", ONCOGENE, vol. 20, 2001, pages 7437 - 7446, XP002267284, DOI: 10.1038/sj.onc.1204935",DISCONTINUED
74,CU,A1,CU 23586 A1,089-440-720-215-746,2010-10-30,2010,CU 20050229 A,2005-11-22,CU 20050229 A,2005-11-22,MÉTODOS Y PROTEÍNAS PARA EL TRATAMIENTO PROFILÁCTICO Y/O TERAPÉUTICO DE LOS CUATRO SEROTIPOS DEL VIRUS DE DENGUE Y OTROS FLAVIVIRUS,"La presente invención está relacionada con la industria farmacéutica, se describe un área conservada de la superficie de la proteína E, empleable en el desarrollo de moléculas de amplio espectro útiles en la prevención y/o tratamiento de las infecciones por virus dengue 1-4 y otros flavivirus. Además la presente invención se relaciona con proteínas quiméricas para uso en el tratamiento profilático y terapéutico contra los cuatro serotipos del virus de dengue y otros flavivirus.",CT INGENIERIA GENETICA BIOTECH,SARRIA NUNEZ MONICA;;TOLEDO MAYORA PATRICIA GRABIELA;;PAEZ MEIRELES ROLANDO;;ZULUETA MORALES AIDA;;GUIROLA CRUZ OSMANY;;FLEITAS SALAZAR NORALVIS;;MARTIN DUNN ALEJANDRO MIGUEL;;HUERTA GALINDO VIVIAN;;GIL VALDES JEOVANIS;;MUSACCHIO LASA ALEXIS S;;MAZOLA REYES YULIET;;GAVILONDO COWLEY JORGE V;;CHINEA SANTIAGO GLAY;;HERMIDA CRUZ LISSET;;AYALA AVILA MARTA;;GONZALEZ ROCHE DIAMILE,,https://lens.org/089-440-720-215-746,Limited Patent,no,0,0,15,15,0,A61K39/00;;A61K39/12;;C07K14/005;;C07K2319/02;;C07K2319/21;;C12N2770/24022;;C12N2770/24122;;A61K2039/55566;;C12N2770/24134;;A61P31/14;;Y02A50/30;;C07K14/18;;C12N15/11;;C07K16/10;;A61K39/12;;C07K14/005;;C07K2319/02;;A61K39/00;;A61K39/12;;C07K2319/21;;C12N2770/24122;;C12N2770/24022;;C12N2770/24134;;A61K2039/55566;;Y02A50/30,A61K39/12;;C12N15/40,,0,0,,,,EXPIRED
75,PT,A,PT 106536 A,068-014-005-092-667,2014-03-13,2014,PT 10653612 A,2012-09-13,PT 10653612 A,2012-09-13,COMPOSIÇÃO DE ÁCIDOS TRITERPENOIDES OBTIDOS DO EXTRATO DE THYMUS MASTICHINA E SUAS UTILIZAÇÕES MEDICINAIS,"O ESTUDO GUIADO PELA CITOTOXICIDADE DOS EXTRATOS DE DICLOROMETANO E ETANOL DE THYMUS MASTICHINA L. UTILIZANDO A LINHA DE CÉLULAS DE CANCRO DO CÓLON HCT PERMITIU A IDENTIFICAÇÃO DE NOVE COMPOSTOS, SACURANETINA (1), ESTERUBINA (2), ÁCIDO OLEANÓLICO (3), ÁCIDO URSÓLICO (4), LUTEÍNA (5), Β-SITOSTEROL (6), ÁCIDO ROSMARÍNICO (7), 6-HIDROXILUTEOLIN-7-O-Β-GLUCOPIRANÓSIDO (8) E 6-HIDROXIAPIGENIN-7-O-Β-GLUCOPIRANÓSIDO (9). ESTES FORAM TESTADOS QUANTO À SUA CITOTOXICIDADE CONTRA A LINHA DE CÉLULAS DE CANCRO DO CÓLON HCT. O COMPOSTO 4 EXIBIU CITOTOXICIDADE COM UM VALOR GI50 DE 6,8 MICROG/ML. UMA FRAÇÃO COMPOSTA POR UMA MISTURA (1:1) DOS ÁCIDOS TRITERPENOIDES 3 E 4 EXIBIU CITOTOXICIDADE MELHORADA COM UM GI50 DE 2,8 ΜICROG/ML, SUGERINDO UM COMPORTAMENTO SINERGÉTICO. A PRESENÇA DESTES CONSTITUINTES IDENTIFICADOS POR ATIVIDADE GUIADA POR CITOTOXICIDADE CONTRA CANCRO DO CÓLON INDICA QUE EXTRATOS DE T. MASTICHINA L. PODEM TER EM MEDICINA, EM TRATAMENTO DE DOENÇAS TUMORAIS E/OU CANCEROSAS.",ECBIO INVESTIGAÇ O E DESENVOLVIMENTO EM BIOTECNOLOGIA S A,BÁRCIA RITA NOGUEIRA;;FILIPE MARIANA ALVES;;ALMEIDA JOANA MARGARIDA MARTO SAMPAIO DE;;CRUZ PEDRO ESTILITA PEREIRA MONTEIRO DA;;CRUZ HÉLDER JOAQUIM SOARES DA;;SANTOS JORGE MIGUEL PEREIRA DE OLIVEIRA DA SILVA;;OLIVA ABEL MARTIN GONZALEZ;;LOURENÇO ANA MARIA FERREIRA DA COSTA;;MÁXIMO PATRÍCIA ISABEL DA SILVEIRA;;GORDO JOANA GOMES ALVES;;CABRITA EURICO JOSÉ DA SILVA,,https://lens.org/068-014-005-092-667,Patent Application,no,1,0,1,1,0,,A61K31/19;;A61K31/191;;A61K36/53,,0,0,,,,DISCONTINUED
76,WO,A1,WO 2023/067125 A1,186-439-679-066-475,2023-04-27,2023,EP 2022079345 W,2022-10-21,EP 21382958 A;;EP 21382959 A;;EP 21382960 A;;EP 21382961 A;;EP 21383082 A;;EP 22382516 A;;EP 22382514 A;;EP 22382517 A;;EP 22382515 A;;EP 22382518 A;;EP 22382896 A;;EP 22382898 A;;EP 22382897 A;;EP 22382895 A,2021-10-22,OLIGOSACCHARIDE COMPLEXES AND USES,"The present disclosure provides complexes comprising: i) a cationic oligosaccharide comprising one or more cationic moieties bonded to a trehalose, a sucrose, or a gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives selected from: a sterol, a helper lipid, an immunomodulator, and a targeting molecule; and uses thereof.",BIONTECH SE;;UNIV SEVILLA;;CONSEJO SUPERIOR DE INVESTIG,MORENO HERRERO JORGE;;HAAS HEINRICH;;ERBAR STEPHANIE;;STAHL THEO BENJAMIN;;GARCIA FERNANDEZ JOSE MANUEL;;BENITO HERNANDEZ JUAN MANUEL;;LOPEZ FERNANDEZ JOSE;;ORTIZ MELLET MARIA DEL CARMEN;;DE LA CRUZ RUIZ NOELIA;;GONZALEZ CUESTA MANUEL;;AMBULUDI EGON JACK JACOBUS;;VLATKOVIC IRENA,,https://lens.org/186-439-679-066-475,Patent Application,yes,16,0,1,15,0,A61K47/549;;A61P31/12;;A61K9/0019;;A61K9/5123;;A61K47/543;;C12N15/88,A61K47/54;;A61K9/00;;A61K9/51;;A61K47/26;;A61P31/12;;C07H15/14;;C07H15/26,,18,13,033-851-384-071-679;;029-865-253-859-83X;;033-851-384-071-679;;007-364-858-655-289;;108-284-544-120-806;;052-092-138-640-885;;031-049-330-348-926;;056-333-402-999-433;;014-750-465-875-837;;002-749-661-776-250;;030-876-838-743-831;;101-563-804-327-465;;058-793-588-893-927,31268107;;10.1039/c9cc04489b;;33540942;;10.3390/pharmaceutics13020206;;pmc7913163;;31268107;;10.1039/c9cc04489b;;10.1002/jps.2600660104;;833720;;10.1016/0008-6215(94)00312-4;;7736467;;10.1016/0008-6215(94)00239-8;;7842445;;10.1021/la502629d;;25130415;;pmc4176395;;10.1039/c5ra03321g;;26251697;;pmc4523246;;30702850;;10.1021/acschembio.9b00063;;12392403;;10.1021/ja028151k;;21253633;;10.1039/c0cc05137c;;10.1021/ja00075a021;;10.1039/c9cc03020d;;31240288,"CARBAJO-GORDILLO ANA I. ET AL: ""Trehalose-based Siamese twin amphiphiles with tunable self-assembling, DNA nanocomplexing and gene delivery properties"", CHEMICAL COMMUNICATIONS, vol. 55, no. 57, 11 July 2019 (2019-07-11), UK, pages 8227 - 8230, XP055907712, ISSN: 1359-7345, DOI: 10.1039/C9CC04489B;;ALDOSARI BASMAH N. ET AL: ""Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines"", PHARMACEUTICS, vol. 13, no. 2, 2 February 2021 (2021-02-02), CH, pages 206, XP055929575, ISSN: 1999-4923, DOI: 10.3390/pharmaceutics13020206;;CARBAJO-GORDILLO ET AL., CHEM. COMM., vol. 55, 2019, pages 8227 - 8230;;THOMAS SORRELL: ""Handbook of Chemistry and Physics"", 1999, UNIVERSITY SCIENCE BOOKS;;""March's Advanced Organic Chemistry"", 2001, JOHN WILEY & SONS;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;""Remington's The Science and Practice of Pharmacy"", 2006, LIPPINCOTT, WILLIAMS & WILKINS;;""Remington: The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;J. M. GARCIA FERNANDEZC. ORTIZ MELLETJ. L. JIMENEZ BLANCOJ. FUENTES MOTAA. GADELLEA. COSTE-SARGUETJ. DEFAYE, CARBOHYDR. RES., vol. 268, 1995, pages 57 - 71;;J. M. GARCIA FERNANDEZA. GADELLEJ. DEFAYE, CARBOHYDR. RES., vol. 265, 1994, pages 249 - 269;;G. O. ASPINALLR. C. CARPENTERL. KHONDO, CARBOHYDR. RES., vol. 165, 1987, pages 281 - 298;;Y.-J. GHANG, J. J. LLOYD, M. P. MOEHLIG, J. K. ARGUELLES, M. METTRY, X. ZHANG, R. R. JULIAN, Q. CHENG, R. J. HOOLEY, LANGMUIR, vol. 30, 2014, pages 10160 - 10166;;S. M. HICKEYT. D. ASHTONJ. M. WHITEJ. LIR. L. NATIONH. Y. YUA. G. ELLIOTTM. S. BUTLERJ. X. HUANGM. A. COOPER, RSC ADV., vol. 5, 2015, pages 28582 - 28596;;Y. WUA. KAURE. FOWLERM. M. WIEDMANNR. YOUNGW. R. J. D. GALLOWAYL. OLSENH. F. SOREA. CHATTOPADHYAYT. T.-L. KWAN, ACS CHEM. BIOL., vol. 14, 2019, pages 526 - 533;;L. LIUM. ROZENMANR. BRESLOW, J. AM. CHEM. SOC., vol. 124, 2002, pages 12660 - 12661;;BONG. D. BONG ET AL., CHEM. COMMUN., vol. 47, 2011, pages 2853 - 2855;;D. M. KNEELAND ET AL., J. AM. CHEM. SOC., vol. 115, 1993, pages 10042 - 10055;;L. I. PILKINGTON ET AL., CHEM. COMMUN., vol. 55, 2019, pages 8868 - 8871",PENDING
77,EP,A1,EP 4285933 A1,185-247-211-785-877,2023-12-06,2023,EP 22382517 A,2022-05-30,EP 22382517 A,2022-05-30,OLIGOSACCHARIDE COMPLEXES AND USES,"The present disclosure provides complexes i) a cationic oligosaccharide comprising one or more cationic moieties bonded to a trehalose, a sucrose, or a gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives selected from: a sterol, a helper lipid, an immunomodulator, and a targeting molecule; and used thereof
",BIONTECH SE;;CONSEJO SUPERIOR INVESTIGACION;;UNIV SEVILLA,MORENO HERRERO JORGE;;HAAS HEINRICH;;ERBAR STEPHANIE;;STAHL THEO BENJAMIN;;GARCIA FERNANDEZ JOSE MANUEL;;BENITO HERNANDEZ JUAN MANUEL;;LOPEZ FERNANDEZ JOSE;;ORTIZ MELLET MARIA DEL CARMEN;;DE LA CRUZ RUIZ NOELIA;;GONZALEZ CUESTA MANUEL;;JACOBUS AMBULUDI EGON JACK;;VLATKOVIC IRENA,,https://lens.org/185-247-211-785-877,Patent Application,yes,19,0,1,15,0,A61K47/61;;A61P37/02;;A61K2039/53;;A61K39/12;;C12N2760/16134;;A61K2039/55511;;A61K39/39,A61K47/61;;A61P37/02,,23,16,033-851-384-071-679;;046-372-293-366-053;;020-796-951-271-247;;030-876-838-743-831;;042-923-524-761-652;;096-245-315-692-418;;008-446-646-053-599;;012-705-986-050-149;;033-851-384-071-679;;108-284-544-120-806;;052-092-138-640-885;;101-563-804-327-465;;031-049-330-348-926;;056-333-402-999-433;;014-750-465-875-837;;002-749-661-776-250,31268107;;10.1039/c9cc04489b;;25268544;;10.1021/jm501182w;;10.1039/d1ob01816g;;34668911;;21253633;;10.1039/c0cc05137c;;12526715;;10.1021/bc025592k;;10.1021/bc025593c;;12526716;;23872329;;10.1016/j.carres.2013.06.017;;10.1016/j.carbpol.2014.03.050;;24906726;;31268107;;10.1039/c9cc04489b;;10.1016/0008-6215(94)00312-4;;7736467;;10.1016/0008-6215(94)00239-8;;7842445;;10.1021/ja00075a021;;10.1021/la502629d;;25130415;;pmc4176395;;10.1039/c5ra03321g;;26251697;;pmc4523246;;30702850;;10.1021/acschembio.9b00063;;12392403;;10.1021/ja028151k,"CARBAJO-GORDILLO ANA I. ET AL: ""Trehalose-based Siamese twin amphiphiles with tunable self-assembling, DNA nanocomplexing and gene delivery properties"", CHEMICAL COMMUNICATIONS, vol. 55, no. 57, 11 July 2019 (2019-07-11), UK, pages 8227 - 8230, XP055907712, ISSN: 1359-7345, DOI: 10.1039/C9CC04489B;;RODRIGUEZ LAVADO JULIO ET AL: ""Trehalose- and Glucose-Derived Glycoamphiphiles: Small-Molecule and Nanoparticle Toll-Like Receptor 4 (TLR4) Modulators"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 21, 13 November 2014 (2014-11-13), US, pages 9105 - 9123, XP055907720, ISSN: 0022-2623, DOI: 10.1021/jm501182w;;GRECO VALENTINA ET AL: ""Mono- and dialdehyde of trehalose: new synthons to prepare trehalose bio-conjugates - Organic & Biomolecular Chemistry (RSC Publishing)"", ORGANIC & BIOMOLECULAR CHEMISTRY, 13 October 2021 (2021-10-13), pages 9427 - 9432, XP055909513, Retrieved from the Internet <URL:https://pubs.rsc.org/en/content/articlelanding/2021/OB/D1OB01816G> [retrieved on 20220405], DOI: DOI https://doi.org/10.1039/D1OB01816G;;MINGMING MA ET AL: ""Stabilization of vesicular and supported membranes by glycolipid oxime polymers"", CHEMICAL COMMUNICATIONS, VOL. 47, N. 10, 1 January 2011 (2011-01-01), pages 2853 - 2855, XP055442187, Retrieved from the Internet <URL:http://pubs.rsc.org/en/content/articlepdf/2011/cc/c0cc05137c> [retrieved on 20180118];;REINEKE THERESA M. ET AL: ""Structural Effects of Carbohydrate-Containing Polycations on Gene Delivery. 1. Carbohydrate Size and Its Distance from Charge Centers"", BIOCONJUGATE CHEMISTRY, vol. 14, no. 1, 1 January 2003 (2003-01-01), US, pages 247 - 254, XP055907379, ISSN: 1043-1802, DOI: 10.1021/bc025592k;;REINEKE THERESA M. ET AL: ""Structural Effects of Carbohydrate-Containing Polycations on Gene Delivery. 2. Charge Center Type"", BIOCONJUGATE CHEMISTRY, vol. 14, no. 1, 1 January 2003 (2003-01-01), US, pages 255 - 261, XP055907376, ISSN: 1043-1802, DOI: 10.1021/bc025593c;;POTEWAR TATERAO M ET AL: ""Efficient microwave assisted synthesis of novel 1,2,3-triazole-sucrose derivatives by cycloaddition reaction of sucrose azides and terminal alk"", CARBOHYDRATE RESEARCH, PERGAMON, GB, vol. 379, 28 June 2013 (2013-06-28), pages 60 - 67, XP028696696, ISSN: 0008-6215, DOI: 10.1016/J.CARRES.2013.06.017;;PETROVA KRASIMIRA T ET AL: ""Amide-linkedN-methacryloyl sucrose containing polymers"", CARBOHYDRATE POLYMERS, APPLIED SCIENCE PUBLISHERS , LTD BARKING, GB, vol. 110, 28 March 2014 (2014-03-28), pages 38 - 46, XP028851850, ISSN: 0144-8617, DOI: 10.1016/J.CARBPOL.2014.03.050;;CARBAJO-GORDILLO ET AL., CHEM. COMM., vol. 55, 2019, pages 8227 - 8230;;THOMAS SORRELL: ""Handbook of Chemistry and Physics"", 1999, UNIVERSITY SCIENCE BOOKS;;""March's Advanced Organic Chemistry"", 2001, JOHN WILEY & SONS;;S. M. BERGE ET AL.: ""describes pharmaceutically acceptable salts in detail"", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;""Remington's The Science and Practice of Pharmacy"", 2006, LIPPINCOTT, WILLIAMS & WILKINS;;""Remington: The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;J. M. GARCIA FERNANDEZC. ORTIZ MELLETJ. L. JIMENEZ BLANCOJ. FUENTES MOTAA. GADELLEA. COSTE-SARGUETJ. DEFAYE, CARBOHYDR. RES., vol. 268, 1995, pages 57 - 71;;J. M. GARCIA FERNANDEZA. GADELLEJ. DEFAYE, CARBOHYDR. RES., vol. 265, 1994, pages 249 - 269;;CAS, no. 2051-49-2;;D. M. KNEELANDK. ARIGAV. M. LYNCHC. Y. HUANGE. V. ANSLYN, J. AM. CHEM. SOC., vol. 115, 1993, pages 10042 - 10055;;T. KIMY.-J. KIMI.-H. HAND. LEEJ. HAMK. S. KANJ. W. LEE, BIOORG. MED. CHEM. LETT., vol. 25, 2015, pages 62 - 66;;Y.-J. GHANGJ. J. LLOYDM. P. MOEHLIGJ. K. ARGUELLESM. METTRYX. ZHANGR. R. JULIANQ. CHENGR. J. HOOLEY, LANGMUIR, vol. 30, 2014, pages 10160 - 10166;;S. M. HICKEYT. D. ASHTONJ. M. WHITEJ. LIR. L. NATIONH. Y. YUA. G. ELLIOTTM. S. BUTLERJ. X. HUANGM. A. COOPER, RSC ADV, vol. 5, 2015, pages 28582 - 28596;;Y. WUA. KAURE. FOWLERM. M. WIEDMANNR. YOUNGW. R. J. D. GALLOWAYL. OLSENH. F. SOREA. CHATTOPADHYAYT. T.-L. KWAN, ACS CHEM. BIOL., vol. 14, 2019, pages 526 - 533;;L. LIUM. ROZENMANR. BRESLOW, J. AM. CHEM. SOC., vol. 124, 2002, pages 12660 - 12661",PENDING
78,WO,A2,WO 2005/029082 A2,161-448-310-750-688,2005-03-31,2005,EP 2004010841 W,2004-09-24,ES 200302213 A,2003-09-24,METHODS FOR THE IN VITRO DIAGNOSIS AND IN VITRO PROGNOSIS OF CANCER OF THE PANCREAS AND FOR THE DEVELOPMENT OF DRUGS AGAINST CANCER OF THE PANCREAS AND/OR PANCREATITIS,"The present invention refers to an in vitro method to detect pancreatic ductal adenocarcinoma and/or pancreatitis in an individual, to determine the stage or severity of said conditions in an individual, or to monitor the effect of therapy administeied to an individual with either one or both of said conditions; to screen for, identify, develop and evaluate the efficacy of compounds for the treatment of said conditions of the pancreas aimed at developing new medicinal products, as well as agents that inhibit the expression and/or activity of the DRM protein and/or the NBL1 protein, and/or the effects of said expression.",PROGENIKA BIOPHARMA SA;;DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUDERO GARCIA DE GALDEANO PE;;ARGUEELLES SANCHEZ MARIA ELADI;;DE LOS TOYOS GONZALEZ JUAN RAM;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;BARNEO SERRA LUIS;;ARIZ LOPEZ DE CASTRO USUE;;SIMON BUELA LAUREANO,DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUDERO GARCIA DE GALDEANO PE;;ARGUEELLES SANCHEZ MARIA ELADI;;DE LOS TOYOS GONZALEZ JUAN RAM;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;BARNEO SERRA LUIS;;ARIZ LOPEZ DE CASTRO USUE;;SIMON BUELA LAUREANO,,https://lens.org/161-448-310-750-688,Patent Application,yes,0,6,4,4,32,C07K16/18;;G01N33/57438;;G01N33/68;;G01N33/57438;;G01N33/6893;;G01N2500/00;;G01N2800/067,C07K16/00;;C07K16/18;;G01N33/574;;G01N33/68,,0,0,,,,PENDING
79,WO,A3,WO 2005/029082 A3,178-083-086-983-214,2005-09-22,2005,EP 2004010841 W,2004-09-24,ES 200302213 A,2003-09-24,METHODS FOR THE IN VITRO DIAGNOSIS AND IN VITRO PROGNOSIS OF CANCER OF THE PANCREAS AND FOR THE DEVELOPMENT OF DRUGS AGAINST CANCER OF THE PANCREAS AND/OR PANCREATITIS,"The present invention refers to an in vitro method to detect pancreatic ductal adenocarcinoma and/or pancreatitis in an individual, to determine the stage or severity of said conditions in an individual, or to monitor the effect of therapy administeied to an individual with either one or both of said conditions; to screen for, identify, develop and evaluate the efficacy of compounds for the treatment of said conditions of the pancreas aimed at developing new medicinal products, as well as agents that inhibit the expression and/or activity of the DRM protein and/or the NBL1 protein, and/or the effects of said expression.",PROGENIKA BIOPHARMA SA;;DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUDERO GARCIA DE GALDEANO PE;;ARGUEELLES SANCHEZ MARIA ELADI;;DE LOS TOYOS GONZALEZ JUAN RAM;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;BARNEO SERRA LUIS;;ARIZ LOPEZ DE CASTRO USUE;;SIMON BUELA LAUREANO,DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUDERO GARCIA DE GALDEANO PE;;ARGUEELLES SANCHEZ MARIA ELADI;;DE LOS TOYOS GONZALEZ JUAN RAM;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;BARNEO SERRA LUIS;;ARIZ LOPEZ DE CASTRO USUE;;SIMON BUELA LAUREANO,,https://lens.org/178-083-086-983-214,Search Report,yes,4,0,4,4,0,C07K16/18;;G01N33/57438;;G01N33/68;;G01N33/57438;;G01N33/6893;;G01N2500/00;;G01N2800/067,C07K16/00;;C07K16/18;;G01N33/574;;G01N33/68,,3,3,090-433-846-511-962;;017-186-900-863-545;;002-880-498-827-946,12651607;;10.1016/s0002-9440(10)63911-9;;pmc1851213;;pmc232332;;10.1128/mcb.17.8.4801;;9234736;;10.1016/s1097-2765(00)80067-2;;9660951,"IACOBUZIO-DONAHUE ET AL: ""Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays"", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 162, no. 4, April 2003 (2003-04-01), pages 1151 - 1162, XP009027111, ISSN: 0002-9440;;TOPOL L Z ET AL: ""IDENTIFICATION OF DRM, A NOVEL GENE WHOSE EXPRESSION IS SUPPRESSED IN TRANSFORMED CELLS AND WHICH CAN INHIBIT GROWTH OF NORMAL BUT NOT TRANSFORMED CELLS IN CULTURE"", MOLECULAR AND CELLULAR BIOLOGY, WASHINGTON, DC, US, vol. 17, no. 8, August 1997 (1997-08-01), pages 4801 - 4810, XP002066577, ISSN: 0270-7306;;HSU D R ET AL: ""The Xenopus dorsalizing factor gremlin identifies a novel family of secreted proteins that antagonize BMP activities"", MOLECULAR CELL, CAMBRIDGE, MA, US, vol. 1, April 1988 (1988-04-01), pages 673 - 683, XP002066230, ISSN: 1097-2765",PENDING
80,MX,A,MX 2010012348 A,051-956-711-487-705,2012-05-15,2012,MX 2010012348 A,2010-11-12,MX 2010012348 A,2010-11-12,COMPOSITION BASED ON GERMINAL ZWITTERIONIC LIQUIDS AS WETTABILITY MODIFIERS IN PROCESSES FOR THE IMPROVED RECOVERY OF OIL.,"The present invention refers to the application of germinal zwitterionic liquids of the bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta iminoacid type or salts as rock wettability modifiers such as limestone, dolomite, grit, quartz or heterogeneous lithologies, in the presence of brine with a high content of divalent ions such as calcium, magnesium, barium and strontium, high temperature and pressure, in improved processes of oil recovery. The wettability modifiers have zwitterionic liquids of the bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta iminoacid type, using distilled water or brine as a dissolvent with a high content of divalent ions such as calcium and magnesium or organic solvents derived from alcohols comprising methanol, ethanol, isopropanol or mixtures thereof, 6 aromatics such as isomers of xylem, toluene or diesel, gasoline or mixtures thereof. The zwitterionic liquids of the bis-N-alkyl polyether or b is-N-alkenyl polyether or bis-N-aryl polyether bis-beta iminoacid or the salts thereof are obtained upon reacting an aminealkyl or alkenyl or aromatic and a reactant polyether derived from the ethylene oxide or propylene or copolymer thereof, which may contain a tosyl or mesyl group structure; the reacting product is subsequently reacted with unsaturated acids such as acrylic acid or methacrylic acid and subsequently may or may not be neutralised with alkaline metal bases such as sodium or potassium hydroxide, potassium or sodium carbonates or bicarbonates.",MEXICANO INST PETROL,RIVERA LUIS SILVESTRE ZAMUDIO;;CONDE HIRAM ISAAC BELTRAN;;GONZALEZ EDUARDO BUENROSTRO;;CERVANTES VIOLETA YASMIN MENA;;ALTAMIRANO RAUL HERNANDEZ;;RAMIREZ SIMON LOPEZ;;VALENCIA CECILIA DE LOS ANGELES DURAN;;CRUZ JOSE LUIS MENDOZA DE LA;;MARTINEZ JORGE ALBERTO GARCIA;;ROJERO ERICK EMANUEL LUNA;;ALVAREZ DAVID AARON NIETO,,https://lens.org/051-956-711-487-705,Patent Application,no,0,7,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C02F1/04;;C07D211/98;;E21B43/22,,0,0,,,,ACTIVE
81,EP,A1,EP 2644685 A1,102-437-801-431-581,2013-10-02,2013,EP 11839690 A,2011-11-09,MX 2010012348 A;;MX 2011000134 W,2010-11-12,COMPOSITION COMPRISING ZWITTERIONIC GEMINAL LIQUIDS AS WETTABILITY MODIFIERS IN IMPROVED OIL RECOVERY PROCESSES,"The present invention relates to the application of geminals zwitterionics liquids based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts thereof as wettability modifiers of rocks such as limestone, dolomite, sand, quartz or heterogeneous lithologies, in the presence of brines with high content of divalent ions such as calcium, magnesium, barium and strontium, high temperature and pressure in processes of enhanced oil recovery. Wettability modifier comprises a geminal zwitterionic liquid based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts, using as solvent distilled or brine with a high content of divalent ions such as calcium and magnesium or organic solvents compounds derived from alcohols like methanol, ethanol, isopropanol or mixtures thereof, or aromatic as isomers of xylene, toluene, or diesel, gasoline or mixtures thereof. Geminals zwitterionics liquids based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts are obtained by reacting an alkyl or alkenyl amine and an reactive polyether derivative of ethylene or propylene oxide or copolymer of these, which may contain in their structure mesyl or tosyl groups, and subsequently the reaction product is reacted with unsaturated acids such as acrylic acid or methacrylic acid and subsequently may or may not be neutralized with alkali metal bases such as the sodium or potassium hydroxide, carbonates or bicarbonates of potassium or sodium.",MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,,https://lens.org/102-437-801-431-581,Patent Application,yes,0,5,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C09K8/584;;C07C229/12;;C10G1/04;;C11D1/06,,0,0,,,,ACTIVE
82,CN,A,CN 103459567 A,095-061-764-912-276,2013-12-18,2013,CN 201180064989 A,2011-11-09,MX 2011000134 W;;MX 2010012348 A,2010-11-12,Composition comprising zwitterionic geminal liquids as wettability modifiers in improved oil recovery processes,"The invention relates to the use of zwitterionic geminal liquids of type bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta imino acids or the salts thereof as modifiers of the wettability of rock, such as limestone, dolomite, sandstone, quartz or heterogeneous lithologies, in the presence of brine having a high concentration of divalent ions, such as calcium, magnesium, barium and strontium, at a high temperature and pressure, in improved oil recovery processes.",MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,,https://lens.org/095-061-764-912-276,Patent Application,no,6,6,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C10L1/224;;C07C227/18;;C07C229/26;;C09K8/584;;C10G75/02,,0,0,,,,ACTIVE
83,US,A1,US 2013/0296200 A1,133-352-242-418-138,2013-11-07,2013,US 201113884925 A,2011-11-09,MX 2010012348 A;;MX 2011000134 W,2010-11-12,COMPOSITION BASED ON GEMINALS ZWITTERIONICS LIQUIDS AS WETTABILITY MODIFIERS IN ENHANCED OIL RECOVERY PROCESSES,"The present invention relates to the application of geminals zwitterionics liquids based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts thereof as wettability modifiers of rocks such as limestone, dolomite, sand, quartz or heterogeneous lithologies, in the presence of brines with high content of divalent ions such as calcium, magnesium, barium and strontium, high temperature and pressure in processes of enhanced oil recovery. Wettability modifier comprises a geminal zwitterionic liquid based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts, using as solvent distilled or brine with a high content of divalent ions such as calcium and magnesium or organic solvents compounds derived from alcohols like methanol, ethanol, isopropanol or mixtures thereof, or aromatic as isomers of xylene, toluene, or diesel, gasoline or mixtures thereof. Geminals zwitterionics liquids based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts are obtained by reacting an alkyl or alkenyl amine and an reactive polyether derivative of ethylene or propylene oxide or copolymer of these, which may contain in their structure mesyl or tosyl groups, and subsequently the reaction product is reacted with unsaturated acids such as acrylic acid or methacrylic acid and subsequently may or may not be neutralized with alkali metal bases such as the sodium or potassium hydroxide, carbonates or bicarbonates of potassium or sodium.",HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON;;MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,INSTITUTO MEXICANO DEL PETROLEO (2013-06-12),https://lens.org/133-352-242-418-138,Patent Application,yes,3,13,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C09K8/584,507/241;;507/244,0,0,,,,ACTIVE
84,CA,A1,CA 2817681 A1,017-505-292-767-335,2012-05-18,2012,CA 2817681 A,2011-11-09,MX 2010012348 A;;MX 2011000134 W,2010-11-12,COMPOSITION BASED ON GEMINALS ZWITTERIONICS LIQUIDS AS WETTABILITY MODIFIERS IN ENHANCED OIL RECOVERY PROCESSES.,"The invention relates to the use of zwitterionic geminal liquids of type bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta imino acids or the salts thereof as modifiers of the wettability of rock, such as limestone, dolomite, sandstone, quartz or heterogeneous lithologies, in the presence of brine having a high concentration of divalent ions, such as calcium, magnesium, barium and strontium, at a high temperature and pressure, in improved oil recovery processes.",MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,,https://lens.org/017-505-292-767-335,Patent Application,no,0,0,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C10L1/224;;C07C227/18;;C07C229/26;;C09K8/584;;C10G75/02,,0,0,,,,ACTIVE
85,WO,A1,WO 2012/064168 A1,000-291-401-880-321,2012-05-18,2012,MX 2011000134 W,2011-11-09,MX 2010012348 A,2010-11-12,COMPOSITION COMPRISING ZWITTERIONIC GEMINAL LIQUIDS AS WETTABILITY MODIFIERS IN IMPROVED OIL RECOVERY PROCESSES,"The invention relates to the use of zwitterionic geminal liquids of type bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta imino acids or the salts thereof as modifiers of the wettability of rock, such as limestone, dolomite, sandstone, quartz or heterogeneous lithologies, in the presence of brine having a high concentration of divalent ions, such as calcium, magnesium, barium and strontium, at a high temperature and pressure, in improved oil recovery processes.",MEXICANO INST PETROL;;HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,,https://lens.org/000-291-401-880-321,Patent Application,yes,9,1,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C10L1/224;;C07C227/18;;C07C229/26;;C09K8/584;;C10G75/02,,5,2,049-361-453-092-270;;042-094-312-641-346,10.1007/s11743-009-1152-4;;10.1016/j.susc.2004.01.018,"Z. XIE ET AL.: ""Synthesis and properties of alkylbetaine zwitterionic gemini surfactants"", J. SURFACT. DETERG., vol. 13, 2010, pages 51 - 57, XP001551900;;DATABASE WPI Week 201048, Derwent World Patents Index; AN 2010-F55215, XP008170308;;DATABASE WPI Week 201062, Derwent World Patents Index; AN 2010-J98190, XP008170309;;H. CHEN ET AL.: ""The interfacial tension between oil and gemini surfactant solution"", SURFACE SCIENCE, vol. 552, 2004, pages L53 - L57, XP055120729;;See also references of EP 2644685A4",PENDING
86,CA,C,CA 2817681 C,027-242-048-312-655,2016-01-12,2016,CA 2817681 A,2011-11-09,MX 2010012348 A;;MX 2011000134 W,2010-11-12,COMPOSITION BASED ON GEMINALS ZWITTERIONICS LIQUIDS AS WETTABILITY MODIFIERS IN ENHANCED OIL RECOVERY PROCESSES,"The invention relates to the use of zwitterionic geminal liquids of type bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta imino acids or the salts thereof as modifiers of the wettability of rock, such as limestone, dolomite, sandstone, quartz or heterogeneous lithologies, in the presence of brine having a high concentration of divalent ions, such as calcium, magnesium, barium and strontium, at a high temperature and pressure, in improved oil recovery processes.",MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,,https://lens.org/027-242-048-312-655,Granted Patent,no,0,0,14,14,0,C10G1/04;;C10G2300/4006;;C10G2300/44;;C07C229/12;;C09K8/584;;C11D1/06;;C10G1/04;;C10G2300/4006;;C10G2300/44;;C07C229/12;;C09K8/584,C10L1/224;;C07C227/18;;C07C229/26;;C09K8/584;;C10G75/02,,0,0,,,,ACTIVE
87,CO,A2,CO 6870041 A2,025-689-578-638-191,2014-02-20,2014,CO 13138762 A,2013-06-07,MX 2010012348 A,2010-11-12,Composiciones base líquidos zwitterionicos geminales como modificaciones de la mojabilidad en procesos de recuperación mejorada de petróleo,,MEXICANO INST PETROL,BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON;;LOPEZ RAMIREZ SIMON;;DURAN VALENCIA CECILIA DE LOS ANGELES;;MENA CERVANTES VIOLETA YASMIN;;ZAMUDIO RIVERA LUIS SILVESTRE;;HERNANDEZ ALTAMIRANO RAUL;;BELTRAN CONDE HIRAM ISAAC,,https://lens.org/025-689-578-638-191,Patent Application,no,0,0,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C10L1/224,,0,0,,,,ACTIVE
88,ES,T3,ES 2721921 T3,138-684-266-539-885,2019-08-06,2019,ES 13823919 T,2013-12-16,CU 20120179 A;;CU 2013000008 W,2012-12-27,Composición de vacuna del virus del dengue,"Composiciones vacunales que comprenden al menos un antígeno basado en la proteína de la cápsida del virus dengue (VD) y el oligonucleótido identificado como SEQ ID NO. 1. La composición vacunal que comprende una proteína de fusión formada por la cápsida del VD2 y el dominio III de la proteína de la envoltura del mismo serotipo, agregada con el oligonucleótido identificado como SEQ ID NO. 1, genera los mayores niveles de respuesta inmune celular y protección en ratones, al compararla con la generada por formulaciones del mismo antígeno agregado con oligonucleótidos de potencial capacidad adyuvante, reportados antioriomente. La efectividad de las composiciones que comprenden el oligonucleótido de SEQ ID NO. 1 fue demostrado en primates no humanos. Estas composiciones pueden ser monovalentes, bivalentes y tetravalentes y se combinan en diferentes regímenes de inmunización para inducir respuesta inmune funcional frente a los cuatro serotipos virales.",CT INGENIERIA GENETICA BIOTECNOLOGIA,HERMIDA CRUZ LISSET;;GIL GONZALEZ LÁZARO;;IZQUIERDO OLIVA ALIENYS;;MARCOS LOPEZ ERNESTO;;SUZARTE PORTAL EDITH;;GUILLEN NIETO GERARDO;;GUZMAN TIRADO MARÍA;;VALDES PRADO IRIS;;LAZO VAZQUEZ LAURA;;GARCIA ARECHAVALETA ANGÉLICA;;ALVAREZ VERA MAYLING;;CASTRO VELAZCO JORGE;;LOPEZ FERNANDEZ LÁZARO;;RAMIREZ BARTUTIS ROSA;;PEREZ FUENTES YUSLEIDI;;PEREZ GUEVARA;;ROMERO FERNANDEZ YAREMY,,https://lens.org/138-684-266-539-885,Granted Patent,no,0,0,27,27,0,A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;A61K39/12;;A61P31/12;;A61P31/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K16/10;;C12N7/00;;C12N2770/24122;;C12N2770/24121;;C12N2770/24151;;C12N2770/24161;;C12N2770/00;;C07K16/10;;C07K14/005;;A61K2039/53;;A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;Y02A50/30;;A61K39/12,A61K39/12;;C07K14/005,,0,0,,,,ACTIVE
89,MX,A,MX 2020009027 A,161-539-621-250-692,2020-11-26,2020,MX 2020009027 A,2020-08-28,MX 2020009027 A,2020-08-28,MONITORING AND ALERTING SYSTEM FOR THE PRESERVATION OF HEALTH.,"The present invention relates to a system and its process, through a technological platform for monitoring and alerting, which prevents infections or abnormalities early for the preservation of the health of confined people. It is useful in centers, educational institutions, lodgings, restaurants, and/or in any type of events, where there is an intention, obligation or need to take care of the health of individuals and people, generating timely information so that the entity and/or the medical service or health institutions take actions in each case presented by the platform. The Platform receives information from various peripheral devices (personal or mass capture) that emit signals, considered as sensors used to measure vital signs.",PROCESS MAN AND SOLUTIONS S A DE C V,VARGAS MEDINA PEDRO GUIUSEPE;;LOPEZ RODRIGUEZ EDUARDO ISRAEL;;ELOISA FIGUEROA OSCAR IVAN;;RODRÍGUEZ BOJORQUEZ SULEMY GUADALUPE;;ITURBE CRUZ IRVING JONHATAN;;GALVÁN HERNÁNDEZ ALEN ULISES;;ESPINOSA RUIZ JORGE YAEL;;CHACON GUTIÉRREZ LUIS ALONSO;;GONZALEZ RIVAS HUGO MANUEL;;SÁNCHEZ FERNANDO;;MUÑOZ VIVAS MARLO ALEXANDER;;CARLOS ÁLVAREZ CRUZ;;AGUILAR MARTÍNEZ DENY;;RUBIO DÁVILA RICARDO ALBERTO;;MONTOYA PALOMARES EDGAR;;LUCERO ZARCO DIANA PAOLA;;MONTES SAN AGUSTÍN RAQUEL;;MARTÍNEZ PUERTO JOSE LUIS;;SALAZAR SÁNCHEZ LEHI ISAAC,,https://lens.org/161-539-621-250-692,Patent Application,no,0,0,1,1,0,,G16H40/67,,0,0,,,,PENDING
90,CA,C,CA 2894134 C,189-022-018-774-517,2021-04-06,2021,CA 2894134 A,2013-12-16,CU 20120179 A;;CU 2013000008 W,2012-12-27,DENGUE VIRUS VACCINE COMPOSITION,"Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.",CENTRO DE INGENIERIA GENETICA Y BIOTECHNOLOGIA,HERMIDA CRUZ LISSET;;GIL GONZALEZ LAZARO;;IZQUIERDO OLIVA ALIENYS;;MARCOS LOPEZ ERNESTO;;SUZARTE PORTAL EDITH;;GUILLEN NIETO GERARDO ENRIQUE;;GUZMAN TIRADO MARIA GUADALUPE;;VALDES PRADO IRIS;;LAZO VAZQUEZ LAURA;;GARCIA ARECHAVALETA ANGELICA DE LA CARIDAD;;ALVAREZ VERA MAYLING;;CASTRO VELAZCO JORGE;;LOPEZ FERNANDEZ LAZARO;;RAMIREZ BARTUTIS ROSA LISET;;PEREZ FUENTES YUSLEIDI DE LA CARIDAD;;PEREZ GUEVARA;;ROMERO FERNANDEZ YAREMY,,https://lens.org/189-022-018-774-517,Granted Patent,no,0,0,27,27,8,A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;A61K39/12;;A61P31/12;;A61P31/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K16/10;;C12N7/00;;C12N2770/24122;;C12N2770/24121;;C12N2770/24151;;C12N2770/24161;;C12N2770/00;;C07K16/10;;C07K14/005;;A61K2039/53;;A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;Y02A50/30;;A61K39/12,A61K39/12;;C07K14/005,,0,0,,,,ACTIVE
91,AU,B2,AU 2013/369626 B2,003-625-848-828-18X,2017-07-27,2017,AU 2013/369626 A,2013-12-16,CU 20120179 A;;CU 2013000008 W,2012-12-27,Dengue virus vaccine composition,"Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.",CT INGENIERIA GENETICA BIOTECNOLOGIA,HERMIDA CRUZ LISSET;;GIL GONZALEZ LAZARO;;IZQUIERDO OLIVA ALIENYS;;MARCOS LOPEZ ERNESTO;;SUZARTE PORTAL EDITH;;GUILLEN NIETO GERARDO ENRIQUE;;GUZMAN TIRADO MARIA GUADALUPE;;VALDES PRADO IRIS;;LAZO VAZQUEZ LAURA;;GARCIA ARECHAVALETA ANGELICA DE LA CARIDAD;;ALVAREZ VERA MAYLING;;CASTRO VELAZCO JORGE;;LOPEZ FERNANDEZ LAZARO;;RAMIREZ BARTUTIS ROSA LISET;;PEREZ FUENTES YUSLEIDI DE LA CARIDAD;;PEREZ GUEVARA OLGA LIDIA;;ROMERO FERNANDEZ YAREMY,,https://lens.org/003-625-848-828-18X,Granted Patent,no,1,0,27,27,0,A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;A61K39/12;;A61P31/12;;A61P31/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K16/10;;C12N7/00;;C12N2770/24122;;C12N2770/24121;;C12N2770/24151;;C12N2770/24161;;C12N2770/00;;C07K16/10;;C07K14/005;;A61K2039/53;;A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;Y02A50/30;;A61K39/12,C07K14/005;;A61K39/12,,2,2,136-108-830-527-175;;003-877-494-523-32X,10.1016/j.virol.2009.08.029;;19783271;;22750482;;10.1016/j.actatropica.2012.06.006,"VALDES, I. et al. ""A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice"", Virology, 2009, Vol. 394, Pages 249-258.;;LAZO, L. et al., Acta Tropica, 2012, Vol. 124, Pages 107-112.",INACTIVE
92,AR,A1,AR 094238 A1,123-559-253-525-620,2015-07-22,2015,AR P130104975 A,2013-12-20,CU 20120179 A,2012-12-27,COMPOSICION VACUNAL CONTRA EL VIRUS DENGUE,"Composiciones vacunales que comprenden al menos un antígeno basado en la proteína de la cápsida del virus dengue (VD) y el oligonucleótido identificado como SEQ ID Nº 1. La composición vacunal que comprende una proteína de fusión formada por la cápsida del VD2 y el dominio III de la proteína de la envoltura del mismo serotipo, agregada con el oligonucleótido identificado como SEQ ID Nº 1, genera los mayores niveles de respuesta inmune celular y protección en ratones, al compararla con la generada por formulaciones del mismo antígeno agregado con oligonucleótidos de potencial capacidad adyuvante, reportados anteriormente. La efectividad de las composiciones que comprenden el oligonucleótido de SEQ ID Nº 1 fue demostrado en primates no humanos. Estas composiciones pueden ser monovalentes, bivalentes y tetravalentes y se combinan en diferentes regímenes de inmunización para inducir respuesta inmune funcional frente a los cuatro serotipos virales.",CT INGENIERIA GENETICA BIOTECNOLOGIA,GERARDO ENRIQUE GUILLEN NIETO;;LAZARO GIL GONZALEZ;;ALIENYS IZQUIERDO OLIVA;;MARIA GUADALUPE GUZMAN TIRADO;;IRIS VALDES PRADO;;ANGELICA DE LA CARIDAD GARCIA ARECHAVALETA;;EDITH SUZARTE PORTAL;;YAREMY ROMERO FERNANDEZ;;ERNESTO MARCOS LOPEZ;;LAURA LAZO VAZQUEZ;;MAYLING ALVAREZ VERA;;LISSET HERMIDIA CRUZ;;JORGE CASTRO VELAZCO;;LAZARO LOPEZ FERNANDEZ;;ROSA LISET RAMIREZ BARTUTIS;;OLGA LIDIA PEREZ GUEVARA;;YUSLEIDI DE LA CARIDAD PEREZ FUENTES,,https://lens.org/123-559-253-525-620,Patent Application,no,0,0,27,27,0,A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;A61K39/12;;A61P31/12;;A61P31/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K16/10;;C12N7/00;;C12N2770/24122;;C12N2770/24121;;C12N2770/24151;;C12N2770/24161;;C12N2770/00;;C07K16/10;;C07K14/005;;A61K2039/53;;A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;Y02A50/30;;A61K39/12,A61K39/12;;A61P31/12;;C07K14/08,,0,0,,,,DISCONTINUED
93,PH,A1,PH 12015501446 A1,061-481-113-626-193,2015-09-14,2015,PH 12015501446 A,2015-06-22,CU 20120179 A;;CU 2013000008 W,2012-12-27,DENGUE VIRUS VACCINE COMPOSITION,"Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.",CT INGENIERIA GENETICA BIOTECH,LISSET HERMIDA CRUZ;;LAZARO GIL GONZALEZ;;ALIENYS IZQUIERDO OLIVA;;ERNESTO MARCOS LOPEZ;;EDITH SUZARTE PORTAL;;ENRIQUE GUILLEN NIETO GERARDO;;GUADALUPE GUZMAN TIRADO MARIA;;IRIS VALDES PRADO;;LAURA LAZO VAZQUEZ;;CARIDAD GARCIA ARECHAVALETA ANGELICA DE LA;;MAYLING ALVAREZ VERA;;JORGE CASTRO VELAZCO;;LAZARO LOPEZ FERNANDEZ;;LISET RAMIREZ BARTUTIS ROSA;;CARIDAD PEREZ FUENTES YUSLEIDI DE LA;;LIDIA PEREZ GUEVARA OLGA;;YAREMY ROMERO FERNANDEZ,,https://lens.org/061-481-113-626-193,Patent Application,no,0,0,27,27,0,A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;A61K39/12;;A61P31/12;;A61P31/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K16/10;;C12N7/00;;C12N2770/24122;;C12N2770/24121;;C12N2770/24151;;C12N2770/24161;;C12N2770/00;;C07K16/10;;C07K14/005;;A61K2039/53;;A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;Y02A50/30;;A61K39/12,A61K39/12;;C07K14/005,,0,0,,,,ACTIVE
94,CN,A,CN 104936616 A,120-075-162-146-561,2015-09-23,2015,CN 201380068237 A,2013-12-16,CU 2013000008 W;;CU 20120179 A,2012-12-27,DENGUE VIRUS VACCINE COMPOSITION,"Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.",CT INGENIERIA GENETICA BIOTECH,HERMIDA CRUZ LISSET;;GIL GONZALEZ LAZARO;;IZQUIERDO OLIVA ALIENYS;;MARCOS LOPEZ ERNESTO;;SUZARTE PORTAL EDITH;;GUILLEN NIETO GERARDO ENRIQUE;;GUZMAN TIRADO MARIA GUADALUPE;;VALDES PRADO IRIS;;LAZO VAZQUEZ LAURA;;GARCIA ARECHAVALETA ANGELICA DE LA CARIDAD;;ALVAREZ VERA MAYLING;;CASTRO VELAZCO JORGE;;LOPEZ FERNANDEZ LAZARO;;RAMIREZ BARTUTIS ROSA LISET;;PEREZ FUENTES YUSLEIDI DE LA CARIDAD;;PEREZ GUEVARA OLGA LIDIA;;ROMERO FERNANDEZ YAREMY,,https://lens.org/120-075-162-146-561,Patent Application,no,0,0,27,27,0,A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;A61K39/12;;A61P31/12;;A61P31/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K16/10;;C12N7/00;;C12N2770/24122;;C12N2770/24121;;C12N2770/24151;;C12N2770/24161;;C12N2770/00;;C07K16/10;;C07K14/005;;A61K2039/53;;A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;Y02A50/30;;A61K39/12,A61K39/12;;C07K14/005,,2,2,054-192-739-245-830;;006-815-477-934-405,10.1016/j.vaccine.2010.01.022;;pmc2837772;;20097152;;10.1128/cvi.00382-10;;pmc3067388;;21209159,"CLEMENTS DE ET AL: ""development of a recombinant tetravalent dengur virus vaccine: immunogenicity and efficacy studies in mice and monkeys"", 《VACCINE》;;VALDES I ET AL: ""the chimeric protein domain iii-capsid of dengue virus serotype 2 (den-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with den-2"", 《CLIN VACCINE IMMUNOL》",ACTIVE
95,KR,A,KR 20150100660 A,184-619-693-375-130,2015-09-02,2015,KR 20157015888 A,2013-12-16,CU 20120179 A;;CU 2013000008 W,2012-12-27,DENGUE VIRUS VACCINE COMPOSITION,,CT INGENIERIA GENETICA BIOTECH,HERMIDA CRUZ LISSET;;GIL GONZALEZ LAZARO;;IZQUIERDO OLIVA ALIENYS;;MARCOS LOPEZ ERNESTO;;SUZARTE PORTAL EDITH;;GUILLEN NIETO GERARDO ENRIQUE;;GUZMAN TIRADO MARIA GUADALUPE;;VALDES PRADO IRIS;;LAZO VAZQUEZ LAURA;;GARCIA ARECHAVALETA ANGELICA DE LA CARIDAD;;ALVAREZ VERA MAYLING;;CASTRO VELAZCO JORGE;;LOPEZ FERNANDEZ LAZARO;;RAMIREZ BARTUTIS ROSA LISET;;PEREZ FUENTES YUSLEIDI DE LA CARIDAD;;PEREZ GUEVARA OLGA LIDIA;;ROMERO FERNANDEZ YAREMY,,https://lens.org/184-619-693-375-130,Patent Application,no,1,0,27,27,16,A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;A61K39/12;;A61P31/12;;A61P31/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K16/10;;C12N7/00;;C12N2770/24122;;C12N2770/24121;;C12N2770/24151;;C12N2770/24161;;C12N2770/00;;C07K16/10;;C07K14/005;;A61K2039/53;;A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;Y02A50/30;;A61K39/12,A61K48/00,,0,0,,,,ACTIVE
96,CA,A1,CA 2894134 A1,176-773-917-571-831,2014-07-03,2014,CA 2894134 A,2013-12-16,CU 20120179 A;;CU 2013000008 W,2012-12-27,DENGUE VIRUS VACCINE COMPOSITION,"Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.",CT DE INGENIRIA GENETICA Y BIOTECNOLOGIA,HERMIDA CRUZ LISSET;;GIL GONZALEZ LAZARO;;IZQUIERDO OLIVA ALIENYS;;MARCOS LOPEZ ERNESTO;;SUZARTE PORTAL EDITH;;GUILLEN NIETO GERARDO ENRIQUE;;GUZMAN TIRADO MARIA GUADALUPE;;VALDES PRADO IRIS;;LAZO VAZQUEZ LAURA;;GARCIA ARECHAVALETA ANGELICA DE LA CARIDAD;;ALVAREZ VERA MAYLING;;CASTRO VELAZCO JORGE;;LOPEZ FERNANDEZ LAZARO;;RAMIREZ BARTUTIS ROSA LISET;;PEREZ FUENTES YUSLEIDI DE LA CARIDAD;;PEREZ GUEVARA OLGA LIDIA;;ROMERO FERNANDEZ YAREMY,,https://lens.org/176-773-917-571-831,Patent Application,no,0,0,27,27,8,A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;A61K39/12;;A61P31/12;;A61P31/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K16/10;;C12N7/00;;C12N2770/24122;;C12N2770/24121;;C12N2770/24151;;C12N2770/24161;;C12N2770/00;;C07K16/10;;C07K14/005;;A61K2039/53;;A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;Y02A50/30;;A61K39/12,A61K39/12;;C07K14/005,,0,0,,,,ACTIVE
97,MY,A,MY 190698 A,036-106-947-494-915,2022-05-11,2022,MY PI2015702127 A,2013-12-16,CU 2013000008 W;;CU 20120179 A,2012-12-27,DENGUE VIRUS VACCINE COMPOSITION,"Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain Ill of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.",CT INGENIERIA GENETICA BIOTECNOLOGIA,LISSET HERMIDA CRUZ;;LAZARO GIL GONZALEZ;;ALIENYS IZQUIERDO OLIVA;;ERNESTO MARCOS LOPEZ;;EDITH SUZARTE PORTAL;;GERARDO ENRIQUE GUILLEN NIETO;;MARIA GUADALUPE GUZMAN TIRADO;;IRIS VALDES PRADO;;LAURA LAZO VAZQUEZ;;ANGELICA DE LA CARIDAD GARCIA ARECHAVALETA;;MAYLING ALVAREZ VERA;;JORGE CASTRO VELAZCO;;LAZARO LOPEZ FERNANDEZ;;ROSA LISET RAMIREZ BARTUTIS;;YUSLEIDI DE LA CARIDAD PEREZ FUENTES;;OLGA LIDIA PEREZ GUEVARA;;YAREMY ROMERO FERNANDEZ,,https://lens.org/036-106-947-494-915,Granted Patent,no,0,0,27,27,0,A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;A61K39/12;;A61P31/12;;A61P31/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K16/10;;C12N7/00;;C12N2770/24122;;C12N2770/24121;;C12N2770/24151;;C12N2770/24161;;C12N2770/00;;C07K16/10;;C07K14/005;;A61K2039/53;;A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;Y02A50/30;;A61K39/12,C07K14/005;;A61K39/12,,0,0,,,,ACTIVE
98,PH,B1,PH 12015501446 B1,081-908-296-241-194,2015-09-14,2015,PH 12015501446 A,2015-06-22,CU 20120179 A;;CU 2013000008 W,2012-12-27,DENGUE VIRUS VACCINE COMPOSITION,"Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.",CENTRO DE INGENIERIA GENTICA Y BIOTECNOLOGIA,HERMIDA CRUZ LISSET;;GIL GONZALEZ L ZARO;;IZQUIERDO OLIVA ALIENYS;;MARCOS LOPEZ ERNESTO;;SUZARTE PORTAL EDITH;;GUILLN NIETO GERARDO ENRIQUE;;GUZMAN TIRADO MAR¡A GUADALUPE;;VALDS PRADO IRIS;;LAZO VAZQUEZ LAURA;;GARCIA ARECHAVALETA ANGLICA DE LA CARIDAD;;ALVAREZ VERA MAYLING;;CASTRO VELAZCO JORGE;;LOPEZ FERNANDEZ L ZARO;;RAMIREZ BARTUTIS ROSA LISET;;PREZ FUENTES YUSLEIDI DE LA CARIDAD;;PREZ GUEVARA OLGA LIDIA;;ROMERO FERNANDEZ YAREMY,,https://lens.org/081-908-296-241-194,Granted Patent,no,0,0,27,27,0,A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;A61K39/12;;A61P31/12;;A61P31/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K16/10;;C12N7/00;;C12N2770/24122;;C12N2770/24121;;C12N2770/24151;;C12N2770/24161;;C12N2770/00;;C07K16/10;;C07K14/005;;A61K2039/53;;A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;Y02A50/30;;A61K39/12,A61K39/12;;C07K14/005,,0,0,,,,ACTIVE
99,HK,A1,HK 1209647 A1,106-561-907-161-915,2016-04-08,2016,HK 15110603 A,2015-10-28,CU 2013000008 W;;CU 20120179 A,2012-12-27,DENGUE VIRUS VACCINE COMPOSITION,,CT INGENIERIA GENETICA BIOTECH,HERMIDA CRUZ LISSET L;;GIL GONZALEZ LAZARO L;;IZQUIERDO OLIVA ALIENYS A;;MARCOS LOPEZ ERNESTO E;;SUZARTE PORTAL EDITH E;;GUILLEN NIETO GERARDO ENRIQUE GE;;GUZMAN TIRADO MARIA GUADALUPE MG;;VALDES PRADO IRIS I;;LAZO VAZQUEZ LAURA L;;GARCIA ARECHAVALETA ANGLICA DE LA CARIDAD ADLC;;ALVAREZ VERA MAYLING M;;CASTRO VELAZCO JORGE J;;LOPEZ FERNANDEZ LAZARO L;;RAMIREZ BARTUTIS ROSA LISET RL;;PEREZ FUENTES YUSLEIDI DE LA CARIDAD YDLC;;PEREZ GUEVARA OLGA LIDIA OL;;ROMERO FERNANDEZ YAREMY Y,,https://lens.org/106-561-907-161-915,Patent Application,no,0,0,27,27,0,A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;A61K39/12;;A61P31/12;;A61P31/14;;A61P37/04;;A61P43/00;;Y02A50/30;;C07K16/10;;C12N7/00;;C12N2770/24122;;C12N2770/24121;;C12N2770/24151;;C12N2770/24161;;C12N2770/00;;C07K16/10;;C07K14/005;;A61K2039/53;;A61K2039/55505;;A61K2039/55561;;A61K2039/70;;C12N2770/24134;;Y02A50/30;;A61K39/12,A61K/;;C07K/,,0,0,,,,PENDING
